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ABSTRACT 
 Adeno-associated virus serotype 2 (AAV-2) has been developed as a gene 
therapy vector.  Antibody and cell-mediated immune responses to AAV-2 or AAV-2 
transfected cells may confound the therapeutic use of such vectors in the clinic.  In this 
study, cell-mediated and humoral immune responses to AAV-2 were characterised from 
a panel of healthy blood donors.  The extent of AAV-2-specific antibody in humans was 
determined by examination of circulating AAV-2-specific total IgG levels in plasma 
from 45 normal donors.  41 donors were seropositive and responses were dominated by 
IgG1 and IgG2 subclasses.  Conversely, AAV-2-specific IgG3 levels were consistently 
low in all donors.  Cell-mediated immune recall responses were detectable in nearly half 
the population studied.  In vitro re-stimulation with AAV-2 of peripheral blood 
mononuclear cell (PBMC) cultures from 16 donors elicited interferon-gamma (IFN-γ) 
(10 donors), interleukin-10 (IL-10) (8 donors) and interleukin-13 (IL-13) (4 donors).  
Using a series of overlapping peptides derived from the sequence of the VP1 viral 
capsid protein, a total of 59 candidate T-cell epitopes were identified.  HLA 
characterisation of donors revealed that the population studied included diverse 
haplotypes, but that at least 17 epitopes were recognised by multiple donors and could 
be regarded as immunodominant.  These data indicate that robust immunological 
memory is established to AAV-2.  The diversity of sequences recognised suggests that 
attempts to modify the AAV-2 capsid, as a strategy to avoid confounding immunity, will 
not be feasible. 
xiii 
 
 It was hoped that murine mesenchymal stem cells (MSC) might be amenable to 
transformation using an AAV-2-based vector, rendering the MSC as a potential platform 
to deliver transgene products whilst avoiding the immune memory for AAV-2 
characterised herein.  However, murine MSC appeared resistant to transduction using an 
AAV-2 GFP vector.  To assess the impact of transfection of MSC with a plasmid vector, 
a lipofection protocol, utilising a plasmid encoding indoleamine 2,3-dioxygenase (IDO), 
was instead adopted.  Transfection was successful, MSC morphology was not altered 
and osteogenic and adipogenic functions remained.  However, MSC cell numbers in 
culture declined sharply in the 24 hours following transfection and growth rates were 
poor for up to 7 days.  Cell surface markers were also altered, with increased MHC class 
I observed in transfected cultures.  Perhaps most significantly, transfected MSC 
displayed a reduced capacity to suppress mitogen-driven lymphocyte proliferation.  
Further optimisation of the lipofection protocol might reduce MSC death and restore 
proliferation, but the observed changes in murine MSC immunomodulatory function as 
a result of IDO transfection coupled with the cell death and loss of proliferation 
indicates that lipofection is a suboptimal method for the transfection of murine MSC.   
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INTRODUCTION 
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1.1  GENE THERAPY 
 Gene therapy is the treatment of genetic disorders by insertion of functional 
replacement genes or gene silencing sequences into a recipient’s cells.  At the time of 
writing, well over 1,300 clinical trials utilising some form of gene therapy had been 
completed, approved or were in progress (Edelstein et al., 2007).  Gene therapy may be 
mediated by a wide range of gene delivery systems including naked DNA (Nishikage et 
al., 2004; Pevsner-Fischer et al., 2007), silencing oligonucleotides (Uprichard, 2005), 
liposomal complexes (Felgner et al., 1987) and recombinant viruses (McTaggart & Al-
Rubeai, 2002; Robbins & Ghivizzani, 1998).  Viral vectors have to date been the most 
popular gene delivery systems used in trials, being central to two thirds of all gene 
therapy trials as of 2007, with vectors based on the adenoviruses or retroviruses used in 
nearly 48% of clinical trials overall (Edelstein et al., 2007).  Of the studies reviewed by 
Edelstein et al., lipofection and naked DNA transfection comprised the bulk of non-viral 
delivery systems.  The dominance of viral vectors may be a reflection of their key 
advantages.  These vectors have well defined tissue tropisms, and their envelopes and 
capsids can be modified to alter tissue specificity (Grimm et al., 2003).  Viruses also 
possess natural means to efficiently transduce host cells, whilst naked DNA may be 
inefficient even in vitro, often requiring administration by gene gun or the target cells to 
be made chemically competent or to undergo electroporation (Nishizaki et al., 2000; 
Roos et al., 2009).  Mammalian viruses, having co-evolved with humans and related 
species, are also more likely to have adapted means to avoid or subvert human immune 
responses, which in a therapeutic setting might help to minimise recipient immune 
recognition of vectors or transduced cells. 
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 Despite these features, clinical trials utilising adenoviral and retroviral vectors 
have met with mixed results, including a number of high-profile serious adverse events.  
In 1999, an 18 year old male patient enrolled in a phase I trial to assess the safety of 
vectors based on adenovirus serotype 5 (Ad5) for the treatment of partial ornithine 
transcarbamylase, experienced massive systemic inflammation and multi-organ failure, 
dying 96 hours following administration of the vector into his right hepatic artery (Raper 
et al., 2003).  Three years later, a phase I trial investigating the use of retroviral vectors 
for the treatment of X-linked severe combined immunodeficiency (SCID-X1) 
(Cavazzana-Calvo et al., 2000) was halted when two of the ten children enrolled 
developed a leukaemia-like condition confirmed to be a direct result of insertional 
mutagenesis into a proto-oncogene (Hacein-Bey-Abina et al., 2003).  After the trial was 
re-started, a third child developed a similar condition, though triggered by a different 
insertional mutation.  Although two of the children responded to chemotherapy and 
went into remission, one did not respond and died in 2004 (Hacein-Bey-Abina et al., 
2008).  The safety profile of vectors based on adenoviruses and retroviruses has since 
improved, with no further fatalities reported.  However, these early failures, especially 
in such small patient cohorts, undermined confidence in these systems, prompting 
research into alternative viral systems which might reduce the risks of severe immune 
responses and oncogenesis.  Amongst these were vectors based on the adeno-associated 
viruses (AAV) which have seen increasing use in clinical trials in recent years (Coura & 
Nardi, 2007; Edelstein et al., 2007; Edelstein et al., 2004).   
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1.2  ADENO-ASSOCIATED VIRUSES 
1.2.1  Wild type AAV  
 AAV was first discovered as a contaminant of adenovirus (Ad) viral stocks in 
1965 (Atchison et al., 1965; Blacklow et al., 1967).  Due to the lack of an obvious 
pathology resulting from AAV infection, the virus received little attention until the 
advent of gene therapy.  AAV belongs to the Parvoviridae family of single-stranded 
non-enveloped viruses.  The virus particle is 20-25 nm in diameter and consists of a 
single-stranded DNA (ssDNA) genome of 4.6 kilobase length for AAV-2 (Srivastava et 
al., 1983), (varying between 4.5- 5.0 kilobases depending on serotype) (Figure 1.1 A) 
enclosed within a capsid composed of 60 monomer subunits arranged into a structure 
with icosahedral symmetry, with three subunits comprising each face of the icosahedron 
(Figure 1.1 B) (Xie et al., 2002).  There are two open reading frames, Rep and Cap, 
flanked by two identical inverted terminal repeats (ITR), each 145 base pairs (bp) in 
length (Figure 1.1 A) (Janik et al., 1984; Mendelson et al., 1986).  The Rep open 
reading frame encodes four non-structural proteins, Rep78, Rep68, Rep52 and Rep40 
which are involved in the viral replication cycle (Figure 1.2).  These have molecular 
masses of 78, 68, 52 and 40 kDa respectively (Mendelson et al., 1986).  The Cap open 
reading frame codes for three structural proteins VP1, VP2 and VP3 (87, 73 and 62 kDa 
respectively; Figure 1.2) (Janik et al., 1984) each of which comprises one capsid 
subunit, with 60 subunit monomers forming a capsid in the stoichiometric ratio of 
1:1:10 (Buller & Rose, 1978).  The VP2 and VP3 products are produced by alternative 
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mRNA splicing of VP1 and by alternative start codon usage (Becerra et al., 1988; 
Cassinotti et al., 1988).  
Figure 1.1  A schematic representation of the wild-type AAV genome (A) and the viral 
capsid (B).  A)  The ssDNA AAV genome is flanked by two ITR sequences and 
contains two open reading frames (Rep and Cap).  There are three promoter regions (p5, 
p19 and p40).  B)  The viral capsid has T=1 icosahedral symmetry.  Each of the 20 
triangular faces is composed of three diamond-shaped subunits (example shaded blue) 
which are coded for by the Cap ORF.  Thus the capsid is composed of 60 subunits.  
Each subunit meets its neighbours at three axes of icosahedral symmetry; the two-fold 
axis (a), the five-fold axis (b) and the three-fold axis (c). Figure 1.1 A was adapted by 
the author from Russell and Kay, 1999.  Figure 1.1 B was rendered by the author, based 
on the structure determined by Xie et al., 2002. 
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Figure 1.2  A schematic representation of the AAV-2 ssDNA genome and the gene 
products coded for by the Rep and Cap open reading frames.  The Rep open reading 
frame codes for four non-structural products; Rep 78, Rep 68, Rep 52 and Rep 42.  The 
Cap open reading frame codes for three capsid subunit monomers; VP1, VP2 and VP3.  
Each monomer acts as one of the 60 subunits of the viral capsid shown in Figure 1.1 B.  
Figure 1.2 adapted by the author from Russell and Kay, 1999. 
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 At least eleven AAV serotypes, primarily differentiated by their immunoglobulin 
binding affinities, have been characterised to date (Atchison et al., 1965; Blacklow et 
al., 1967; Chiorini et al., 1999; Mori et al., 2004; Muramatsu et al., 1996).  AAV-2, 3, 
and 5 were isolated from human clinical specimens (Chiorini et al., 1999).  AAV-1 and 
4 are of simian origin, although serotype 1 can infect humans (Atchison et al., 1965).  
AAV-6 is considered to have arisen from a recombination of AAV-2 and AAV-1 due to 
co-infection, based on its similarity to AAV-1 and analysis of its genome (Rutledge et 
al., 1998).  AAV-7 and AAV-8 were isolated from rhesus monkey (Gao et al., 2002), 
whilst serotypes 10 and 11 were identified in cynomolgus monkeys (Mori et al., 2004). 
 The replication cycle of AAV has not been fully characterised (Douar et al., 
2001; Straus et al., 1976; Xiao et al., 2002).  AAV is a replication defective and helper-
dependent virus and requires co-infection with a helper virus such as Herpes virus, 
Vaccinia virus or Adenovirus (Ad) in order to complete its replication cycle (Atchison, 
1970; Atchison et al., 1965; Buller et al., 1981; Schlehofer et al., 1986).  The exact 
mechanism of cell entry of many non-enveloped viruses is not known, and this is the 
case for many AAV serotypes.  The primary receptor for cell surface binding
 
of AAV-1 
has not been identified.  Serotypes 7
 
and 8 also have no known receptor, but they share 
close structural homology with AAV-1 and therefore may share a common receptor 
(Gao et al., 2002).  The primary receptor for AAV-2 is heparin sulphate proteoglycan 
(HSPG) (Summerford & Samulski, 1998).  It appears that HSPG may, at least in part, 
determine the ability and efficiency of AAV serotypes to infect cells.  Thus, the low 
levels of HSPG present on the lung epithelium may account for the difficulties facing 
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AAV-2 transduction of lung epithelial cells in vivo (Duan et al., 1998; Halbert et al., 
1997).  
 The alpha V beta 5 (αVβ5) integrin and fibroblast growth factor-1 (FGF-1) are 
also involved as co-receptors in AAV-2 internalisation (Qing et al., 1999; Summerford 
et al., 1999). AAV-4 and 5 require the presence of membrane associated 2,3-linked 
sialic acid in order to have a tropism for lung epithelial cells (Walters et al., 2001).  
Binding of these serotypes is not identical however, with AAV-5 binding sialic acid on 
N-linked
 
carbohydrates, whereas AAV-4 interacts with sialic acid on O-linked
 
carbohydrates (Walters et al., 2002).  Although it has been shown that AAV-3 interacts 
with HSPG in a similar manner to AAV-2 (Opie et al., 2003), it is unclear whether this 
interaction is relevant to internalisation.  Attempts to block transduction of lung 
epithelium by AAV-6 using soluble heparin sulfate (HS) do not demonstrate any 
significant neutralising effect (Halbert et al., 2001), suggesting that this serotype does 
not require HS binding. 
 Following HSPG binding, AAV-2 is internalised via clathrin coated pits, 
possibly with the help of the αVβ5 receptor integrin (Summerford et al., 1999).  
Mutagenesis of the capsid domain that interacts with αVβ5 reduces AAV-2 transduction 
of HEK-293 cells by one order of magnitude (Asokan et al., 2006).  Once internalised 
into the early endosome the acidic pH allows the virus to be released into the cytosol by 
a poorly understood process (Douar et al., 2001).  In the cytosol the virus migrates to the 
perinuclear compartment and translocates to the nucleus to unload the virus genetic 
material.  Unpacking of the viral genome may occur shortly prior to or during nuclear 
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entry via the nuclear pore complex in the absence of a helper virus but when co-infected 
with Adenovirus helper, translocation appears more rapid and disassembly of the capsid 
occurs after nuclear entry (Xiao et al., 2002).  Following the release of genetic material, 
single-stranded AAV genomes convert to double-stranded forms and concatemers 
(Straus et al., 1976; Vincent-Lacaze et al., 1999).  Replication is facilitated by the ITR 
which each form a T-shaped hairpin loop structure which allows self-priming activity at 
the free 3' hydroxyl group (Figure 1.4) (Hauswirth & Berns, 1979).  In the absence of 
helper viruses AAV may preferentially integrate into a locus of chromosome 19 (19q13-
qter, henceforth referred to as AAVS1) at a low frequency (Cheung et al., 1980).  AAV 
appears to package the ssDNA genome into preformed capsid particles, possibly via 
pores located at the five-fold axes of symmetry, mutation of which reduces packaging 
efficiency (Bleker et al., 2006).  The newly assembled virus particles are released from 
the host cell following helper virus-mediated cell lysis (Goncalves, 2005). 
 
1.2.2 AAV as a gene therapy vector 
 Several serotypes of AAV have been investigated for use as gene therapy vectors 
or recombinant vaccine vehicles (Arruda et al., 2005; High et al., 2004; Kaplitt et al., 
2007; Moss et al., 2007; Moss et al., 2004; Wagner et al., 2002; Zhang et al., 2003).  A 
selection of trials approved, completed and ongoing is summarised in Table 1.1.  A 
number of features of AAV make it an attractive vector for gene therapy.  AAV has the 
ability to transduce a wide range of dividing and non-dividing cell types and thus could 
target a great number of chronic genetic disorders such as haemophilia B, cystic fibrosis 
10 
 
and alpha-1-antitrypsin deficiency (Mueller & Flotte, 2008).  Although the small 
genome of AAV limits its cloning capacity to about 4.4 kb (Dong et al., 1996), this is 
still large enough to contain reporter genes, such as GFP and Lac-Z as well as 
therapeutic genes such as the cystic fibrosis transmembrane regulator (CFTR) gene for 
the treatment of cystic fibrosis (Wagner et al., 1999) and the factor IX (F.IX) gene for 
the treatment of haemophilia B (Monahan et al., 1998).  Even with the full coding 
sequence of these genes included, tissue-specific regulatory sequences have also been 
successfully incorporated into AAV vectors.  It is notable however, that even insertion 
of these relatively short sequences requires the removal of the entire viral genome, 
except for the ITR sequences (Figure 1.3), which are required for DNA packing into the 
capsid during vector preparation (Tratschin et al., 1984).  By far the most popular and 
best characterised AAV serotype used in clinical studies is AAV-2 (Mueller & Flotte, 
2008), which will be the main focus for the remainder of this chapter. 
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Indication/transgene Serotype Route Clinical phase Status
alpha-1-Anitrypsin Deficiency/AAT AAV-1 intramuscular Phase I Active
alpha-1-Anitrypsin Deficiency/AAT AAV-2 intramuscular Phase I Completed
Alzheimer's/Nerve Growth Factor (B-NGF) AAV-2 intracranial Phase I/II Inactive
Amaurotic Familial Idiocy (Batten's)/CLN2 AAV-2 intracranial Phase I Active
Arthritis/TNFR:Fc (tgAAC94) AAV-2 intra-articular Phase I Completed
Arthritis/TNFR:Fc (tgAAC94) AAV-2 intra-articular Phase I/II Active
Canavan's disease/aspartoacylase AAV-2 intracranial Phase I Active
Cardiac failure/SERCA2a AAV-6 intracardiac Phase I N/A
Cardiac failure/SERCA2a AAV-1 intracardiac Phase I N/A
Cystic fibrosis/CFTR AAV-2 intranasal Phase I Completed
Cystic fibrosis/CFTR AAV-2 aerosol Phase I Completed
Cystic fibrosis/CFTR (tgAAVCF) AAV-2 aerosol Phase I Inactive
Cystic fibrosis/CFTR (tgAAVCF) AAV-2 intrasinusal Phase I/II Inactive
Duchenne muscular dystrophy/mini-dystrophin AAV-5 Phase I N/A
Epilepsy/neuropeptide Y (NPY) AAV-1, 2 intracranial Phase I N/A
Factor IX deficiency/Factor IX minigene AAV-2 intramuscular Phase I Completed
Factor IX deficiency/Factor IX minigene AAV-2 intra-arterial Phase I Completed
Leber congenital amaurosis (Retinal degeneration)/RPE65 AAV-2 intraocular Phase I Active
Leber congenital amaurosis (Retinal degeneration)/RPE66 AAV-2 intraocular Phase I N/A
Limb girdle dystrophy/Gamma sarcoglycan AAV-2 Phase I N/A
Limb girdle dystrophy/Gamma sarcoglycan AAV-1 Phase I N/A
Parkinson's disease/GAD65 AAV-2 intracerebral Phase I Completed
Parkinson's disease/hAADC AAV-2 intracerebral Phase I Active
Parkinson's disease/Secreted neurturin (Cere-120) AAV-2 intracranial Phase I Completed
Parkinson's disease/Secreted neurturin (Cere-120) AAV-2 intracranial Phase II Active
Parkinson's disease/GAD65 AAV-2 intracerebral Phase II N/A
Table 1.1 Selection of clinical trials currently approved by the US FDA as of February 2008
a
a
 Data derived from multiple sources as reviewed in Mueller et al. (Mueller & Flotte, 
2008) 
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Figure 1.3  A schematic representation of the AAV-2 genome compared to a 
generalised recombinant AAV vector genome comprising a promoter and a transgene.  
In the vector, both the Rep ORF and Cap ORF are excised entirely, leaving the ITR 
sequences as the only remaining endogenous viral DNA in the vector. Figure 1.3 
adapted by the author from Russell and Kay, 1999. 
A 
B 
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 As mentioned in Section 1.2, AAV may integrate site-specifically into the host 
genome (Cheung et al., 1980; Kotin et al., 1990).  This further enhances the appeal of 
AAV as a gene therapy vector, as integration of a transgene might allow for stable 
expression, thereby eliminating the need for re-administration.  The ITR sequences, 
which each consist of a single strand of DNA in a T hairpin loop, contain a terminal 
resolution site (TRS), a Rep product binding site (RBS) as well as an exposed 3’ 
hydroxyl terminus (Figure 1.4), have a priming activity during viral replication and are 
involved in integration but do not control the specificity of integration (Russell & Kay, 
1999).  The specificity of integration instead appears to be controlled by products of the 
Rep ORF, which is generally removed in vector preps (Weitzman et al., 1994).    It is 
unclear whether this specificity can be retained in a vector whilst still maintaining a 
useful cloning capacity.  A loss of site-specificity raises the risk of a detrimental 
integration, potentially resulting in a loss of function mutation or perhaps oncogenesis, 
however it remains to be seen whether integration can be induced to occur with useful 
frequency, site-directed or otherwise. 
 AAV serotypes have widely varying tissue tropisms (Table 1.2).  AAV-1, for 
example, preferentially infects muscle tissue (Chao et al., 2000), whereas AAV-2 can 
infect a number of tissues such as muscle and the central nervous system but 
preferentially infects liver and kidney cells.  AAV-3 infects hematopoietic stem cells, 
and AAV-5 has a tissue tropism for the retina (Rabinowitz et al., 2004).  As new 
applications of the vectors based upon these serotypes are investigated, further tissue 
tropisms are being revealed (Wu et al., 2006). 
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Figure 1.4  Expanded schematic view of the secondary structure of one of the ITR 
flanking regions of the wild type and vector AAV-2 genomes.  The ITR consists of a 
single strand of DNA in a T hairpin loop.  The ITR also contains a terminal resolution 
site (TRS), a Rep product binding site (RBS) as well as an exposed 3’ hydroxyl 
terminus.  Figure 1.4 adapted by the author from Russell and Kay, 1999. 
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a
 Data derived from multiple sources as reviewed 
by Wu et al., 2006. 
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 By far the most attractive feature of AAV as a vector is the apparent lack of a 
significant inflammatory response, which has been examined in recombinant infection 
studies in animal models (Zaiss et al., 2002).  Nevertheless, there is clearly some form 
of immune memory to AAV in humans, as evidenced by extensive evidence of AAV 
specific antibodies in approximately 80% of sampled populations (Chirmule et al., 
1999; Erles et al., 1999).  Numerous studies have demonstrated that humoral memory 
for AAV-2 may impact negatively on transduction (Halbert et al., 1997; Xiao et al., 
1999; Xiao et al., 2000).  Although there was little evidence of cell-mediated 
recognition of AAV in humans at the commencement of this study (Chirmule et al., 
1999), more recent work has suggested that AAV may induce some cytotoxic responses 
(Chen et al., 2006; Manno et al., 2006; Sabatino et al., 2005).  It is possible that, given 
the poor inflammatory responses, the initiation of this memory may be heavily 
influenced by inflammation in response to the presence of pathogenic helper viruses 
during natural infection (Atchison, 1970; Buller et al., 1981; Schlehofer et al., 1986).  
Because adaptive immunity to AAV-2 is induced, it is clear that understanding of the 
immune response to the virus must be improved if AAV vectors are to be used 
effectively in a clinical setting. 
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1.3  IMMUNE RESPONSES TO AAV AND AAV VECTORS 
1.3.1 Innate immunity to AAV-2 
 The modesty of AAV-specific immune responses reported to date have 
suggested a reduced risk of vector or transduced cell destruction following 
administration (Zaiss et al., 2002; Zaiss & Muruve, 2005).  The innate immune response 
to AAV-2 appears to be weak and transient in animal models and in vitro (Ohshima et 
al., 2008; Stilwell & Samulski, 2004; Zaiss et al., 2002).  In mice, transient type 1 
interferon and TNF-α mRNA production was shown to be induced following AAV-2 
transduction of the liver (Zaiss et al., 2002).  Despite this, there was no detection of 
IFN-γ, IL-6 or IL-1β in that study.  Similarly, transient expression of the chemokines 
RANTES, MIP-1β and MIP-2 has been observed in mouse models but only at 
exceptionally high AAV-2 doses (1×10
11
 total particles) (Zaiss et al., 2002).   
 The response in the murine liver appears to be entirely dependent on the 
presence of liver dendritic cells (DC) (Zaiss & Muruve, 2005) as depletion of these cells 
appears to abrogate the innate response.  Macrophage inhibitory cytokine (MIC-1) and 
interferon-induced staf50 are increased in fibroblasts cell cultures exposed to AAV 
capsid proteins (Stilwell & Samulski, 2004) and some infiltration of neutrophils, 
monocytes and NK cells is observed in livers of mice inoculated with AAV-2 (Zaiss et 
al., 2002).  In another animal model, canine bone marrow-derived DC could be 
activated by AAV-2 transfection and led to elevated CD80, CD86 and IFN-β mRNA 
(Ohshima, Shin et al. 2008).  Despite these data, little is known about the course of the 
innate response to primary AAV-2 infection in humans, beyond the prevalence of 
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infection (Blacklow et al., 1968b; Gao et al., 2004).  AAV-2 sequences have been 
detected in the total cellular DNA of greater than 6% of adult humans, with most 
frequent detection in the liver and bone marrow (Gao et al., 2004).  AAV-2 was also 
isolated from 23% of children examined in an US nursery population (Blacklow et al., 
1968a).   
 The classical complement pathway is only induced weakly by high titres of 
AAV-2 and the virus does not activate the alternative complement pathway (Zaiss et al., 
2008).  The AAV-2 capsid binds complement protein iC3b and Factor H, both of which 
regulate the complement cascade by blocking the cleavage of C3 into C3a and C3b 
(Zaiss et al., 2008).  The prevalence of active AAV-2 infection and the viral tropism for 
the liver, raise the possibility that innate responses in humans might resemble those seen 
in mice; however no immunological data are available on the response to AAV-2 in 
human tissues. 
 
1.3.2  Adaptive immunity to AAV-2 
 The introduction of an AAV vector into an organism presents the adaptive 
immune system with two potential targets.  Firstly there is the transgene product, which 
could be presented in the context of MHC class I on the target cell.  However, an 
immune response to a transgene product is not an issue specific to AAV-based vectors, 
unless it is found that the vector itself in some way modulates that response.  The second 
potential target is the vector itself, processed elements of which might be presented to 
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CD8
+
 cytotoxic T-cells via MHC class I molecules on target cells or MHC II on 
professional antigen presenting cells (APC), if APC are transduced or have engulfed 
vector particles.  It is also possible that both phagocytic cells and the vector target cells 
might process the exogenous protein of the viral vector via an alternative antigen 
processing pathway (cross-presentation) and present the resulting peptides in the context 
of MHC class I (Peter et al., 2005).  The vector capsid may also be recognised by the 
humoral response, being either directly recognised by naive B cells or via T-cell-
dependent or independent activation.  AAV does not carry any matrix proteins within 
the capsid at the time of infection, a factor which limits the number of potential 
exogenous antigens to the VP capsid proteins only.   
 Despite the modest innate responses to AAV-2 (Ohshima et al., 2008; Zaiss et 
al., 2002), observation of the adaptive humoral response in animal models has 
demonstrated that AAV-2 infection consistently generates robust primary responses 
including neutralising antibody (Chirmule et al., 2000; Halbert et al., 1997; Halbert et 
al., 1998; Xiao et al., 1999; Xiao et al., 2000).  The humoral immune response to AAV-
2 has been characterised in humans, but with varied reports of seroprevalence between 
30-96% depending on the population sampled (Chirmule et al., 1999; Erles et al., 1999; 
Halbert et al., 2006).  This broad range might reflect the lack of standardised methods 
for assessing AAV-2 serology.  AAV-2 infection is thought to have occurred in at least 
20% of humans before the age of 10 years (Erles et al., 1999).  The detection of AAV 
DNA in amniotic fluid also suggests that virus may be present at birth in many humans, 
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possibly due to reactivated latent infection in the mother during pregnancy (Tobiasch et 
al., 1994). 
 The cell-mediated adaptive immune response to AAV has received little 
attention and there has been some assumption that AAV does not provoke a significant 
response (Büning et al., 2003; Hernandez et al., 1999).  The detection of AAV-2-specific 
IgM (Erles et al., 1999) might indicate that AAV-2 behaves like a T-cell independent 
antigen.  However there is evidence of notable cell-mediated responses to AAV-2 from 
a recent gene therapy trial which reported declining transgene expression and 
indications of tissue damage, with a concurrent CD8
+
 cytotoxic T-cell response (Manno 
et al., 2006).  Mouse models have since been used to characterise some CD8
+ T-cell
 
responses to AAV-2 in greater detail, demonstrating that exogenously-derived AAV-2 
capsid epitopes are cross-presented to CD8
+
 cytotoxic T-cells and that cytotoxic 
responses can be directed against transduced cells (Chen et al., 2006; Li et al., 2009; Li 
et al., 2007; Wang et al., 2007).  However inbred mouse strains display limited MHC 
diversity in comparison to the highly polymorphic human HLA genes, and cell-mediated 
immunity in mice may not reflect immunity in human populations.   
 The detection of CD8
+
 recognition of AAV-2 implies the presence of CD4
+
 T 
helper cell responses, as these are typically a pre-requisite for cytotoxic responses.  
There is some evidence of CD4
+
 helper T-cell responses to AAV-2 capsids in humans 
(Chirmule et al., 1999) and mice (Chen et al., 2006).  Chirmule’s group observed 
PBMC proliferation along with some IFN-γ production in cultures from a small subset 
of human donors, a finding suggestive of a Th1 response.  Chen’s group identified MHC 
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class II restricted epitopes on the AAV-2 capsid which stimulated IFN-γ production in 
mouse T-cells, again indicating CD4
+
 recognition.  The modest CD4
+
 responses 
observed to date contrast with the robust CD4+ recall responses to the related 
Parvovirus B19 (B19V) previously found in PBMC cultures from late convalescent 
adults (Corcoran et al., 2000).  Based on the emerging data on cellular responses to 
AAV-2 in humans and animal models, it is clear that the cell-mediated response to 
AAV-2 needs further characterisation in the natural host if the virus is to be used 
confidently in a clinical setting. 
 
1.4  STEM CELLS 
 In 1908 Alexander Maksimov suggested the use of the term “stem cell” to 
describe cells of a highly potent nature which he had earlier postulated to exist in the 
bone marrow (Maximow, 1906).   However, the stem cell hypothesis remained 
unsupported until 1963 when McCulloch and Till demonstrated the colony-forming 
capacity of a subpopulation of spleen cells (Siminovitch et al., 1963).  They also showed 
that the colony forming cells were clonal in nature (Becker et al., 1963).  This work 
demonstrated one of the key traits now associated with stem cells; extended self-renewal 
in an undifferentiating state.  Embryonic stem cells were first isolated from the 
blastocyst stage of murine embryo development in 1981 (Martin, 1981) but it was not 
until 1998 that embryonic stem cells could be reliably isolated from human blastocysts 
and cultured (Thomson et al., 1998).  Ethical issues surrounding embryonic stem cell 
research, in particular issues pertaining to the storage and usage of human embryos in 
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research, have hampered the development of the field considerably (Wert & Mummery, 
2003).  However, research into various forms of adult-derived stem cells has continued 
apace since their initial characterisation in cord blood samples in 1978 (Prindull et al., 
1978).   
 Stem cells are a highly diverse group of cells sharing a number of key features 
which make them of interest in therapeutic research.  The cells are typically defined in 
functional terms as being unspecialised, self-renewing cells which may differentiate in 
vivo to generate cells of a specific tissue type or of multiple different types (Moore & 
Lemischka, 2006).  Thus the two key features used to classify stem cells are typically 
the capacity for self-renewal and the capacity to produce specialised cells.    
Differentiation should arise from asymmetric cell division, whereby two daughter cells 
are generated; one remaining of the stem cell type and the other differentiating into a 
specialised cell type.  On the basis of the extent of this development potential, potency, 
plasticity or differentiation capacity, stem cells may broadly classified as totipotent, 
pluripotent or multipotent (Martinez-Agosto et al., 2007; Temple, 2001). 
 Totipotent stem cells are capable of producing cells of all types either directly or 
via further differentiation into less potent stem cells (Mountford, 2008).  This potency 
extends to the production of extraembryonic cells such as the cells of the amniotic 
membrane and placenta.  The pluripotent cells of the blastocyst, by contrast cannot 
produce extraembryonic cells but can differentiate into less potent stem cells of all three 
germ layers; the endoderm, mesoderm and ectoderm which give rise to all of the tissues 
and organs of triploblastic animals (Martinez-Agosto et al., 2007).  The stem cells of 
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these layers are typically referred to as multipotent and are typically capable of 
differentiation into cells of only their specific germ layer or tissue origin.   
 Multipotent stem cells are not confined to the tissues of developing embryos or 
foetuses but can be found in many tissues of adult animals (Mountford, 2008).  
Typically these multipotent cell types function to replace dead or damaged cells in their 
respective tissues.  The perception that adult stem cells were typically unipotent and thus 
less flexible in differentiation function than ES cells resulted in a much greater focus on 
ES cells in therapeutic research.  However, the observation that adult stem cells may 
display multipotency (Jackson et al., 1999) and possibly pluripotency (Verfaillie, 2002) 
has generated renewed interest in adult stem cell lineages as therapeutic agents.   
 First identified and studied amongst the adult stem cells initially were the 
hematopoietic stem cells (HSC) found in the bone marrow (Shizuru et al., 2005), 
peripheral blood and cord blood (Prindull et al., 1978).  These cells were shown firstly 
to restore cell populations of the hematopoietic lineage (Hellman et al., 1970) and later 
cells of non hematopoietic lineage such as muscle, liver and lung (Jackson et al., 1999; 
Krause et al., 2001; Lagasse et al., 2000).  The cells are relatively well characterised in 
terms of cell surface markers, with CD34 generally considered to be a marker for 
hematopoietic potential, although this appears to vary over the developmental lifetime of 
the cell (Matsuoka et al., 2001).  
 Another population of stem-like cells is found in the bone marrow, termed 
mesenchymal stem or marrow stromal cells (MSC), a cell type first identified by 
Friedenstein in 1966.  The cells were fibroblast-like, adherent cells growing in bone 
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marrow cell culture (Friedenstein & Petrokova, 1966).  MSC form part of the stromal 
trabecular scaffold, a structure closely associated with the endosteum and which 
interacts with hematopoietic stem cells (HSC) (Sakaguchi et al., 2004).  Human MSC 
were first isolated from postnatal bone marrow (Friedenstein et al., 1974).   They have 
been identified in diverse tissues such as skeletal muscle (Jankowski et al., 2002), 
adipose tissue (De Ugarte et al., 2003; Gronthos et al., 2001), periosteum, trabecular 
bone and deciduous dental pulp (Miura et al., 2003).  In their undifferentiated state, 
MSC are spindle-shaped adherent cells (Friedenstein & Petrokova, 1966).  Irrespective 
of origin, these cells have the capacity for extended self-renewal in an unspecialised 
state in culture.  They also have the potential to differentiate into cartilage, bone, 
adipose tissue, skeletal and cardiac muscle, tendon, ligament, neural precursors, 
endothelial cells and pancreatic islet cells (Chen et al., 2004; Crigler et al., 2006; Ogura 
et al., 2004; Oswald et al., 2004; Pittenger et al., 1999; Wakitani et al., 1994).   
 Although MSC have been isolated from diverse tissues, the bone marrow 
remains the best characterised source, with an estimated prevalence of between 0.001% 
and 0.01% of the total bone marrow cell population (Pittenger et al., 1999).  Despite 
being relatively rare in the marrow, MSC are readily isolated and expanded in vitro by 
isolation of mononuclear cells and culture of adherent cells in medium containing FCS 
(Bruder et al., 1997). 
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1.5  MESENCHYMAL STEM CELLS 
 A definitive characterisation of MSC remains a challenge, with many sources in 
the literature providing vague or conflicting definitions (Bianco et al., 2008).  Cell 
populations that might also be defined as MSC are also often identified as marrow 
stromal cells or marrow progenitor cells.  Differences in phenotypic and functional 
characteristics are likely to be due to the lack of agreed methods for MSC isolation.  
There are significant differences between research groups regarding tissue origin, 
isolation methods and culture conditions (D'Ippolito et al., 2004; Kucia et al., 2006; 
Pittenger et al., 1999). 
 Another source of ambiguity is the lack of any unique cell surface marker for 
human MSC.  Despite these conflicts, some consensus can be found amongst the 
research groups as to how MSC are defined.  Cell surface receptors such as Stro1, 
CD29, CD44, CD73, CD90, CD105 and CD166 are typically expressed on MSC 
regardless of tissue of origin (Barry et al., 2005; Ryan et al., 2005).  By contrast, it is 
agreed that hematopoietic lineage markers such as CD11b, CD14 and CD45 should not 
be expressed (Barry et al., 2005; Ryan et al., 2005).  A similarly conflicting set of data 
defines MSC functional characteristics.  It is generally agreed that MSC adhere to tissue 
culture grade plastic within the first 5 days of culture isolation, that they should form 
fibroblast-like colonies and display a fibroblast-like, stellate or spindle-like morphology 
(Pittenger et al., 1999).  Also, MSC are multipotent and can differentiate into 
fibroblasts, osteocytes, chondrocytes and adipocytes (Chen et al., 2004; Crigler et al., 
2006; Ogura et al., 2004; Oswald et al., 2004; Pittenger et al., 1999; Wakitani et al., 
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1994).  Murine MSC share similar phenotypic and functional traits, some MHC class I 
surface expression along with Sca-1, CD44, CD90, CD105, CD106, but no MHC class 
II, CD11b, CD11c, CD14 or CD45 (English et al., 2007). 
 The bone marrow can also give rise to a number of cell populations with stem 
cell-like properties, but which differ from MSC. One population, termed multipotent 
adult progenitor cells (MAPC), are indirectly isolated from marrow tissue, from long-
term culture (Jiang et al., 2002b).  Isolation was initially from culture of greater than 6 
months in media supplemented with epidermal growth factor (EGF), platelet-derived 
growth factor (PDGF-BB), and leukaemia inhibitory factor (LIF).  These cells have been 
isolated from human, mouse and rat long-term culture.  They are characterised 
phenotypically as expressing SSEA-1, Oct-3, Oct-4 and Rex-1 but being negative for 
cKit, MHC I, MHC II, CD31, CD34, CD44 and CD45 (Reyes & Verfaillie, 2001).  
Functionally, the cells display a capacity to differentiate in vitro beyond mesenchymal 
cell types to give astrocytes, endothelial cells and hepatocytes (Jiang et al., 2002a).  It 
has also been shown that these cells can be isolated from diverse mouse tissues such as 
the brain and skeletal muscle (Jiang et al., 2002b).   
 Marrow-isolated adult multilineage-inducible (MIAMI) cells are another 
multipotent bone marrow population (D'Ippolito et al., 2004).  The cells are isolated by 
adhesion to fibronectin coated dishes.  They express the Oct-4 and Rex-1 transcription 
factors under hypoxic culture conditions and have been shown to differentiate into the 
mesenchymal stem cell lineages as well as neural and pancreatic lineages (D'Ippolito et 
al., 2004).  In 2006, a population of very small embryonic-like (VSEL) cells was 
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isolated from murine bone marrow.  VSEL cells are phenotypically positive for Sca-1, 
CD45, SSEA-1 and positive for the transcription factors Oct-4, Nanog, Rex-1 and Rif-1 
(Kucia et al., 2006).  When cultured using a sarcoma feeder cell layer, VSEL cells form 
embryoid bodies (Kucia et al., 2006).  Another population with similarities to MSC 
were isolated from human cord blood.  The cells, dubbed unrestricted somatic stem cells 
(USSC), display a capacity to differentiate into hepatic cells and cardiomyocytes 
(Kogler et al., 2004).  At least one study has suggested that MSC-like cord blood cells 
cannot form fibroblastic colony forming units (CFU-F), a trait that stands in marked 
contrast to bone marrow MSC (Wexler et al., 2003).   MAPC, VSEL and MIAMI cells 
have only been derived from culture and it is unclear whether these represent 
populations which exist normally in vivo (D'Ippolito et al., 2004; Jiang et al., 2002b; 
Reyes & Verfaillie, 2001). 
 
1.5.1  Heterogeneity and ageing of MSC 
 The cells typically isolated using most MSC isolation protocols are functionally 
heterogeneous and may contain a mixture of undifferentiated progenitors and lineage-
restricted precursors with varying differentiation capacities (Muraglia et al., 2000).  This 
heterogeneity within isolated populations is further compounded by differences between 
the populations isolated by different groups.  The results of efforts to culture and 
differentiate MSC have shown highly variable results (Jiang et al., 2002a; Pittenger et 
al., 1999) and thus the molecular mechanisms that control MSC self renewal and 
differentiation are difficult to study.  As MSC are increasingly studied for characteristics 
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such as immunomodulation, the heterogeneity introduced during isolation as well as the 
lack of standardised isolation protocols are likely to further impact on the comparability 
of data sets between groups as well as the objective reproducibility of results. 
 One of the defining characteristics of stem cell is their potential for self-renewal 
over extended culture times.  This self renewal is based on clonal expansion, a form of 
mitosis resulting in two identical daughter cells (Bruder et al., 1997).  The molecular 
mechanisms which govern this capacity for self renewal are not well understood and 
much research is ongoing into the factors which control MSC decisions to clonally 
expand or differentiate, functions which need to be controllable if MSC are to be 
clinically useful.  Self-renewal has been broadly associated with telomerase activity 
(Greenwood & Lansdorp; Parsch et al., 2004).  Telomeres are regions of repetitive DNA 
found at the ends of chromosomes which protect the chromosome from damage during 
chromosomal replication.  Telomeres are replenished and extended by telomerase and 
without the activity of this enzyme, cell proliferation ceases and the cell undergoes 
senescence.   
 It has been observed that the decline in stem cell self-renewal correlates with a 
decline in telomere length and telomerase activity.  In contrast to ES cells, MSC have a 
reduced capacity for self-renewal due to reduced telomerase activity (Verfaillie, 2002).  
MSC can become senescent following repeated passaging in vitro culture (Bonab et al., 
2006; DiGirolamo et al., 1999) and a decrease in plasticity can also be observed in late 
passages (DiGirolamo et al., 1999).  Other studies have shown that donor age affects the 
rate of in vitro senescence in MSC (Stenderup et al., 2003).  Cell age, be it due to long 
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term passage or donor aging, increases the probability of transformation due to the 
accumulation of chromosomal abnormalities.  This tendency highlights the risk of 
possible tumour development in a therapeutic setting and indeed some studies have 
demonstrated spontaneous transformation in both human and murine MSC (Miura et al., 
2006; Rubio et al., 2005).  These findings suggest that early passages of MSC should be 
used in therapy to avoid the risk of transformation and should thus be the main focus of 
research to that end. 
 
1.5.2  MSC potency 
 It has generally been assumed that the differentiation of pluripotent stem cells 
into germ layer stem cells during embryogenesis is an irreversible event and that all of 
the subsequently differentiating stem cells, progenitor cells and mature cells of each 
lineage maintain that specification throughout adulthood.  It has however been found 
that adult stem cells can differentiate into tissues of an alternate germ origin (Rossant, 
2006; Wagers & Weissman, 2004).  This capacity to differentiate is termed adult stem 
cell potency, and several mechanisms have been proposed to account for this effect.  
Some studies have suggested that stem cells will undergo de-differentiation to a more 
potent cell type before undergoing differentiation into a cell of the trans-tissue origin, a 
process referred to as trans-differentiation.  It has also been proposed that trans-
differentiation may be mediated by signals in the new local microenvironment (Okada, 
1980).  Alternatively, it has been suggested that potency in therapeutic settings is 
acquired as a result of cell-cell fusion between donor stem cells and host tissue cells 
30 
 
(Wang et al., 2003).  Gender mismatched bone marrow derived cells were shown to 
undergo fusion with recipient hepatocytes.  Cytogenic analysis of the repopulated 
hepatocytes showed that the cells were found to be heterozygous for donor-specific 
alleles indicating incidences of diploid to diploid fusion and diploid to tetraploid fusion 
(Wang et al., 2003).  Contradicting this, Tran et al. showed that trans-differentiation and 
not cell-cell fusion was responsible for differentiation of bone marrow-derived cells into 
epithelial cells (Tran et al., 2003).  The group demonstrated that male bone marrow 
transplant into female recipients resulted in the detection of diploid Y-chromosomal 
buccal cells, ruling out the involvement of cell-cell fusion. 
 It is clear that the means by which multipotent cells exhibit greater plasticity is 
not well understood and it is likely that a combination of the mechanisms investigated 
are at work in the in vivo setting.  Although the level of potency exhibited in these 
studies support the hypothesis that cells with potency close to pluripotency exist within 
the adult, it is not yet clear whether such cells are common or truly present in vivo rather 
than being an artefact of cell culture techniques. 
 Differentiation is tightly regulated and controlled by various transcription 
factors, cytokines, growth factors and extracellular matrix molecules.  The regulation of 
adult stem cell differentiation involves transcriptional modification.  Several genes have 
been identified whose expression is increased during MSC differentiation into 
osteocytes, adipocytes and chondrocytes, which may represent master control genes 
(Baksh et al., 2004; Song et al., 2006).  Song et al. identified eight genes covering a 
broad range of cellular functions, suggesting the complexity of differentiation 
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commitment.  The genes included period homolog1 (PER1), nebulette (NEBL), 
neuronal cell adhesion molecule (NRCAM), FK506 binding protein 5 (FKBP5), 
interleukin 1 type II receptor (IL1R2), zinc finger protein 145 (ZNF145), tissue inhibitor 
of metallo-proteinase 4 (TIMP4), and serum amyloid (Song et al., 2006).  It appears that 
adipogenesis is regulated by the nuclear receptor and transcription factor peroxisome 
proliferators-activated receptor gamma (PPAR-γ) as well as fatty acid synthase.  
Adipogenesis can be suppressed by IL-1 and TNF-α through the NF-κB pathway 
(Suzawa et al., 2003).  Some cell signalling pathways that have been implicated in stem 
cell differentiation include the Stat3, Notch, TGF-β and Wnt pathways.  Notch activity 
has been shown to affect a diverse range of developmental processes controlling cell 
differentiation, proliferation, morphogenesis and organ formation (Artavanis-Tsakonas 
et al., 1995). It has also been shown that components of this signalling pathway showed 
altered transcriptional regulation during human EC and ES cell differentiation (Walsh & 
Andrews, 2003).  Bone morphogenic protein (BMP) plays an important role in a number 
of diverse embryonic events including the induction of mesoderm, hematopoeisis and 
epidermis formation and signals via the TGF-β pathway (Johansson & Wiles, 1995; 
Wiles & Johansson, 1999).  It has been recently suggested that the self-renewal of 
murine HSC (Reya et al., 2003) and osteogenesis in murine MSC are regulated by the 
Wnt/β-catenin signalling pathway (Chang et al., 2007).   
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1.5.3  MSC biology in vivo 
 MSC contribute to the repair of tissue damage in vivo (Amado et al., 2005), but 
evidence of significant engraftment or in vivo differentiation is less convincing (Iso et 
al., 2007).  Despite initial encouraging results from in vivo studies, it has not been 
conclusively demonstrated that adult stem cells engraft and differentiate into the 
required specialised tissues to repair damaged or diseased tissue (Jones & McGonagle, 
2007).  It is now believed that factors secreted by MSC, such as hepatocyte growth 
factor (HGF), are responsible for promoting the survival repair and proliferation of 
injured cells or through promotion or resident local progenitors (Crigler et al., 2006; 
Zwezdaryk et al., 2007).  This hypothesis is supported by observations that MSC 
express the interleukin 1 receptor antagonist (Ortiz et al., 2007) which alters the tissue 
microenvironment. 
 
1.6  MSC IMMUNOMODULATION 
 The non-embryonic source of MSC and their reduced likelihood of neoplasia due 
to a more limited differentiation potential, have made these cells attractive candidates 
for application in regenerative medicine (Barry & Murphy, 2004).  However, whilst 
self-derived MSC should pose few immunological problems, in practice regenerative 
medicine is likely to rely on banked, HLA-mismatched (allogeneic) cells to repair or 
replace damaged tissue.  Normally, allogeneic cells are deleted by the host immune 
response (Cerottini & Brunner, 1974).  Surprisingly however, there have been many 
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findings which demonstrate that MSC do not obey the normal rules of allogeneic 
rejection (Aggarwal & Pittenger, 2005; Spaggiari et al., 2006; Tse et al., 2003).   
 MSC possess a wide variety of immunomodulatory capabilities (Figure 1.5), 
constitutively producing Th suppressive cytokines such as prostaglandin E2 (PGE2) and 
transforming growth factor beta 1 (TGF-β1).  When stimulated with IFN-γ MSC will 
also produce indoleamine 2,3-dioxygenase (IDO) which is known to inhibit T-cell 
proliferation and NK function (Frumento et al., 2002; Meisel et al., 2004).  Numerous 
studies have demonstrated that both murine and human MSC suppress both alloantigen-
and mitogen-driven T-cell proliferation in vitro (Di Nicola et al., 2002; Glennie et al., 
2005; Krampera et al., 2003; Ryan et al., 2005).  It has similarly been shown that MSC 
physically hindered B cell proliferation (Augello et al., 2005), and inhibited NK cell 
proliferation and cytotoxicity (Spaggiari et al., 2006).   
 Murine MSC responded to stimulation with Pam3Cys, a ligand for TLR2, by 
producing increased IL-6, as well as reducing their basal motility, increasing clonal 
expansion and reducing differentiation along the osteogenic, adipogenic and 
chondrogenic pathways (Pevsner-Fischer et al., 2007) (Figure 1.5).  Stimulation of TLR 
3 and 4 in human MSC results in increased IDO activity.  Given than MSC have been 
demonstrated to express mRNA for TLR 1-8, it is likely that they are sensitive to other 
innate immune signals (Opitz et al., 2009; Pevsner-Fischer et al., 2007).  MSC also 
possess receptors for a range of soluble factors associated with adaptive immune 
responses including receptors for IFN-γ, IL-13, IL-10, IL-17 and IL-4 suggesting a 
capacity to respond differentially to local Th1, Th2, T-reg and Th17 responses (da Silva 
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Meirelles et al., 2008; Silva et al., 2003).  MSC also express receptors for a range of 
chemokines including CCR1, CCR4, CCR7, CCR10 and CXCR5 (Von Lüttichau et al., 
2005).  The broad palette of immune receptors and homing receptors expressed by MSC 
suggests a highly responsive, versatile and complex relationship with both the innate 
and adaptive arms of the immune response and it is likely that further investigations will 
continue to yield a diversity of interactions between MSC and the immune system. 
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  MSC appear to maintain their immunomodulatory functions even in models of 
inflammation (English et al., 2007).  Incubation of murine MSC with the pro-
inflammatory cytokines IFN-γ and TNF-α did not negatively impact upon MSC-
mediated immunosuppression of splenocyte proliferation.  Furthermore, expression of 
PGE2, programmed death ligand 1 (PD-L1) and IDO was differentially regulated by the 
two cytokines.  Cyclooxegenase 2 (COX-2) and PGE2 expression was upregulated by 
both IFN-γ and TNF-α whilst the surface expression of PD-L1 was induced by IFN-γ 
but not TNF-α.  Using blocking studies, English et al. demonstrated that PD-L1 
induction was non-essential in the suppressive role of MSC, whilst IDO appeared to be a 
pre-requisite (English et al., 2007).  Similar studies in humans have shown that IFN-γ 
stimulation enhances MSC-mediated suppression of T-cell proliferation, and that TNF-α 
and IFN-γ stimulation of human MSC produces differential phenotypes similar to those 
seen in murine studies (Ryan et al., 2007). 
 MSC also appear to modulate dendritic cell (DC) function.  In a study by English 
et al. in 2008, DC co-cultured with murine MSC and stimulated with TNF-α failed to 
upregulate maturation markers (English et al., 2008).  MSC were also shown to reduce 
the capacity of ovalbumin-pulsed DC to support antigen specific CD4+ T-cell 
proliferation. Co-culture of MSC with DC resulted in reduced expression of CCR7 by 
DC following stimulation and significantly less DC migration in response to CCL19.  
MSC also prevented loss of E-cadherin by DC, a protein which functions to anchor DC 
to tissues (English et al., 2008). 
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 The capacity for MSC to escape immune recognition and to suppress T-cell 
activation, both in vivo and in vitro, is counterintuitive and it is difficult to suggest an 
evolutionary benefit for such a function given that allotransplanation is a procedure with 
no obvious natural analogue.  The only comparable natural occurrence in mammals is 
the induction of maternal tolerance of the fetal allograft, raising the possibility that MSC 
immune evasion in allogeneic conditions is an exapted function that may share many 
features with the fetal immune evasion.  A number of in vivo studies have suggested a 
role for MSC in the acquisition of alloantigen tolerance.  Koc et al. showed no evidence 
of alloreactive T-cells and no incidence of GVHD when allogeneic MSC were 
transplanted into patients with Hurler’s syndrome or metachromatic leukodystrophy 
(Koc et al., 2002).  
 
1.7  TRANSFECTION AND TRANSDUCTION OF MSC 
 The recognition of viral-based gene therapy vectors by the recipient immune 
system may be a significant obstacle to meeting safety and efficacy requirements 
(Hacein-Bey-Abina et al., 2008; Manno et al., 2006; Raper et al., 2003).  Although 
vector modification and recipient immunosuppression represent possible solutions to 
this problem (Halbert et al., 1998; Manning et al., 1998), an alternative strategy would 
be to conduct transductions on human cells ex vivo and then infuse those cells, now 
expressing the therapeutic gene product, into the recipient (Gadi et al., 2001).  Typically 
such a strategy would demand that the transduced cells be autologous to the recipient, 
which is not practical for all applications.  However, as MSC have been shown to evade 
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allorecognition (Barry et al., 2005; Ryan et al., 2005) and to have significant 
immunomodulatory capabilities (English et al., 2007; English et al., 2008; Ryan et al., 
2007), they may represent attractive candidate cells for such ex vivo transduction.  For 
certain applications such as tissue engineering, it may also be desirable to modify MSC 
to constitutively express cis-acting growth factors (Partridge & Oreffo, 2004).  Virally 
transduced MSC and transfected MSC have been investigated for use in tissue 
engineering (Partridge & Oreffo, 2004) and the delivery of therapeutics to tumours, into 
which MSC readily engraft (Mohr et al., 2008; Studeny et al., 2002).  Requirements of 
such applications are efficient transduction, stable transgene expression over an 
extended time and minimal cytotoxic effects.  It is also preferable to retain the other 
potential therapeutic characteristics of MSC, such as immunomodulatory capacity and 
potency. 
 A comparative study of several viral and non-viral gene delivery systems was 
carried out by McMahon et al. using bone-marrow derived rat MSC (McMahon et al., 
2006).  Lentiviral vectors gave transduction efficiencies of up to 95%, and resulted in 
only low levels of MSC toxicity.  MSC potency was also not affected by the 
transduction protocol.  Adenovirus-based vectors also proved relatively effective, but a 
significant dose-dependent increase in cell death was observed.  Rat MSCs were 
refractory to transduction by AAV serotypes 1, 2, 4, 5, and 6.  Transfection using 
plasmid DNA with Lipofectamine resulted in moderate transfection levels at the cost of 
some cytotoxicity.  Electroporation was both highly cytotoxic and failed to produced 
adequate transfection (McMahon et al., 2006).   
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 Human MSC transduced with an adenovirus-based vector carrying the apoptosis-
inducing TNF-related apoptosis-inducing factor (TRAIL) gene were shown to give 
efficient induction of TRAIL production and to inhibit the growth of A549 xenografts in 
mice (Mohr et al., 2008).  Ad-transduced MSC did not induce PBMC proliferation in 
vitro, allaying concerns that Ad transduction might render the MSC more immunogenic.  
The majority of gene therapy treatments for bone repair investigated to date have also 
used vectors based on adenovirus (Chang et al., 2003; Kofron & Laurencin, 2006; 
Lieberman et al., 1998).  Typically the transgenes delivered are members of the bone 
morphogenetic protein (BMP) family.  BMP2-producing murine MSC induced 
heterotrophic bone formation when administered to severe combined immune deficient 
mice (Lieberman et al., 1998).   
 Viral-based vector systems are generally held to be preferable for MSC 
applications, particularly those based on lentivirus and adenovirus (Chang et al., 2003; 
McMahon et al., 2006; Mohr et al., 2008) due to their well-established safety profile in 
conventional gene therapy combined with optimal transduction efficiency and low 
cytotoxicity (Djeha et al., 2001; Kremer & Perricaudet, 1995; Levine et al., 2006).  
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1.8  AIMS 
 It was hypothesised that immune memory for AAV-2 in the Irish population may 
confound the use of AAV-2 vectors.  Although a thorough test of this hypothesis would 
require extensive clinical work beyond the scope of the present study, an examination of 
adaptive immune memory for AAV-2 in an Irish blood donor group (Chapters 3 and 4) 
would none-the-less provide evidence to support or reject this hypothesis.  Secondary to 
this hypothesis, it was suggested that confounding effects, if present, might be mitigated 
by identification and modification of common immunogenic elements of the AAV-2 
virus.  This hypothesis might be adequately tested by examination of in vitro responses 
to specific elements of the AAV-2 capsid (Chapter 5) in the Irish blood donor group 
previously examined.  Finally, it was hypothesised that AAV-2 might be a useful vector 
for the transduction of MSC.  This would be tested by performing in vitro transduction 
of murine MSC and examining the cultures for transgene product upregulation as well 
as verifying that the other therapeutic characteristics of MSC remain intact.  
Thus, the aims of this study were: 
a) To characterise the humoral immunological memory for AAV-2 in a human 
population (Chapter 3) 
b) To characterise the human cell-mediated recall response to AAV-2 in the same 
population (Chapter 4) 
c) To identify the AAV-2 capsid sequences recognised (epitopes) by the cell-
mediated human immune response (Chapter 5) 
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d) To assess the impact of AAV-2 transduction on murine MSC (Chapter 6). 
In this way, a greater understanding of AAV-2 interaction with the human immune 
system would be achieved and clinical/therapeutic practise could be refined. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 MATERIALS 
2.1.1  Materials for cell isolation and cell culture 
2.1.1.1  Low endotoxin fetal calf serum (LE FCS)  
 LE FCS (BioSera, East Sussex, UK) was heat-inactivated (LE HI FCS) at 60˚C 
for 20 minutes prior to being aliquoted for storage at -20˚C.  All new batches of LE FCS 
were batch tested for their capacity to stimulate lymphocyte proliferation (Section 
2.2.5.1) prior to use in culture media. 
2.1.1.2  Complete Roswell Park Memorial Institute medium 1640 (cRPMI) 
 cRPMI was constituted as RPMI 1640 (Invitrogen, Carlsbad, CA) with 1 unit/ml 
penicillin (Invitrogen), 1 µg/ml streptomycin (Invitrogen), 2mM L-glutamine 
(Invitrogen), 25 µM β-mercaptoethanol (Invitrogen) and 10% (v/v) LE HI FCS.  cRPMI 
was stored at 4˚C and warmed to 37˚C prior to use with cells.  cRPMI was used for all 
extended incubations involving human peripheral blood mononuclear cells (PBMC) or 
murine lymphocytes. 
2.1.1.3  Complete Hank’s balanced salt solution (cHBSS) 
 cHBSS was constituted as HBSS (Invitrogen) with 10 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid buffer (HEPES; Sigma-Aldrich) and 1% (v/v) LE HI 
FCS.  cHBSS was stored at 4˚C and warmed to 37˚C prior to use with cells.  cHBSS 
was used for the dilution of human whole blood and mouse spleen homogenates. 
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2.1.1.4  Complete Dulbecco’s modified Eagle’s medium (cDMEM) 
 cDMEM contained low glucose DMEM (Invitrogen) with 1 unit/ml penicillin, 1 
µg/ml streptomycin and 10% (v/v) LE HI FCS.  cDMEM was stored at 4˚C and warmed 
to 37˚C prior to use with cells.  cDMEM was used for thawing and long term culture of 
cryopreserved human embryonic kidney cells (HEK-293). 
2.1.1.5  Complete modified Eagle’s medium alpha (cαMEM)  
 cαMEM was constituted as MEM-α medium (Invitrogen) with 1 unit/ml 
penicillin, 1 µg/ml streptomycin, 2mM L-glutamine, 10% (v/v) LE HI FCS and 10% 
(v/v) HI horse serum (HS).  cαMEM was stored at 4˚C and warmed to 37˚C prior to use 
with cells.  cαMEM was used for thawing of cryopreserved murine mesenchymal stem 
cells (MSC) and for long term culture of MSC. 
2.1.1.6  OptiMEM (transfection studies) 
 OptiMEM (Invitrogen) was stored at 4˚C and warmed to 37˚C prior to use with 
cells.  OptiMEM was used serum-free for the dilution of transfection reagents. 
2.1.1.7  Media for cryopreservation 
 Human PBMC were suspended in RPMI 1640 (Invitrogen) supplemented with 
20% (v/v) heat inactivated LE FCS and 10% (v/v) dimethylsulphoxide (DMSO; Sigma-
Aldrich, Arklow, Ireland).  Murine MSC were suspended in MEM-α supplemented with 
20% (v/v) LE FCS and 10% (v/v) DMSO (Sigma-Aldrich).  HEK293 cells were 
suspended in DMEM supplemented with 20% (v/v) LE FCS and 10% (v/v) DMSO. 
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2.1.1.8  Trypsin-ethylenediaminetetraacetic acid (EDTA) 
 0.25 mM Trypsin-EDTA (Invitrogen) was used to detach adherent MSC and 
HEK293 cells from culture vessels.  Trypsin-EDTA was stored at -20˚C and warmed to 
37˚C before use with cell cultures. 
2.1.1.9  Phosphate buffered saline (PBS) 
 PBS was used at a working concentration of 137 mM NaCl, 10 mM sodium 
phosphate dibasic, 2.7 mM KCl, 2 mM potassium phosphate monobasic.  Buffer was 
prepared in dH2O and the pH was adjusted to 7.4.  The working dilution was made up 
from a 10x stock solution and was sterilised by autoclaving for all cell culture 
applications. 
2.1.1.10  Ethidium bromide / acridine orange (EB/AO) 
 EB/AO for viable cell counting (Sigma-Aldrich) was dissolved at a stock 
concentration of 1 µg/ml EB and 1 µg/ml AO in PBS.  Due to its carcinogenic 
properties, EB/AO-contaminated consumables and sharps were segregated and disposed 
of as chemically hazardous waste. 
 
2.1.2  Materials for molecular methods 
2.1.2.1  General materials for molecular methods 
 Water:  Nuclease-free distilled H2O (Promega, Dublin, Ireland) was used for 
dilutions of nucleic acid solutions.  TAE buffer:  Tris-acetate EDTA buffer was prepared 
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as a 10x stock solution containing 48.4 g of Tris base, 11.42 ml of glacial acetic acid, 
100 ml of 500 mM Na2 EDTA (pH 8.0) made up to 1000 ml with dH2O. 
2.1.2.2  Materials for RNA isolation 
 Trizol:  Trizol (Invitrogen) was stored at 4˚C and was used for lysis of all cell 
types.  Poly-acryl carrier:  Poly-acryl carrier (Molecular Research Inc., Cincinnati, OH) 
was stored at 4˚C.  DNAse:  Genomic DNA was removed from RNA isolates by addition 
of DNAse I (118068-015; Invitrogen) as detailed in Section 2.2.4.1. 
2.1.2.3  Materials for cDNA synthesis 
 cDNA master mix:  Master mix for cDNA synthesis contained Superscript II 
reverse transcriptase (200 U/ml; Invitrogen), 5x first strand buffer (Y02353; Invitrogen), 
MgCl2 (25 mM; Promega), dNTP mixture (100 mM; Promega), Oligo dT primer (0.5 
mg/ml; Promega); dithiothreitol (0.1 M DTT; Invitrogen) RNAse inhibitor (10 U/ml; 
Invitrogen) prepared as described in method 2.2.4.2. 
2.1.2.4  Materials for polymerase chain reaction (PCR) 
 Primers:  Primers for detection of specific products are listed and detailed in full 
(Table 2.1).  All primers were designed using Primer3 (Whitehead Institute, Cambridge, 
MA), validated using NetPrimer (Premier Biosoft, Palo Alto, CA) and synthesised by 
MWG Operon, (Ebersberg, Germany).  PCR master mix:  Primers and cDNA were 
mixed with 10x thermophilic DNA polymerase buffer (M190A; Promega), MgCl2, 
dNTP mixture and Taq polymerase (GoTaq; Promega) as described in Sections 2.2.4.3 
and 2.2.4.4. 
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2.1.2.5  Materials for genomic DNA isolation 
 DNA was isolated from PBMC using a Generation Capture Column kit (Qiagen, 
California, USA) following the manufacturer’s protocol.  Briefly, cell suspensions were 
passed through a solid matrix column which lysed cells on contact whilst retaining 
DNA.  The column was then washed using a provided purification buffer before the 
DNA was eluted from the column at high temperature (95˚C) using the provided elution 
buffer. 
 
2.1.3  Materials for immunoassays 
2.1.3.1  General ELISA reagents 
 Flat bottomed, 96-well polystyrene microtitre plates (MaxiSorp; Nunc, 
Langenselbold, Germany) were used as the reactive surface for all ELISA experiments.  
PBS was prepared as in Section 2.1.1.9 without sterilisation.  0.05% (v/v) Tween 20 
(Sigma-Aldrich) in PBS was used as the normal washing buffer.  For the coating buffer, 
a 100 mM solution of NaHCO3 in dH2O and a 100 mM solution Na2CO3 in dH2O were 
Primers were designed using Primer 3 based on the coding IDO or GAPDH coding 
sequences.  Primers were synthesised by MWG Operon. 
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mixed in a ratio 7:3.  This solution was then diluted 1:3 in dH2O.  Coating buffer was 
stored at 4˚C and used within 1 week.  Streptavidin-horseradish peroxidise (Strep-HRP; 
RPN1231V; GE Healthcare) was used for colorimetric detection of biotinylated 
detection antibodies in all ELISA experiments.  3,3’,5,5’-Tetramethylbenzidine (TMB; 
Sigma-Aldrich) was used as a substrate for strep-HRP in all ELISA experiments. 
2.1.3.2  Materials for total IgG ELISA 
 0.5% (v/v) Tween 20 (Sigma-Aldrich) in PBS was used as a highly concentrated 
washing buffer during some steps.  AAV-2 antigen was as described in Section 2.1.5.1.  
Antigen was diluted in using carbonate coating buffer and adsorbed onto to polystyrene 
plates.  The reactive surface was blocked using PBS containing 5% (w/v) Sucrose 
(Sigma-Aldrich), 1% (w/v) BSA and 0.05% (v/v) Tween 20.  1% (w/v) skimmed milk 
powder (Marvel) in PBS was used for the dilution of analyte samples and detection 
antibody.  Anti-human IgG conjugated to biotin (Sigma-Aldrich) diluted in reagent 
diluent, was used for analyte detection. 
2.1.3.3  Materials for IgG subclass ELISA 
 Anti-human IgG1, 2, 3 and 4 antibodies conjugated to biotin (Merck, 
Nottingham, England) and diluted in reagent diluent, were used for IgG1, 2, 3 and 4 
analyte detection, respectively.  A pooled control serum containing standardized 
concentrations of human IgG subclasses 1, 2, 3 and 4 (Nordic Labs, Tilburg, Holland) 
was used as a reference serum and was directly coated to the assay plate. 
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2.1.3.4  Materials for cytokine ELISA 
 5% (w/v) BSA was dissolved in PBS and mixed overnight at 4
o
C and used as a 
blocking buffer for IL-10 and IFN-γ ELISA experiments.  Buffer was stored at 4oC and 
used within 1 week.  The reagent diluent was 1% (w/v) Marvel milk powder dissolved 
in PBS and mixed overnight at 4
o
C.  Diluent was stored at 4
o
C and used within 2 days.  
RPMI 1640 (Invitrogen) was used as a diluent for the recombinant IFN-γ and IL-10 
standards as supernatant samples were dissolved in cRPMI.  Anti-human IL-10 
(Immunotools, Friesoythe, Germany), diluted in carbonate coating buffer served as a 
capture antibody for IL-10.  Anti-human IFN-γ (Immunotools), diluted in carbonate 
coating buffer was used as a capture antibody for IFN-γ.  Anti-human IL-10 biotin 
(Immunotools) was diluted in reagent diluent and was used as a detection antibody for 
IL-10.  Anti-human IFN-γ biotin (Immunotools) was diluted in reagent diluent and 
served as a detection antibody for IFN-γ.  Recombinant human IL-10 (rhIL-10) 
standards (Immunotools) were serially diluted in standard diluent.  Recombinant human 
IFN-γ (rhIFN-γ) standards (Immunotools) were also serially diluted in standard diluent. 
 5% (w/v) sucrose and 1% (w/v) bovine serum albumin (BSA; Sigma-Aldrich) 
were dissolved in PBS and mixed overnight at 4˚C.  This buffer served as a blocking 
reagent for the IL-13 ELISA.  Blocking buffer was stored at 4˚C and used within 1 
week.  0.1% (w/v) BSA and 0.05% Tween 20 (Sigma-Aldrich), dissolved in PBS and 
mixed overnight at 4˚C, was used as a reagent diluent for the IL-13 ELISA.  Diluent was 
stored at 4˚C and used within 1 week.  RPMI 1640 (Invitrogen) was used as a diluent for 
the recombinant IL-13 standard as supernatant samples were dissolved in cRPMI.  Anti-
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human IL-13 (R&D Systems, Minneapolis, MN) was diluted in carbonate coating buffer 
and used as a capture antibody for IL-13.  Anti-human IL-13 biotin (R&D Systems) was 
diluted in reagent diluent and used as a detection antibody for IL-13.  Recombinant 
human IL-13 (rhIL-13) standards (R&D Systems) were serially diluted in standard 
diluent. 
2.1.3.5  Materials for Bradford method protein quantification 
 Bovine serum albumin (BSA) was used as a protein standard:  A 1 mg/ml BSA 
(Sigma-Aldrich) stock solution was prepared in dH2O and stored at –20
o
C.  Bio-Rad 
Protein Assay Dye Reagent (Bio-Rad, Hertfordshire, UK) was used to determine protein 
sample concentrations colourimetrically according to a well established method 
(Bradford, 1976). 
2.1.3.6  Materials for western blot 
 The following materials and reagents were employed: A resolving gel consisting 
of 2.5 ml H2O, 5 ml 30% acrylamide bis (Bio-Rad), 2.5 ml 1.5 M Tris (Sigma-Aldrich), 
0.1 ml 10% (w/v) SDS (Sigma-Aldrich), 0.1 ml 10% (w/v) APS (Sigma-Aldrich), 4 µl 
TEMED (Sigma-Aldrich).  A stacking gel comprising 3.4 ml H2O, 830 µl acrylamide 
bis, 630 µl Tris, 50 µl 10% (w/v) SDS, 50 µl 10% (w/v) APS, 4 µl TEMED.  A loading 
buffer containing 70 mM Tris-HCl, 26.3% (v/v) glycerol, 10% (w/v) SDS, 0.5% (w/v) 
bromophenol blue in dH2O.  5% (v/v) β-mercaptoethanol was added to loading buffer 
immediately prior to use.  The running buffer was 240 mM Tris, 1.9 M glycine (Merck 
KGaA, Darmstadt, Germany), 35 mM SDS in 1000 ml of dH2O.   
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 Nitrocellulose membranes (Sartorius Stedim Biotech S.A., Aubagne, France) 
were used as the blotting surface.  Mouse- and human-reactive anti-IDO IgG (Millipore, 
Billerica, MA), raised in mouse were used as detecting antibodies and for secondary 
antibody goat anti-mouse IgG was used (Millipore).  Transfer buffer was 25 mM Tris, 
190 mM glycine, 20% (v/v) methanol in 1000 ml dH2O.  Transfer buffer was used only 
if pH on formulation was between 8.0 and 8.3.  If pH was outside of this range, the 
buffer was discarded.  Strep-HRP was as described in Section 2.1.3.1.  The 
colourimetric reagent used was BM Chemiluminescence Western Blotting Substrate 
(Roche Diagnostics GmbH, Mannheim, Germany). 
 
2.1.4  Materials for cell function assays 
2.1.4.1  Materials for in vitro human lymphoproliferative responses 
 Lymphoprep (Axis-Shield, Oslo, Norway) was used undiluted for isolation of 
human PBMC by density centrifugation.  AAV-2:  AAV-2 vectors used for PBMC 
stimulations were as described in Section 2.1.5.1  5% ethylenediaminetetraacetic acid 
(EDTA; Sigma-Aldrich) was diluted to 5% (w/v) in dH2O before being autoclaved for 
use with human PBMC.  Tritiated thymidine (3H-thymidine; GE Healthcare) was 
provided labelled at carbon 6 with a single tritium [6-3H].  Radioactivity of stock at 
purchase was 37 MBq/ml.  Material was stored at 4˚C. 
 Peptides synthesised from the AAV-2 VP1 capsid sequence were provided by 
Mimotopes Pty Ltd (Clayton, Victoria).  The peptides were provided as a set of 91 20-
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mer sequences each having a 12-mer overlap with the adjacent sequence (Table 2.2).  
The full VP1 sequence incorporates the VP2 and VP3 peptides of the AAV-2 capsid 
(Xie et al., 2002), thus the overlapping VP1 peptides allow for full coverage of the 
AAV-2 capsid.  Peptides were reconstituted in 0.1% (v/v) acetic acid at a concentration 
of 25 mg/ml, aliquoted and stored at -80
o
C.  Before use, peptides were diluted in PBS to 
a working concentration of 1 mg/ml.  All peptides supplied had an average purity of 
>70%. 
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2.1.4.2  Materials for in vitro murine MSC immunomodulatory activity 
 Ficoll (Histopaque 1083; Sigma-Aldrich) was used undiluted for isolation of 
murine blood mononuclear cells from spleen homogenates by density centrifugation.  
Carboxyfluorescein diacetate, succinimidyl ester (CFSE; Sigma-Aldrich) was used for 
detection of murine lymphocyte proliferation by flow cytometry. 
2.1.4.3  Materials for differentiation of MSC into osteoclasts (bone cells) 
 A 10 mM stock solution of Dexamethasone (Sigma-Aldrich) was made by 
dissolving 0.039 g dexamethasone in 10 ml dH2O.  Dexamethasone was diluted 1:1000 
prior to use.  5 mM β-glycerophosphate (Sigma-Aldrich) was made by dissolving 0.864 
g of β-glycerophosphate into 8 ml of αMEM.  A 50 mM solution of L-ascorbic acid 
(Sigma-Aldrich) was made by dissolving 0.014 g L-ascorbic acid in 1 ml αMEM.  0.1 
mg/ml L-thyroxine was made up by dissolving 0.01 g of L-thyroxine in 100 ml αMEM.  
To make osteogenesis differentiation medium, cαMEM was supplemented with 1 nM 
dexamethasone, 2 mM β-glycerophosphate, 50 nM L-ascorbic acid and 50 ng/ml L-
thyroxine.  Medium was stored at 4˚C for up to one month.  Medium was filter sterilised 
and warmed to 37˚C before use.  Staining of differentiated cultures was performed using 
Alizarin Red S:  The working solution was prepared with 0.5 g of Alizarin red S 
(Sigma-Aldrich) dissolved in 50 ml dH2O.  pH was adjusted to between 4.1 and 4.3 
using 0.1% (v/v) ammonium hydroxide. 
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2.1.4.4  Materials for differentiation of MSC into adipocytes (fat cells) 
 A 10 mM stock solution of Dexamethasone (Sigma-Aldrich) was made by 
dissolving 0.039 g dexamethasone in 10 ml dH2O.  Dexamethasone was filter sterilised 
and diluted 1:1000 prior to use.  Insulin (Sigma-Aldrich) was prepared at a stock 
concentration of 20 mg/ml in 100 mM acetic acid.  Stocks were stored at -20˚C.  Insulin 
was diluted 1:10 and filter sterilised before addition to adipogenesis medium.  500 mM  
3-isobutyl-methyl-xanthine (IBMX; Sigma-Aldrich) was prepared by dissolving 250 mg 
of IBMX in 2.25 ml DMSO.  Stocks were stored at 4˚C and were filter sterilised before 
use.  10 mg/ml indomethacin 500 mM was prepared by dissolving 10 mg of 
indomethacin in 1 ml ethanol.  Stocks were stored at 4˚C and were filter sterilised before 
use.  Adipogenic differentiation medium was composed of cαMEM supplemented with 
10 nM dexamethasone, 5 ng/ml of insulin, 16.65 ng/ml indomethacin and 0.11 ng/ml 
IBMX.  Medium was stored at 4˚C for up to one month.  Medium was filter-sterilised 
and warmed to 37˚C before use.  Differentiated cultures were stained with Oil Red O.  A 
stock solution was prepared by adding 0.3 g of Oil Red O (Sigma-Aldrich) to 100 ml 
isopropanol.  The working solution was made by adding 6 parts of stock solution to 4 
parts of dH2O.  The solution was mixed and then allowed to stand for 10 minutes at 
room temperature before being filter sterilised.  Working solution was made fresh for 
each assay run. 
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2.1.4.5  Materials for HPLC detection of kynurenine concentrations 
 The mobile phase was an isocratic buffer made up as a mixture of 5 mM aqueous 
zinc acetate solution, dissolved in high-performance liquid chromatography (HPLC)-
grade water, and HPLC-grade acetonitrile (Sigma-Aldrich) at a ratio of 92:8 and a pH of 
4.9 (Vignau et al., 2004).  Quantification was facilitated by use of a purified L-
kynurenine reference standard (K8625; Sigma-Aldrich). 
 
2.1.5  Materials for transfection and transduction  
2.1.5.1  AAV-2GFP 
 AAV-2 vectors were kindly provided by REMEDI at NUI Galway and consisted 
of an unmodified AAV-2 capsid encasing a modified AAV-2 genome encoding an 
eGFP reporter gene regulated by a CMV promoter (Figure 2.1).  Virus preparations 
were purified using an iodixanol density gradient followed by elution through a heparin 
column.  Titres were determined by real time PCR following DNase 1 and proteinase K 
degradation steps.  Concentrations were expressed as DNase resistant particles per 
microlitre (drp/µl).  Virus preparations were resuspended in sterile PBS-MK buffer 
(PBS, 1 mM MgCl2, 2.5 mM KCl) and stored at -80
o
C until use.  All reagents for vector 
preparation were filter sterilized or autoclaved prior to use. 
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2.1.5.2  Materials for transfection with human IDO gene 
 The pCMV-Sport6 IDO plasmid (Figure 2.2) was kindly provided by REMEDI 
at NUI Galway and consisted of a pCMV-Sport6 plasmid (Invitrogen) with a human 
IDO gene ligated into the multiple cloning site between the NotI and SalI restriction 
sites.  The transgene was regulated by a constitutive CMV promoter. The plasmid also 
contained an ampicillin resistance gene (AmpR).  Lipofectamine 2000:  Lipofectamine 
liposomal vectors were acquired from Invitrogen. 
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Figure 2.1  A schematic representation of the wild type AAV-2 genome (A) and the 
recombinant vector genome as kindly provided by REMEDI, NUI Galway (B).  In the 
vector, both the Rep and Cap open reading frames are excised entirely.  An eGFP 
reporter gene regulated by a constitutive cytomegalovirus (CMV) promoter replaces 
these open reading frames, leaving the non-coding inverted terminal repeats (ITR) as the 
only remaining parts of the endogenous AAV-2 genome. 
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Figure 2.2  A schematic of the pCMV-Sport6 plasmid (Invitrogen) used in 
conjunction with Lipofectamine 2000 to transfect the murine IDO gene into murine 
MSC under the control of the CMV constitutive promoter.  The plasmid contained an 
AmpR ampicillin resistance gene usable as a selection marker in bacterial culture. The 
transgene, a murine IDO gene was ligated between the NotI and SalI restriction sites. 
 
F1 intergenic region
AmpR
pUC ori
PCMV
SV40pA
MCS
pCMV-Sport6
NotI (774)
SalI (795)
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2.2  METHODS 
2.2.1  Cell isolation methods 
2.2.1.1  Human peripheral blood mononuclear cell (PBMC) isolation by density gradient 
centrifugation 
 Human whole blood from healthy donors was provided by the Irish Blood 
Collections office at Blood Transfusion Service (St. James's Hospital, Dublin 2).  PBMC 
were isolated by density centrifugation using Lymphoprep density centrifugation 
solution (Bøyum, 1968).  Whole blood was prepared in sterile T-75 tissue culture flask 
containing 5 ml of filter-sterilised 5% EDTA and then diluted approximately 1:4 with 
cHBSS.  Sterile 50 ml tubes were prepared, each containing 10 ml of Lymphoprep.  
Diluted blood was then layered on to the Lymphoprep using transfer pipettes to a total 
volume of 40 ml.  Tubes were centrifuged at 400 × g for 25 minutes with acceleration 
settings at minimum and the rotor break switched off.  Following centrifugation, the 
mononuclear cell layers were removed into fresh 50 ml tubes.  Cells were diluted at least 
1:2 with cHBSS.  Tubes were centrifuged at 800 × g for 5 minutes with normal break 
and acceleration settings.  Supernatants were discarded and the pellets were resuspended 
in 10 ml of cHBSS.  Tubes were again centrifuged for 5 minutes at 800 × g.  
Supernatants were once again discarded and the pellets were resuspended in 2 ml 
cRPMI.  Suspensions were pooled by donor and each was filtered through a 40 μm mesh 
filter to remove any remaining clots, debris or cell clumps.  Cell counts were then 
performed using a 1:50 dilution of PBMC suspension in a solution of EB/AO. 
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2.2.1.2  Mouse splenocyte isolation by density centrifugation 
 Splenocytes were isolated by density centrifugation using Ficoll density 
centrifugation solution.  Spleens were isolated from female BALB/c mice and 
homogenised through a 40 µm mesh filter into cHBSS.  Splenocytes cells were isolated 
by density centrifugation rather than by red blood cell lysis in order to maximise 
mononuclear cell yield for downstream naive T-cell isolation.  Cell suspensions were 
layered onto Ficoll and centrifuged at 600 × g for 25 minutes with centrifuge 
acceleration on the lowest setting and rotor brake disabled.  Mononuclear cell layers 
were removed and pooled in cRPMI.  Splenocytes were pelleted by centrifugation at 600 
× g and resuspended in fresh cRPMI. 
2.2.1.3  Mouse naive T-cell isolation by magnetic depletion 
 Splenocytes were processed using a naive T-cell isolation kit (MAGM205; R 
and D Systems) according to manufacturer’s protocol.  The kit included a biotinylated 
antibody cocktail and streptavidin-conjugated ferrofluid designed to deplete a 
splenocyte suspension of monocytes and mature lymphocytes, leaving a CD3
+
 CD4
+
 
CD62L
+
 enriched population.  Cells were suspended in kit selection buffer at a 
concentration of 2×10
8
 cells/ml in sterile polystyrene FACS tubes.  10 µl of antibody 
cocktail solution was added per 1×10
7
 cells to be processed and the cells were mixed 
gently.  Cells were incubated at 4˚C for 15 minutes.  12.5 µl of ferrofluid solution was 
added per 1×10
7
 cells to be processed and the cells were again mixed gently.  Cells were 
incubated at 4˚C for 15 minutes and then tubes were placed in a magnetic block and 
incubated for 6 minutes at room temperature.  After this incubation step, cells still in 
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suspension were removed from tubes whilst still in the magnetic block.  Cells were 
placed in fresh tubes and incubated in the magnetic block for a further 6 minutes.  
Unbound cell suspensions, containing the depleted naive CD4+ cell population were 
removed from tubes, centrifuged at 600 × g for 5 minutes and resuspended in cRPMI.   
 
 
 
Hamster antibody (Ham).  Mouse antibody (Mu). 
Target Fluorochrome Isotype Manufacturer
CD3e FITC Ham IgG Immunotools
CD62L PE Rat IgG2a Immunotools
MHC I FITC Mu IgG2a eBioscience
MHC II PE Rat IgG2b eBioscience
CD90 FITC Mu IgG1 Immunotools
Sca-1 PE Rat IgG2a eBioscience
Table 2.3  Conjugated anti-mouse antibodies used for flow cytometry
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2.2.2  Cell culture methods 
2.2.2.1  Culture of murine MSC 
 Murine mesenchymal stem cells (MSC) were kindly provided by Dr. Karen 
English and Laura Tobin at the Mahon laboratory, isolated as previously described 
(English et al., 2007).  MSC for use in this study were obtained from cryopreserved 
stocks stored at a concentration of 1×10
6
 cells/ml between passages 3 and 9.  On 
recovery, cells were resuspended in 33 ml of cαMEM and seeded into a T-175 vented-
cap tissue culture flask (Sarstedt, Nümbrecht, Germany).  Cultures were incubated at 
37˚C and 5% CO2.  Growth medium was replaced every 3-4 days and cultures were split 
once they reached 70% confluence.  MSC were used up to a maximum of passage 12.  
Cultures were split by removal of growth medium, washing with sterile PBS and 
incubation with Trypsin-EDTA for up to 15 minutes.  Once cells were observed to 
detach from the culture flask, Trypsin-EDTA activity was neutralised with an equal 
volume of cαMEM.  Cells were pelleted by centrifugation at 600 × g for 5 minutes and 
then resuspended in cαMEM for counting with EB/AO and seeding into fresh culture 
flasks.  Seeding density was 2×10
3
 cells per cm
2
. 
 MSC were validated by examination of morphology, potency, 
immunomodulatory capacity as described in Chapter 6.  Surface expression of MHC 
class I, MHC class II, CD90 and Sca-1 was also assessed by flow cytometry as 
described in Chapter 6.  Fluorescently-labelled antibodies used are listed in Table 2.3. 
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2.2.2.2  Culture of human HEK-293 cells 
 Human embryonic kidney cells (HEK-293) were obtained from cryopreserved 
stocks stored at a concentration of 1×10
6
 cells/ml.  Cells were resuspended in 33 ml of 
cDMEM per recovered cryotube and seeded into a T-175 vented-cap tissue culture flask 
(Sarstedt).  Cultures were incubated at 37˚C and 5% CO2.  Growth medium was 
replaced every 3-4 days and cultures were split once they reached 70% confluence.  
Passage was performed as for murine MSC (Section 2.2.2.1) with cαMEM substituted 
with cDMEM. 
2.2.2.3  Cell cryopreservation in liquid nitrogen 
 Cells required for storage were removed from long term culture and spun down 
at 600 × g for 5 minutes.  A 50% recovery rate was assumed when calculating cells 
needed for storage.  The pellet was resuspended in a small volume of freezing medium 
(Section 2.1.1.7) to give a final concentration of 2×10
7
 cells/ml.  Suspensions were 
distributed into cryotubes (Nunc) at 2 ml per tube.  Cryotubes were transferred to N2 
vapour phase for 24 hours after which the tubes were moved to N2 liquid storage. 
 
2.2.3  Molecular techniques 
2.2.3.1  RNA isolation 
 Cells were lysed in trizol at a concentration of 1×10
6
 cells per ml.  5μl of 
Polyacryl Carrier was immediately added to the lysate and mixed.  If RNA isolation was 
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to take place at a later time, lysates were frozen at –80oC for up to one week.  200 μl of 
chloroform was added per ml of lysate and samples were shaken for 15 seconds.  
Samples were allowed to stand at room temperature for 15 minutes before being 
centrifuged at 12,000 × g for 15 minutes in a temperature controlled centrifuge set to 
4
o
C.  The upper, clear, aqueous phase (200-300 μl) was transferred to new tubes and 250 
μl of 2-isopropanol was added to each and carefully mixed with a pipette.  Samples were 
then centrifuged at 12,000 × g and 4
o
C for 10 minutes.  The resulting supernatants were 
removed and discarded.  At least 500 μl of 75% ethanol was then added to wash pellets.  
A final centrifugation step was performed on the samples at 12,000 × g and 4
o
C for 5 
minutes.  Supernatants were decanted and the samples were inverted on tissue paper and 
then air dried to remove any remaining liquid.  RNAse-free sterile H2O at room 
temperature was added and mixed with a pipette.  Samples were left standing at 65
o
C in 
a water bath for 15 minutes before being frozen at –80oC.   
 Prior to cDNA synthesis, RNA samples were treated to remove genomic DNA 
contamination.  A mixture of 1 µl DNAse 1 and 1 µl DNAse buffer (200 mM Tris-HCl 
(pH 8.4), 20 mM MgCl2, and 500 mM KCl; Invitrogen) diluted in 3 µl RNAse-free H2O 
was added to each sample in a 1:1 volume ratio and incubated at room temperature for 
15 minutes.  1 µl of 25 mM EDTA (Invitrogen) was added per 10 µl sample and 
samples were incubated on a thermocycler at 65˚C for 10 minutes.  For each RNA 
sample, two DNAse treatments were performed; one to be used for cDNA synthesis and 
one to be an RNA control. 
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2.2.3.2  cDNA synthesis 
 DNAse treated RNA samples were reverse-transcribed into complementary 
DNA (cDNA).  A master mix was prepared containing 2.5 mM 10x buffer, 1.25 mM 
MgCl2, 1 mM dNTP mix, 1 µg Oligo dT primer, 500 units of superscript II RT and10 
units of RNA inhibitor dissolved in nuclease-free dH2O.  Master mix was made up at a 
volume of 40 µl per RNA sample.  40 µl of master mix was added to 10 µl RNA 
sample.  Samples were then incubated on a thermocycler for 10 minutes at 25˚C 
followed by 1 hour at 42˚C and 5 minutes at 95˚C.  The resulting cDNA products were 
quantified using a UV spectrophotometer by reading the optical density at a wavelength 
of 260 nm.  Once quantified, cDNA samples were used immediately for PCR or stored 
at -20˚C and used within one month. 
2.2.3.3  Validation of cDNA samples 
 In order to validate the synthesis of functional cDNA, reverse transcription 
polymerase chain reaction (RT-PCR) was used to amplify cDNA for the detection of 
transcription of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH).  The cDNA samples used for all PCR experiments were equilibrated to a 
concentration of 1 µg in a 25 µl reaction volume.  Each reaction contained cDNA along 
with 2.5 mM MgCl2, 1 mM dNTP mixture, 0.6 units of Taq polymerase, a 1:10 dilution 
of 10x reaction buffer and 0.4 pmol of GAPDH primers (Table 2.1).   
 To control for genomic DNA contamination, cDNA was substituted with an 
equal volume of the corresponding RNA sample.  To control for contamination of 
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master mix reagents, cDNA was substituted with an equal volume of nuclease-free H2O.  
Samples were then incubated on a thermocycler following the PCR programme detailed 
in Table 2.4. 
 
 
  a
 Annealing temperatures were 60˚C for the GAPDH and 
IDO primers. 
b 
Annealing cycle was repeated 30 times for GAPDH. 
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2.2.3.4  PCR for detection of IDO 
 The cDNA samples used for all PCR experiments were equilibrated to a 
concentration of 1 µg in a 25 µl reaction volume.  This equilibration of starting cDNA 
concentration allowed semi-quantitative determination of the relative levels of target 
RNA.  Each reaction contained cDNA along with a Taq polymerase reaction mixture 
(AmpliTaq; Applied Biosystems, Foster City, CA) and 0.4 pmol of the relevant primers 
(Table 2.1).  Controls for genomic DNA contamination and nuclease free water controls 
were prepared as for the GAPDH PCR (Section 2.2.4.3).  Samples were then amplified 
using a thermocycler following the PCR programme described in Table 2.4. 
2.2.3.5  Analysis of PCR products by gel electrophoresis 
 PCR products were visualised by agarose gel electorphoresis.  Gels containing 
1.3% (w/v) agarose (Sigma-Aldrich) and 0.2 µg/ml ethidium bromide (EB; Sigma-
Aldrich) in TAE were used for GAPDH and IDO PCR products.  Samples were mixed 
1:1 with blue-orange tracking dye (Promega) and 10 µl was added to each gel lane.  A 
100 bp DNA ladder (Promega) was also added to each gel to facilitate product band 
molecular weight determination.  100 volts was passed through the gel for 50 minutes or 
until the tracking dye had migrated to the end of the gel.  The presence of EB in the gel 
allowed DNA bands to be visualised and imaged using a UV light.   
2.2.3.6  Genomic DNA isolation 
 Genomic DNA was isolated using a Generation Capture Column Kit (Qiagen). 
Human PBMC suspensions were passed through a solid matrix column which lysed 
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cells on contact whilst retaining DNA.  The column was then washed using a provided 
purification buffer before the DNA was eluted from the column at high temperature 
(95˚C) using the provided elution buffer.  Kits contained capture columns designed to fit 
into 1.5 ml tubes, 1.5 ml waste and sample collection tubes, DNA purification solution 
and DNA elution solution.  A capture column was placed into a 1.5 ml waste tube.  200 
µl of cell suspension containing a maximum of 1×10
7
 cells was pipetted onto the 
column and incubated for 30 minutes at room temperature.  400 µl on DNA purification 
solution was added and the column was incubated at room temperature for 1 minute.  
The waste tube containing the column was then centrifuged at 6,000 × g for 10 seconds.  
The column was removed from the waste tube and inserted into a fresh waste tube.  400 
µl of DNA purification solution was added to the column and incubated at room 
temperature for 1 minute.  Waste tube and column were once again centrifuged at 6,000 
× g for 10 seconds.  200 µl of DNA elution solution was added to the column followed 
by a 10 second centrifugation at 6,000 × g.  The waste tube was discarded and the 
column was inserted into a 1.5 ml sample collection tube.  100 µl of DNA elution 
solution was added to the column which was incubated at 99˚C for 10 minutes.  The 
sample collection tube and column were centrifuged at 6,000 × g for 10 seconds, the 
column was discarded and the eluted DNA sample was immediately analysed. 
2.2.3.7  Characterisation of HLA haplotypes 
 HLA haplotypes were determined for 16 PBMC donors producing in vitro 
proliferative responses to AAV-2 stimulation.  Sequence-specific primer (SSP) PCR for 
HLA A, B, C, DR and DQ were performed.  DNA was isolated from PBMC using a 
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Generation Capture Column kit (Qiagen, California, USA) according to the 
manufacturer’s protocol.  HLA A, B, C, DR and DQ PCR was performed using an SSP-
based PCR kit (Texas BioGene, Texas, USA) featuring a split 96-well tray format.  Each 
tray could be used to determine the haplotype of the HLA A, B C, DR and DQ loci.  
Each well contained lyophilised primers for sequences specific for a variety of alleles of 
these loci.  The resulting PCR samples were resolved on a 2% agarose gel with ethidium 
bromide to allow UV imaging of DNA bands.  The allele for a given locus could be 
determined by the combination of bands present and their molecular weights.  Analysis 
of the gels was performed using SSPal HLA analysis software (Texas BioGene) 
following the manufacturer’s protocol. 
2.2.3.8  Lysis of cells for SDS-PAGE 
 Cells were resuspended in radioimmunoprecipitation assay (RIPA) buffer 
(Sigma) and protease inhibitor (Sigma) in a 7:1 ratio.  Cells were resuspended at a 
concentration of 2×10
7
 cells/ml and mixed by pipetting.  Lysates were stored at -80˚C. 
 
2.2.4  Immunoassays 
2.2.4.1  Enzyme-Linked Immunosorbant Assays: Design and Optimisation 
 An enzyme-linked immunosorbant assay (ELISA) is an assay used to detect 
antibodies or antigens in a sample using an antigen-specific antibody linked to an 
enzyme (Engvall & Perlmann, 1971; Van Weemen & Schuurs, 1971).  Enzyme linkage 
allows detection of the analyte component of a sample using a colorimetric or 
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fluorometric substrate.  The three main ELISA formats are the sandwich, indirect and 
competitive assays.  In a sandwich assay, an antibody specific for the analyte is coated 
onto a surface.  The antibody, termed the capture antibody, is immobilised on the 
surface by adsorption.  The surface is then blocked with a solution containing adsorbing 
molecules, such as proteins or carbohydrates unlikely to be recognised non-specifically 
by the assay reagents.  Blocking covers up any unused binding sites on the reactive 
surface.  The surface is then exposed to the sample and, if the analyte is present, it will 
be bound by the immobilised capture antibody.  A second analyte-specific antibody is 
added to the plate, preferably one with specificity for an epitope that will not be blocked 
or sterically hindered by the binding of the capture antibody.  This second antibody, 
termed the detection antibody, will often either be directly labelled with an enzyme, or 
will be conjugated to biotin, allowing a wide range of biotin ligand-conjugated enzymes 
to be applied.  A colorimetric or fluorometric substrate for the enzyme is added and the 
absorbance or emission is measured.  The resulting values can then be converted to an 
analyte concentration by comparison to a standard curve. 
 At each stage, reagents are incubated on the reactive surface for various time 
periods, typically from 30 minutes up to 24 hours, and at various controlled 
temperatures, typically between 4˚C and 37˚C.  At the start of each step, unbound 
reagents from the previous step are aspirated from the reactive surface.  The surface is 
then typically washed using a pH controlled buffer containing a detergent.  Washing is 
primarily conducted to remove non-specifically bound reagents which may increase the 
assay background reading or compete with specifically-bound reagents at the current 
step.  Indirect assays are used to detect the presence of antibodies specific for a given 
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antigen in a sample, usually a bodily fluid such as blood serum.  Indirect assays follow a 
very similar protocol to the sandwich assay; however there is no capture antibody.  
Instead, the antigen of interest is immobilised on the reactive surface and antibody-
containing samples are used as the analyte.  In a competitive ELISA, a sandwich or 
indirect ELISA is conducted as normal, however the analyte is pre-incubated with an 
unlabelled specific antibody (in the case of a sandwich ELISA) or with the antigen (in 
the case of an indirect ELISA, where the analyte is an antibody).  Thus, when the 
analyte is incubated on the reactive surface, specific binding to the capture antibody or 
surface bound antigen will be reduced by the pre-incubation.  This allows indirect 
quantification of the analyte, and can also be used to validate the specificity of the assay. 
 When a new ELISA is developed, each step of the assay must be optimised to 
ensure specificity, sensitivity and dynamic range in the final read-out.  Specificity is a 
measure of the proportion of samples negative for a given property that are successfully 
identified as negative (Altman and Bland 1994).  In ELISA, specificity is heavily 
dependent on the extent to which reagents at various steps engage in non-specific 
binding.  A related concept is sensitivity, a measure of the proportion of samples 
positive for a given property which are successfully identified as positive (Altman & 
Bland, 1994).  In ELISA, the sensitivity of the assay will depend on how likely it is that 
reagents will bind specifically and how strong that binding will be.  In particular, 
frequent binding in the presence of a scare ligand and resistance to loss of binding 
during subsequent steps will enhance sensitivity.  Thus, sensitivity and specificity are 
concepts closely related to type I and type II errors in statistics.  Often, because of the 
aforementioned processes which underlie specificity and sensitivity in ELISA 
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experiments, it may not be possible to achieve both 100% specificity and 100% 
sensitivity, demanding a compromise.  The dynamic range of the assay is the ratio 
between the ideal highest readout and ideal lowest readout, also referred to as the signal-
to-background ratio.  The dynamic range of the assay will impact on how accurately 
differences between analyte levels will be detected, particularly when levels near the 
negative background level of the assay, thus impacting on assay specificity and 
sensitivity.  The range obtained is itself heavily influenced by both the sensitivity and 
specificity of the assay as well as the choice of readout reagents and equipment.  
Dynamic range is also of importance when constructing standard curves for the 
quantification of the assay readout.  The greater the range in the readout for the 
standards, the higher the precision in the quantitation of the assay read-out will be.   
Indirect assays are of greatest use when studying the humoral immune responses to a 
virus such as AAV (Chapter 3).   
2.2.4.2  Detection of AAV-2-specific total IgG: Method 1 
 AAV-2-specific total IgG in human plasma samples was detected using an 
indirect ELISA.  96-well flat bottomed, high-binding MaxiSorp immuno-plates (Nunc) 
were used as a reactive surface for all iterations of the ELISA.  Sodium hydrogen 
phosphate (1M Na2HPO4; Sigma-Aldrich) was used as an antigen coating buffer with 
AAV-2 antigen at a concentration of 2×10
11
 drp/ml.  50 µl of each sample dilution was 
added to the plate in triplicate.  A negative control consisting of 50 μl PBS was also 
added in triplicate.  Samples were incubated on the plate for 2 hours at 37
o
C.  This 
incubation step was not modified at any point during optimisation.  The plate was 
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washed using low detergent washing buffer (Section 2.1.3.1) and a solution of HRP-
labelled goat anti-human IgG (Perkin-Elmer, Waltham, MA) was prepared at a 
concentration of 2 μg/ml.  50 μl of antibody was added to each well and the plate was 
incubated for two hours at room temperature.  The plate was incubated at room 
temperature for 20 minutes and then washed.  50 μl of TMB substrate was added to each 
well and the reaction was allowed to proceed for 20 minutes at room temperature.  The 
reaction was then stopped by addition of 50 μl of 1M H2SO4 to each well.  The plate 
was then read on a microplate spectrophotometer at a wavelength of 450 nm. All 
washing steps were performed using 0.05% Tween 20 in PBS and blocking was 
performed using a solution of milk protein. 
2.2.4.3  Detection of AAV-2-specific total IgG: Optimised method 
 Plates were coated with AAV-2 at a concentration of 1×10
9 
drp/ml in carbonate 
coating buffer (150 mM Na2CO3, 350 mM NaHCO3, pH9.6) for 12h at 4
o
C.  Plates were 
blocked using 5% (w/v) Sucrose, 1% (w/v) BSA, 0.05% (v/v) Tween 20 in PBS.  
Human blood plasma was diluted 1:2000 in 1% (w/v) skimmed milk powder in PBS and 
incubated on the plates at 37
o
C for 2h.  Plates were probed for human IgG using an anti-
human IgG-biotin (Sigma-Aldrich).  Detection was performed using a strep-HRP 
conjugate and TMB substrate.  Five washes were performed between each step using 
0.05% (v/v) Tween 20 in PBS.  In the absence of AAV-2-specific IgG international 
standards, two known donors (#22 and #41) were selected as representative seropositive 
and seronegative samples.  These were included in all assays.  AAV-2-specific IgG data 
for the negative reference sample was assigned an AAV-2 antibody titre of 1 unit, whilst 
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the reference seropositive donor was assigned an AAV-2 antibody titre of 10 units.  This 
allowed quality control to be performed to control for intra-assay variation, to normalize 
results and to allow a meaningful comparison of data between assays.  Samples were 
considered seropositive if they scored above the seronegative cut off plus two standard 
deviations. 
2.2.4.4  Verification of total IgG ELISA antigen coating 
 Antigen was directly probed using a mouse anti-AAV VP IgG (Source) diluted 
1:1000 in PBS.  50 μl of this antibody was added to each well following a normal 
washing step.  Detection antibody was incubated on the plate at room temperature for 2 
hours.  A secondary antibody, a goat anti-mouse IgG labelled with alkaline phosphatase 
(AKP) was diluted to 1:5000 in PBS.  Following another normal washing step, 50ul was 
added to each well and incubated at room temperature for 2 hours.  The plate was 
washed and the assay was visualised using a p-nitrophenol (pnp) substrate.  The assay 
was read at a wavelength of 405 nm. 
2.2.4.5  Determination of AAV-2-specific IgG ELISA specificity 
 96-well flat bottomed, high-binding MaxiSorp immuno-plates (Nunc) were 
coated with 100 μl AAV-2 (1×109 drp/ml) in carbonate coating buffer or carbonate 
coating buffer alone (negative control) and incubated overnight at 4
o
C.  Plates were 
placed under UV light for 15 minutes to inactivate the virus.  Plates were washed and 
aspirated five times, blocked and incubated overnight at 4
o
C as per Section 3.3.  In 
1.5ml tubes, test samples were incubated with AAV-2 or AAV-5 at concentrations of 
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2×10
10
 drp/ml serial diluted (1:4) to 1.25×10
9
 drp/ml and incubated for 2 hours at 37
o
C 
with agitation.  A sample from each donor was also incubated at 37
o
C with no AAV 
vector added.  A negative control containing no serum was also incubated with AAV-2 
or AAV-5.  Blocked plates were washed as before and 50μl of pre-incubated test 
samples, AAV-2 or AAV-5 samples were added to wells in triplicate and incubated for 
2 hours at 37
o
C with 5% CO2.  Plates were UV inactivated for 15 minutes, washed and 
aspirated five times in high detergent wash buffer and incubated with 50 μl anti-human 
IgG-biotin (700 ng/ml) for 2 hours at room temperature.  Plates were washed and 
aspirated five times in low detergent wash buffer and incubated with streptavidin-HRP 
conjugate (1:200) for 20 minutes at room temperature.  Plates were washed as above and 
TMB substrate was added.  When a strong signal was apparent, development was 
stopped with 1M H2SO4.  Absorbance values were read at 450 nm and were analysed for 
significance against the non-AAV incubated sample using the Student’s paired t-test as 
before. 
2.2.4.6  Determination of AAV-2-specific IgG neutralising activity 
 Plasma samples were co-incubated with AAV-2GFP at a concentration of for 24 
hours.  The vectors and plasma mixtures were then incubated with HEK-293 cells 
following the AAV-2GFP transduction protocol (Section 2.2.6.1).  Neutralising activity 
was demonstrated by reductions in the levels of GFP expression in the HEK-293 target 
cells, as assessed by flow cytometry and detected on FL1. 
2.2.4.7  Detection of AAV-2-specific total IgG subclasses 
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  Assays were performed in an adaptation of the protocol for total IgG detection 
(Section 2.2.4.2).  In addition, control serum containing pooled, standardized 
concentrations of human IgG subclasses 1, 2, 3 and 4 (Nordic Labs, Tilburg, Holland) 
was used as a reference serum.  Reference serum was diluted to 1:3000 in coating buffer 
and underwent a 7-point, 2-fold serial dilution in triplicate before being coated directly 
to the assay plate.  The resulting bound concentrations of IgG subclasses are detailed in 
Table 2.5.  Plates were probed for human IgG using anti-human IgG subclass-biotin 
antibodies for subclasses IgG1-IgG4 (Merck, Nottingham, England).  Detection and 
washing were performed as for the total IgG ELISA. 
2.2.4.8 Detection of human cytokines 
 Cytokine levels for IFN-γ, IL-13 and IL-10 in supernatants from PBMC cultures 
producing proliferation in response to AAV-2 stimulation were determined by sandwich 
ELISA.  Commercial human IFN-γ and human IL-10 ELISA kits (Immunotools, 
Friesoythe, Germany) or matched antibodies for human IL-13 (R&D Systems, 
Minneapolis, USA) were used for cytokine detection.  For IFN-γ and IL-10 assays, 
capture antibody (Section 2.1.3.4) was diluted 1:100 in carbonate coating buffer.  For 
IL-13, antibody was diluted in carbonate coating buffer to a working concentration of 4 
μg/ml.  In excess of 4.8 ml of coat solution was prepared for each 96-well plate to be 
coated.  Plates were coated with 50 μl of coat solution per well and incubated overnight 
at 4
o
C.   
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 Plates were washed with 300 μl per well of washing buffer such that each well 
was washed and aspirated 3 times.  250-300μl of blocking buffer was added to each well 
and the plates were incubated for two hours at room temperature or overnight at 4
o
C.  
Plates were washed three times with washing buffer.  A 7-point, 2-fold dilution of 
recombinant IFN-γ or IL-10 standard in standard diluent was performed, starting with a 
high standard at a concentration of 1000 pg/ml.  For IL-13, seven recombinant human 
IL-13 (rhIL-13) standards were prepared from stock solution, starting with a high 
standard at a concentration of 8000 pg/ml and diluting 1:2 in standard diluent.  30μl per 
well of samples and standards were added to the coated and blocked wells.  The plates 
were incubated overnight at 4
o
C and then washed five times. 
 IFN-γ and IL-10 detection antibodies were diluted 1:100 in reagent diluent and 
50μl of detection antibody solution was added to each well.  IL-13 detection antibody 
IgG1 (pg/ml) IgG2 (pg/ml) IgG3 (pg/ml) IgG4 (pg/ml)
1860000 1030000 130000 180000
930000 520000 65000 92000
460000 260000 32500 46000
230000 128000 16250 23000
120000 64000 8100 11500
58000 32000 4000 5700
29000 16000 2000 2900
Table 2.5  IgG subclass standard concentrations
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was diluted in reagent diluent to a working concentration of 400 ng/ml.  The plates were 
then incubated for two hours at room temperature and washed five times with washing 
buffer.  Strep-HRP conjugate was diluted 1:200 in reagent diluent and 50μl was added 
to each well.  The plates were incubated at room temperature for 20 minutes.  The plates 
were washed three times and developed with 50μl of TMB per well for 20 minutes.  
Development was performed out of direct light.  The development reaction was stopped 
with 50μl per well of 1M H2SO4.  Plates were read using a spectrophotometer at a 
wavelength of 450 nm.  
2.2.4.9  Bradford protein quantification assay 
 The Bradford protein quantification assay (Bradford, 1976) was used to 
determine protein concentrations in samples for western blotting (Section 2.2.4.10).  A 1 
mg/ml BSA protein stock solution was prepared in dH2O and stored at –20
o
C.  Five 
protein concentration standards (200, 100, 50, 25 and 0 µg/ml) were prepared using 
aliquots of this stock.  Standards were prepared by adding 800 μl of dH2O to each tube.  
A volume of dH2O equal to the volume of BSA to be added was then removed.  With 
the same pipette and pipette tip, the BSA was added to the tube.  The samples were 
thawed to 4
o
C and vortexed to break up frozen material.  If the samples required 
clarification, they were centrifuged for 5 minutes at 13,000 × g to remove cellular 
material.  Samples were diluted in dH2O to 1:200, 1:2000 and 1:20,000.  Dilutions of 
samples and standards were prepared simultaneously.  The required total amount of Bio-
Rad reagent (200 l per sample or standard) was poured into a universal, covered with 
tinfoil and allowed to come to room temperature.  The samples and standards were 
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vortexed for 10 seconds.  All of the tubes were then opened and 200 μl of Bio-Rad 
reagent was added to each to each.  The tubes were then closed and each was mixed by 
inversion 3 times and vortexed for 10 seconds.  Once all tubes had been inverted and 
vortexed, 200 l of each sample or standard was added to a 96-well plate in triplicate.  
Samples and standards were mixed an equal number of times with the pipette before 
removal from the tube.  The absorbance was then read at a wavelength of 595 nm using 
a spectrophotometer. 
2.2.4.10  Western blot for detection of IDO protein  
 Resolving and stacking gels were prepared as described in Section 2.1.3.7 and 
were used within 24 hours of setting.  The protein concentration in samples for analysis 
(Section 2.2.3.8) were determined using the Bradford assay (Section 2.2.4.9) and then 
normalised to a concentration of 5 mg/ml.  10 µl samples were mixed 1:1 with loading 
buffer (Section 2.1.3.7) and heated to 95˚C for 5 minutes.  Gels were placed in a vertical 
electrophoresis unit filled with a 1:10 dilution of running buffer (Section 2.1.3.6).  
Samples, along with a marker ladder, were then loaded into the stacking gel.  The gel 
was subjected to 50 volts for 30 minutes to allow protein samples to migrate through the 
stacking gel and onto the resolving gel.  The gel was then subjected to 120 volts and run 
until the marker dye and loading buffer had reached the bottom of the resolving gel.   
 Protein was then electroblotted to nitrocellulose membranes (Sartorius Stedim 
Biotech, Aubagne, France) following an adaptation of the method of Burnett (Burnette, 
1981).  The gel was placed onto a nitrocellulose membrane and sandwiched between 
two filter papers, two sponges and placed into an ice-cooled electrophoresis rig filled 
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with transfer buffer.  A magnetic mixing bead was placed into the electrophoresis rig 
and the rig was placed onto a magnetic stirrer in order to ensure even cooling of the rig.  
Transfer of protein from the gel onto the nitrocellulose membrane was conducted by 
passing 100 volts through the gel for 1 hour.  The presence of the stained molecular 
weight ladder on the nitrocellulose membrane verified the electro transfer.   
 Nitrocellulose membranes were blocked by submerging in 5% (w/v) skimmed 
milk powder and 0.05% (v/v) Tween 20 in PBS for 1 hour at room temperature and then 
washed with TBS-Tween 20 washing buffer for 20 minutes.  Three 20 minute washes 
were performed between all remaining steps.  Each membrane was incubated with 
mixing overnight at 4˚C with primary antibody (mouse anti-IDO IgG; Millipore, 
Billerica, MA) at a dilution of 1:500 in TBS buffer.  Secondary antibody (goat anti-
mouse IgG; Sigma) was incubated with the membrane for 1 hour at room temperature 
with mixing.  Chemiluminescence reagent (Roche) was prepared as a 100:1 dilution of 
solution A and solution B which was incubated on the membrane at room temperature 
for with mixing for 1 minute. 
 Chemiluminescence reagent was drained from the membrane which was then 
wrapped in cling film, placed into an x-ray cassette (Hypercassette; GE Healthcare) and 
transferred to a dark room.  Film was placed on top of the membrane and left to expose 
for 1 minute, 5 minutes, 30 minutes or 1 hour.  Film was developed by washing in 
development fluid (Kodak GBX Developer; Sigma-Aldrich) and then rinsed in water.  
Film was then fixed in Kodak GBX Fixer solution (Sigma-Aldrich) and again rinsed in 
water. 
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2.2.5  Methods for the assessment of cell function 
2.2.5.1  Detection of in vitro human lymphoproliferative responses to AAV-2 and AAV-
2 capsid peptides 
 Human PBMC were suspended in cRPMI at a concentration of 2×10
6
 cells per 
ml.  Cells were plated in triplicates onto a 96-well tissue culture plate with 200 μl of 
PBMC suspension added to each well.  A solution of AAV-2 vectors (Section 2.1.5.1) in 
cRPMI was prepared with a concentration of 5×10
8
 drp/μl.  25 μl of AAV-2 solution 
was added to each test well, giving a final concentration of 1×10
8
 drp/μl.  Multiplicity of 
infection (MOI) was 5×10
4
.  For the capsid peptide stimulation, AAV-2 was replaced 
with peptides derived from the AAV-2 VP1 capsid protein (Section 2.1.4.1) at a 
concentration of 100 µg/ml.  ConA at a stock concentration of 1 mg/ml was diluted 1:25 
in cRPMI.  25 μl of ConA solution was added to each positive control well.  Negative 
control wells were equilibrated to match positive control and test wells by addition of 25 
μl per well of cRPMI.  The plate was then incubated at 37oC with 5% CO2 for 96 hours.   
 After 96 hours, 100 μl of supernatant was removed from each well and frozen at 
-20
o
C for further analysis by cytokine ELISA.  The removed medium on all wells was 
replaced with cRPMI containing 3H-thymidine.  3H-thymidine was added to each well 
giving a final dilution of 1:400 from stock, equivalent to 92.5 μBq/ml.  The plates were 
then incubated at 37
o
C with 5% CO2 for 5 hours.  After 5 hours the plates were either 
frozen at -20
o
C for analysis on another date or harvested immediately.  Cultures were 
harvested using a 96-well plate harvester (Molecular Devices, Sunnyvale, CA).  The 
well contents were filtered onto glass fibre 96-well size filter mats.  The filter mats were 
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dried at 40
o
C before being sealed in plastic pockets containing 3.5 ml of scintillation 
fluid (GE Healthcare).  The sealed mats were then analysed using a beta scintillation 
counter, producing a beta decay count per minute (CPM) reading for each well.  Results 
obtained were expressed as stimulation indices (SI), calculated as the fold proliferation 
increase over the negative control (Corcoran et al., 2000).  For assays employing VP1 
peptides, SI values were considered positive if they were greater than one standard 
deviation above the mean SI for all peptide stimulated wells. 
2.2.5.2  Detection of in vitro murine MSC immunomodulatory activity by 3H-thymidine 
incorporation assay 
 Normal, plasmid transfected, mock-transfected or IFN-γ stimulated murine MSC 
or growth media alone were incubated on the plates for 24 hours at 37˚C and 5% CO2 to 
allow cell adhesion.  Murine splenocytes were isolated as described in Section 2.2.1.2 
and were suspended in cRPMI at a concentration of 2×10
6
 cells per ml.  Cells were 
plated in triplicates onto a 96-well tissue culture plate with 200 μl of splenocyte 
suspension added to each well.   ConA at a stock concentration of 1 mg/ml was diluted 
1:25 in cRPMI.  25 μl of ConA solution was added to each well to be mitogen 
stimulated.  Negative control wells were equilibrated to match positive control and test 
wells by addition of 25 μl per well of cRPMI.  The plate was then incubated at 37oC 
with 5% CO2 for 96 hours.   
 3H-thymidine was added to each well giving a final dilution of 1:400 from stock, 
equivalent to 92.5 μBq/ml.  The plates were then incubated at 37oC with 5% CO2 for 5 
hours.  After 5 hours the plates were either frozen at -20
o
C for analysis on another date 
84 
 
or harvested immediately.  Cultures were harvested using a 96-well plate harvester as 
detailed in Section 2.2.5.1.  Results obtained were expressed as stimulation indices (SI), 
calculated as the fold proliferation increase over the negative control.   
2.2.5.3  Detection of in vitro murine MSC immunomodulatory activity by CFSE 
timecourse assay 
 96-well sterile culture plates were coated overnight at 4˚C with 20 µg/ml anti-
CD3e mitogen diluted in sterile PBS or PBS alone.  Plates were then washed with sterile 
PBS and normal MSC, transfected MSC or growth media alone were incubated on the 
plates for 24 hours at 37˚C and 5% CO2 to allow cell adhesion.   
 Murine splenocytes were isolated as described in Section 2.2.1.2.  These were 
then used for naive T-cell isolation as described in 2.2.1.3.  Cells were suspended in 
sterile PBS with 0.1% BSA at a concentration of 1×10
7
 cells/ml.  CFSE (Sigma-Aldrich) 
was added to give a final concentration of 10 µM and cells were vortexed.  Cells were 
incubated in a 37
o
C water bath for 10 minutes and mixed frequently.  The reaction was 
quenched by diluting cells 1:10 with cRPMI.  Cells were then centrifuged at 800 × g for 
5 minutes.  Cells were resuspended in at least 1 ml of cRPMI and incubated at room 
temperature for 10 minutes to allow cells to excrete excess CFSE dye.  Cells were 
centrifuged at 800 × g for 5 minutes and the cells were resuspended in required final 
volume of cRPMI.  Stained T-cells were seeded into the culture plate at required 
density.   
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 Culture plates were then incubated at 37˚C and 5% CO2 for a period of 5 days.  
During this time, cells were harvested from the plate once every 24 hours.  Directly 
prior to harvest, 3000 Calibrite-PE beads were added to each well, ensuring that the 
same pipette tip was used for all wells.  Each well was mixed by pumping with a fresh 
pipette tip.  10 µl of propidium iodide (1ug/ml) was added to each well.  Wells were 
mixed thoroughly and transfer to 5 ml polystyrene tubes for FACS analysis. 
2.2.5.4  Differentiation of MSC into osteoclasts (bone cells) 
 Murine MSC were seeded into 6 well plates at a density of 50 cells per cm
2
 in 2 
ml cαMEM.  Plates were incubated at 37oC and 5% CO2 for 10 days.  During this time, 
growth medium was replaced every 3-4 days.  On day 11, expansion medium was 
aspirated and replaced with either bone differentiation medium or fresh cαMEM.  Plates 
were incubated at 37
o
C and 5% CO2 for 3 weeks.  During this time, medium was 
replaced with every 3-4 days.  After 3 weeks of incubation, differentiation medium was 
removed and cells were washed with PBS.  Cells were fixed by addition of 10% 
formalin for 20 minutes at room temperature and then stained with 0.5 ml per well of 
Alizarin Red for 20 minutes at room temperature.  Wells were then washed with dH2O 
until wash became clear.  Plates were then examined by light microscope for red mineral 
deposits. 
2.2.5.5  Differentiation of MSC into adipocytes (fat cells) 
 Murine MSC were seeded into 6 well plates at a density of 50 cells per cm
2
 in 2 
ml cαMEM.  Plates were incubated at 37oC and 5% CO2 for 10 days.  During this time, 
86 
 
growth medium was replaced every 3-4 days.  On day 11, medium was aspirated and 
replaced with either fat differentiation medium or fresh cαMEM.  Plates were incubated 
at 37
o
C and 5% CO2 for 3 weeks.  During this time, medium was replaced every 3-4 
days.  After 3 weeks of incubation, medium was removed and cells were washed with 
PBS.  Cells were fixed by addition of 10% formalin for 20 minutes at room temperature 
and then stained with 0.5ml of freshly-diluted Oil Red-O working solution per well for 
20 minutes at room temperature.  Wells were then washed with dH2O until wash became 
clear.  Plates were then examined by light microscope for red fat globules. 
2.2.5.6  Determination of kynurenine concentration 
 IDO activity was quantified by measuring the concentration of the tryptophan 
metabolite kynurenine in cell culture supernatants.  Protein components of the 
supernatants such as FCS were precipitated by addition of 20% (w/v) trichloroacetic 
acid (10% final volume) and centrifugation at 13,000 rpm for 10 minutes at 4˚C.  
Kynurenine was measured by reversed-phase high performance liquid chromatography 
(HPLC), in an adaptation of a method published elsewhere (Vignau et al., 2004), using a 
1200 series HPLC with a diode array detector (Agilent Technologies, Santa Clara, CA).  
An Eclipse XD8-C18 column (Agilent Technologies) with an 8 nm pore was used for 
sample separation.  The mobile phase was a mixture of 5 mM aqueous zinc acetate 
solution and acetonitrile (Sigma-Aldrich) prepared as described in Section 2.1.4.5.  A 
sample injection volume of 20 µl was used.  Absorbance was measured across the full 
range of wavelengths from 190 to 950 nm.  The concentration of kynurenine was 
quantified by comparison with a kynurenine standard (Sigma-Aldrich) ranging from 0-
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100 µM (Figure 2.4).  Kynurenine was identified in the standards as a peak with a 
retention time of 3.0 to 3.1 minutes detectable at 345 nm.  Control kynurenine was 
dissolved in the same growth medium as the supernatant samples and was subjected to 
the same precipitation process, thus any background kynurenine level, spontaneous L-
tryptophan metabolism or any catalysed L-tryptophan metabolism endogenous to the 
complete growth medium was accounted for.  This also compensated for the reported 
capacity of the TCA precipitation method to breakdown L-tryptophan into kynurenine 
(Miller et al., 2006). 
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Figure 2.4  A representative standard curve for the quantification of kynurenine 
concentrations in culture supernatants by HPLC.  The standard curve was determined in 
duplicate for each HPLC run and error, where present, is indicated with bars.  
Kynurenine had a retention time of between 3 and 3.1 minutes when eluted using an 
isocratic zinc acetate acetonitrile mobile phase.  The concentration of the standards had 
a linear relationship with the area of the kynurenine peak.  Given the peak area (y), 
kynurenine levels in samples could thus be calculated by solving the equation of the line 
for x. 
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2.2.6  Transformation of murine MSC 
2.2.6.1  Transduction of mesenchymal stem cells with AAV-2GFP 
 Murine MSC were seeded on 24 well culture plates in cαMEM at a concentration 
of 1×10
4
 cells/ml.  Plates were incubated overnight at 37
o
C and 5% CO2 to allow MSC 
to adhere to the plate surface.  After 24 hours, medium was removed and replaced with 
AAV-2 in complete cαMEM at MOI of 1000, 10000 or with complete αMEM alone.  
Plates were incubated at 37
o
C and 5% CO2 for 24 hours.  Medium was removed and 
cells were washed twice with sterile PBS to remove free virus.  Fresh cαMEM was 
added to all wells and plates were incubated at 37
o
C and 5% CO2 for 24 hours. 
2.2.6.2  Transfection of mesenchymal stem cells with pCMV-Sport6 IDO 
 Murine MSC were seeded into 24 well plates at a density of 5×10
5
 cells per well 
in 500 µl of cαMEM.  Cells were allowed to adhere and grow by incubation at 37oC and 
5% CO2 for 24 hours.  For each well to be transfected, 0.8 µg of pSport6CMV-IDO 
(Figure 2.2) plasmid DNA was diluted in 50µl of OptiMEM I medium.  2.0 µl of 
Lipofectamine 2000 (Invitrogen) was diluted in 50 µl of OptiMEM I medium for each 
well to be transfected.  DNA and lipofectamine were incubated at room temperature for 
5 minutes before being gently mixed and incubated for a further 20 minutes at room 
temperature to allow DNA-Lipofectamine complex formation.  100 µl of complexes was 
added to each well to be transfected.  Plates were gently mixed by rocking and incubated 
at 37
o
C and 5% CO2 for 24 hours.  Transfection was validated by PCR for the IDO 
transgene (Section 2.2.4.4). 
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2.2.7  Molecular modelling 
 The 3D structure of AAV-2 VP1 (structure 1lp3) was obtained from the Protein 
Data Bank (PDB) and was imaged using Christoph Gille’s Structure based Sequences 
Alignment Program (STRAP; Institut für Biochemie, Charité, Berlin).  STRAP was also 
used to highlight residues corresponding to the candidate T-cell epitopes identified using 
methods described in Section 2.2.5.1.  Where required, Photoshop CS3 (Adobe Systems, 
San Jose, CA) was used for compositing of symmetry axes and labels. 
2.2.8  Multiple sequence alignments 
 Alignment of AAV VP1 amino acid sequences was carried out using ClustalW 
(EMBL-European Bioinformatics Institute) on default settings. 
 
2.3  STATISTICAL METHODS 
2.3.1  General statistical analysis 
 For ELISA and proliferation assays, statistical significance values between test 
replicates and controls were calculated using a paired, two-tailed Student’s t-test.  
Differences were considered statistically significant if p ≤ 0.05.  For proliferation assays 
employing the synthetic VP1 peptides, SI values were considered positive if they were 
greater than one standard deviation above the mean SI for all peptide stimulated wells.  
Correlations were assessed using the Pearson product-moment correlation coefficient.  
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All statistical analyses were conducted using Prism 5 (GraphPad Software Inc., La Jolla, 
CA) or Excel 2007 (Microsoft Corporation, Redmond, WA). 
2.3.2  Precursor cohort analysis 
 CFSE timecourse data (Section 2.2.5.3) was analysed to establish progressor 
fraction, mean time to first division and mean subsequent division time.  Calculations 
were based on precursor cohort numbers, a means of tracking the fate of the starting cell 
population or precursor cohort.  Precursor cohort numbers were calculated using the 
method of Hawkins et al. (Hawkins et al., 2007).  Progressor fraction was calculated as 
the fraction of the total precursor cohort in any division above division 1.  Mean time to 
first division was calculated as the weighted mean time at which cells enter division 2.  
Mean subsequent division time was calculated as the mean time taken for cells to enter 
divisions subsequent to division 2 (Hawkins et al., 2007). 
 
2.4  ETHICS 
 Human whole blood was provided by the Irish Blood Transfusion Service having 
been obtained by venipuncture with informed consent.  Murine materials including bone 
marrow aspirates and splenocytes and human materials including whole blood were 
acquired and used in accordance with ethical approval from the local Research Ethics 
Committee (NUI Maynooth).  
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CHAPTER 3 
THE HUMAN SEROLOGICAL RESPONSE TO  
AAV-2 
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3.1 INTRODUCTION 
 The reported seroprevalence of AAV-2-specific antibody in humans is highly 
variable. Many groups have examined AAV-2-specific IgG (Chirmule et al., 1999; Erles 
et al., 1999; Murphy et al., 2009), IgM (Erles et al., 1999; Murphy et al., 2009) or total 
antibody (Moskalenko et al., 2000) in humans but the reported extent of prevalence 
varied from 30% to 96% depending on geographical location, assay sensitivity and 
subject age.  Studies of humoral immunity in animals following AAV administration 
have also demonstrated robust induction of antibody (Chirmule et al., 2000).  In order to 
assess the extent of immunity to AAV-2 pre-existing in an Irish population, samples of 
whole blood were taken from healthy Irish blood donors provided by the Irish Blood 
Transfusion Service (IBTS).  A total of 45 donors were sampled and assessed for 
humoral immunity to AAV-2 and a subset of these was examined for cellular immunity 
to AAV-2 including specific epitope recognition (Chapters 4 and 5).  This chapter will 
detail the optimisation of methods to detect AAV-2-specific antibodies in plasma 
samples derived from this donor group and will then report the results of the serological 
study.  
 Previously, the antibody response to AAV-2 has been quantified using a variety 
of methods (Chirmule et al., 1999; Erles et al., 1999; Moskalenko et al., 2000), but no 
standardised method for assessing the levels of AAV-2-specific human IgG in serum or 
plasma existed at the beginning of this study.  It was therefore necessary to define the 
parameters by which AAV-2 seroprevalence would be assessed here.  The first two 
sections of this chapter will describe the development and optimisation of ELISA assays 
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designed to measure AAV-2-specific IgG and IgG subclass concentrations in blood 
plasma samples.  The remainder of the chapter will characterise the IgG and IgG 
subclasses in humoral responses to AAV-2 in the Irish population. 
 
3.2 DEVELOPMENT AND OPTIMISATION OF AN ANTI-AAV-2 IGG ANTIBODY ELISA 
3.2.1 Initial ELISA design 
 At the study outset (June 2005), no AAV-2 antibody specific immunoassays or 
standardised AAV-2 positive sera were commercially available.  Methods in the 
literature for assessing titres of AAV-2-specific immunoglobulins in human amniotic 
fluid (Boyle et al., 2003) or serum (Chirmule et al., 1999) also varied considerably.  It 
was therefore necessary to develop a new assay to meet our specific needs.   
 It was decided that the ELISA would take the form of an indirect binding assay 
(Chapter 1.9).  AAV-2 virus particles were to be coated onto a polystyrene plate using a 
pH-adjusted coating buffer.  A MaxiSorp polystyrene surface (Nunc, Langenselbold, 
Germany) was chosen as it would be versatile, having a high affinity for molecules with 
mixed hydrophilic and hydrophobic domains, allowing the easy adaptation of the assay 
for a range of antigens.  The reactive surface would then be blocked to prevent non-
specific binding of later reaction components.  After appropriate washing steps the 
analyte, diluted human plasma, would then be added.  The detection antibody would be 
an anti-human IgG conjugated to streptavidin-horseradish peroxidase.  The level of 
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analyte would then be quantified colourimetrically by adding a TMB substrate, the 
colour change being proportionate to the antibody concentration over a limited range. 
 Several core elements of the ELISA were considered likely to require 
optimisation.  Composition of the antigen coating buffer and concentration of AAV-2 
capsid antigen as well as coating time and conditions would need to be assessed first.  
Washing buffer components and washing procedure at multiple steps would likely have 
a significant impact on assay sensitivity and specificity.  Blocking buffer components, 
blocking time and conditions would be similarly important.  A range of plasma sample 
and detection antibody dilution factors, reagent diluent components as well as 
incubation time and conditions for these reagents would need to be assessed.  Finally, as 
standardised reference sera were not available, control samples would need to be 
selected to allow intra-batch normalisation. 
 Optimisation was carried out as a pilot study using a panel of six plasma samples 
isolated from healthy Irish blood donors (Section 3.2.2).  Once the basic assay 
conditions were established, one strongly-binding plasma (Donor 4) and one non-
binding plasma (Donor 1) were selected to act as positive and negative controls, 
respectively.  These would allow both for an initial assessment of sensitivity and intra-
batch normalisation during the remainder of the optimisation process.  Once the 
optimisation was completed, a panel of plasma samples (n = 45, including some samples 
from the original pilot group) were assessed using the definitive method.  New reference 
samples would be selected at that point as the optimisation process would deplete the 
available samples from the pilot group.  The new samples would be obtained from 
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donors who would also be assessed for cell-mediated immune responses to AAV-2, 
described in Chapter 4.  
 
3.2.2 Optimisation of a method to detect AAV-2-specific IgG 
 Initially, optimisation was focused on titrating analyte (IgG) binding.  The 
ELISA was first carried out as described in Chapter 2.2.4.2.  A positive reference 
plasma sample (Donor 2) was used as the analyte.  The analyte samples were diluted 1:2 
in PBS and serially diluted to 1:20, 1:200 and 1:2000.  A PBS analyte control was also 
included.  A Sodium hydrogen phosphate solution was used as the antigen coating 
buffer with AAV-2 antigen at a concentration of 2×10
11
 drp/ml as described in Chapter 
2.2.4.2.  All washing steps were performed using 0.05% Tween 20 in PBS and a 
solution of milk protein selected as the blocking agent. 
 The results (Figure 3.1 A) showed a significant difference between the 
absorbance readings at 450 nm (A450) for the PBS control and the sample wells.  Each 
sample replicate was compared to the PBS control using a paired t-test and all four 
sample replicates showed a significance of p ≤ 0.05.  The PBS control represented the 
background in this iteration of the experiment.  While the absorbance of control was 
significantly lower than the samples, it still represented a significant reading above 
blank wells.  This suggested that non-specific binding of reagents was occurring. 
Furthermore, no statistically significant titration of the analyte could be observed.  This 
suggested that either a high degree of non-specific binding was also occurring during the 
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analyte binding stage of the assay or that the range of analyte dilutions used represented 
saturating concentrations. 
Figure 3.1  A) Optimisation of the AAV-2-specific human IgG ELISA.  Plasma 
samples were diluted to the indicated factor in PBS and analysed for the presence of 
AAV-2-specific total IgG.  B) A wider sample dilution range and a more specific IgG 
detection antibody produced a detectable analyte titration.  Absorbance levels at 450 
nm represent the mean of triplicate determinations.  Error bars indicate the standard 
deviation in each case. 
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 In order to address this possibility, the ELISA protocol was modified to cover a 
wider sample dilution range. Dilutions chosen in this case were 1:100, 1:1000 and 
1:10000.  Also, to enhance the specificity of the assay, a biotin-labelled anti-human IgG 
detection antibody (Sigma) replaced the HRP-labelled anti-human IgG and was used at a 
concentration of 70ng/ml.  The detection step was otherwise carried out as before.  
Following the incubation with detection antibody, the plate was washed, then 50 μl of 
streptavidin-HRP conjugate (diluted 1:200 in PBS), was added to each well.  The 
improved protocol allowed a titration of analyte (Figure 3.1 B).  The 1:100 dilution was 
significantly above PBS background, whilst the 1:1000 and 1:10000 dilutions were not. 
 Despite this result, the volumes of antigen used for the assay were considered to 
be too high to allow this approach to be useful in the laboratory.  The assay was 
therefore adapted to test two lower antigen coating concentrations; 1×10
11 
drp/ml and 
5×10
10 
drp/ml.  At an analyte dilution of 1:100, no significant difference in plasma 
binding was detected between the two antigen coating dilutions (Figure 3.2 A).  At a 
sample dilution of 1:1000, a significant (p = 0.03) absorbance difference at 450nm was 
detectable between the two antigen coating dilutions, however the difference was small 
(0.016).  It was clear from these results that a reduction in the antigen concentration was 
not impacting on the extent of plasma sample binding, suggesting that the analyte 
binding observed did not represent antigen-specific binding.  
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Figure 3.2  Optimisation of antigen coating concentrations for the AAV-2-specific IgG 
ELISA.  A) Titration of AAV-2 antigen coating.  Antigen was coated at 1×10
11 
drp/ml 
(open bars) and 5×10
10 
drp/ml (shaded bars) and probed with PBS or with plasma 
analyte at dilutions of 1:100 and 1:1000 B) The range of antigen coating concentrations 
was extended and antigen negative controls were incorporated into the assay.  A four 
point, ten-fold titration of the antigen was tested (see key) using the indicated dilutions 
of detection antibody.  Absorbance levels at 450 nm represent the mean of triplicate 
determinations.  Error bars indicate the standard deviation in each case. 
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  To fully examine this problem, a wider antigen binding range was examined and 
antigen negative controls were incorporated into the assay.  A four point, ten-fold 
titration of the antigen was tested, once again using PBS controls and analyte diluted at 
1:100 and 1:1000.  Blocked, antigen-free wells were also probed with analyte in order to 
serve as antigen negative controls.  The results (Figure 3.2 B) failed to demonstrate any 
statistically significant difference between any of the antigen concentrations at either 
analyte dilution. Most notably, no significant difference could be measured between the 
antigen coated wells and the blocked antigen negative wells at any sample dilution.  The 
results of this assay indicated that either antigen was not coating the plate and/or that 
sample was binding non-specifically to the polystyrene surface, possibly indicating a 
failure in the blocking process or inadequate washing.  The latter was a surprising 
possibility as other antigen ELISA in the laboratory used these or similar approaches 
without non-specific binding. 
 The efficacy of antigen coating to the assay plate was determined by direct 
probing with an AAV-2-specific mouse antibody.  Coating was performed at a 
concentration of 1×10
8 
drp/ml in triplicate using phosphate coating buffer.  Additionally, 
a triplicate was coated in the same manner using a carbonate coating buffer (150 mM 
Na2CO3, 350 mM NaHCO3, pH 9.6) to determine whether an alternative buffer might 
enhance antigen binding.  An antigen-negative triplicate was also included on the plate.  
Coating and blocking were carried out as before.  No analyte step was included in this 
experiment.  Antigen was directly probed using a mouse anti-AAV VP IgG (ARP 
American Research Products Inc., Belmont, MA) conjugated to an alkaline phosphatise 
enzyme (AKP).  VP1 antibody binding was colorimetrically detected using a para-
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nitrophenylphosphate (pNPP) substrate and quantified at 405 nm.  Both antigen coated 
triplicates showed a strong signal that was significantly (p ≤ 0.005, indicated with **) 
above the antigen negative background (Figure 3.3 A).  The triplicate wells coated using 
the carbonate coating buffer showed a slightly higher absorbance than the wells where 
antigen was formulated in a phosphate buffer.  The data demonstrated that the antigen 
was successfully coating the plate and was detectable at a concentration lower than that 
used in previous iterations of the assay.  Antigen coating issues could thus be ruled out 
as a confounding factor.  Although the difference observed between the two coating 
buffers did not have statistical significance, the carbonate coating buffer was adopted for 
all subsequent iterations of the assay. 
 Since antigen coating was verified, it was likely that the lack of assay specificity 
was due to non-specific binding of the analyte or some reagent applied after that step.  
Non-specific binding in ELISA may be minimised by optimising blocking, detection 
antibody application and plate washing.  The blocking conditions of the assay were thus 
modified in an attempt to reduce non-specific binding of the reagents to the plates and to 
each other.  The reagent diluents for the sample, detection antibody and strep-HRP 
conjugate dilutions were changed from PBS to 1% (w/v) milk protein in PBS with 
0.05% (v/v) Tween 20.  The plate blocking time was extended to 24 hours at 4
o
C.  In 
addition, a checkerboard reagent titration of antigen coat concentration and plasma 
sample concentration was performed.    
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Figure 3.3  Optimisation of antigen coating buffers and antigen coat concentrations for 
the AAV-2-specific IgG ELISA.  A)  Optimisation of coating buffers. NaHPO4 buffer 
(Phosphate) was compared to NaHCO3 / Na2CO3 buffer (Carbonate).  Both signals were 
significantly above background.  B)  Titration of antigen coating concentrations. 
Absorbance levels at 405 or 450 nm represent the mean of triplicate determinations.  
Error bars indicate the standard deviation in each case. 
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 Antigen was coated at concentrations of 2×10
9 
drp/ml and 2×10
8 
drp/ml and 
blocked as normal using 10% (w/v) skimmed milk powder in PBS Tween.  A set of 
antigen-free wells was also blocked.  Plasma samples were added at a dilution of 1:100.  
Detection antibody was also used at a higher concentration of 700ng/ml.  Absorbance 
could be titrated against antigen concentration (Figure 3.3 B) but the signal strength 
above background was poor (p ≤ 0.05, indicated with *).  The highest concentration of 
antigen coating produced an A450 only marginally above the blocked antigen free 
background wells.  It could be concluded from these data that the major source of the 
non-specific binding derived from a component within donor plasma.  Further 
optimisation of the assay therefore focused on efforts to reduce this background level by 
further modifying blocking and washing steps.  
 Two alternate blocking buffers, 5% (w/v) sucrose, 1% (w/v) BSA and 0.05% 
(v/v) Tween 20 in PBS or 5% (v/v) FCS with 0.05% Tween 20 in PBS, were tested for 
their capacity to reduce the non-specific background using analyte at 1:200 and 1:2000 
dilution factors (Figure 3.4 A).  Blocking with an FCS-based buffer (FCS) resulted in a 
significant (p ≤ 0.05, indicated with *) signal (antigen positive; Ag+) above background 
(antigen negative; Ag-) when the analyte (Donor 4) was diluted to 1:2000.  The sucrose 
blocking buffer performed optimally, giving a signal that was significantly above 
background for both analyte dilutions (p ≤ 0.005, indicated with **).  The sucrose buffer 
was thus adopted from that point onward.  The introduction of a modified washing step 
after sample incubation reduced the antigen negative background significantly (p ≤ 
0.0005, indicated with ***).  Washing at this step was performed with 5 washes and 
aspirates using a washing buffer with increased detergent concentration (0.5% (v/v) 
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PBS-T).  It was this final optimisation step which rendered the ELISA usable and thus 
no further modifications were made to the protocol (Chapter 2.2.4.3). 
 
 
Figure 3.4  Optimisation of blocking buffer and post plasma binding wash step for the 
IgG ELISA. A)  Comparison of FCS and Sucrose blocking buffers using antigen 
coated (Ag+) and antigen free (Ag-) wells.  B)  Comparison of washing steps using 
0.05% Tween PBS and 0.1% Tween PBS.  Antigen positive (+) and antigen negative 
(-) wells are indicated.  Absorbance levels at 450 nm represent the mean of triplicate 
determinations.  Error bars indicate the standard deviation in each case.  Each 
optimisation step was conducted once. 
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3.2.3 Pilot study 
 Quantitative analysis of serological results was hampered by a lack of any 
established AAV-2-specific IgG standard sera at the study outset.  As a consequence, 
the results obtained were assessed relative to in-house reference standards chosen from 
the study group.  A pilot study was conducted to optimise this process.  In the pilot 
study group one donor was identified with strong specific AAV-2-specific reactivity 
(Donor 4) and another with no significant detectable AAV-2-specific recognition 
(Donor 1).  These plasma samples were chosen to be the positive and negative reference 
controls respectively for the duration of the pilot study.   These controls were included 
on all plates read during the pilot study, allowing normalisation of results across 
multiple plates and accounting for intra-batch variation.  Blocked antigen negative wells 
were also incubated with these control plasma samples.  Assay results were discarded if 
the seropositive control plasma signal detected in antigen positive wells was not 
significantly above the corresponding antigen negative wells.   
 An arbitrary unit was assigned to positive and negative samples where the 
absorbance obtained from the positive reference sample was defined as 10 units and the 
negative reference sample defined as 1 unit.  A linear trend line was constructed 
(Chapter 2.2.4.3).  The equation of the line was determined and was used to calculate a 
unit value relative to the controls for each sample absorbance value.  Standard curve 
construction and sample unit calculations were repeated for each plate.  Thus the 
designated seropositive and seronegative control plasma samples served to normalise the 
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results obtained from each individual ELISA plate as well as to control for reagent 
functionality and quality assurance of non-specific backgrounds. 
 The score results (units of IgG) obtained for an initial panel of donors (donors 1, 
2, 3, 4, 6 and 10) (Figure 3.5) did not show a clear delineation between AAV-2 
seropositive and seronegative samples as has been previously seen for the related 
parvovirus B19 (B19V) (Corcoran et al., 2004).  In this pilot study, donors 3 and 6 were 
clearly seropositive for AAV-2-specific IgG.   However, the sample size was too small 
to draw any definite conclusions regarding the definition of AAV-2 seronegative and 
seropositive samples or to comment on the extent of AAV-2 seroprevalence in the Irish 
blood donor population, issues that were more effectively addressed in the full serology 
study discussed later. 
 
Figure 3.5  Optimisation of total IgG ELISA.  Plasma samples from donors 1-4, 6 and 
10 were analysed as per Chapter 2.2.4.2.  AAV-2-specific IgG concentrations are 
presented as units, calculated as described in Chapter 2.2.4.2.  Antigen specific IgG 
levels represent the mean of triplicate determinations and error bars indicate the standard 
deviation.
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3.2.4 Determination of IgG ELISA antigen specificity  
 The specificity of the total IgG ELISA was examined using an antigen 
competition ELISA.  Human plasma samples were pre-incubated alone, or with either 
high concentrations of AAV-2 or with AAV-5.  The ELISA was then carried out as 
normal.  If the assay was specific, the AAV-2 pre-incubation should reduce the amount 
of available specific IgG in the plasma sample through competition.  As a result, the 
colorimetric signal should be reduced in a dose-dependent manner. 
 The competition assay was carried out on a seropositive control plasma sample 
(Donor 41).  The assay was performed as described (Chapter 2.2.4.5).  Plasma was 
diluted 1:200 and pre-incubated at 37
o
C alone, with AAV-2 or with AAV-5.  Pre-
incubation with AAV-2 or AAV-5 was carried out over three virus concentrations 
between 1.25×10
9 
and
 
2.00×10
10 
drp/ml.  Pre-incubation concentrations were limited by 
supplies of AAV-2.  Incubation with 5.00×10
9
 drp/ml produced significant competition 
(Figure 3.6 A, p ≤ 0.05, *) and 2.00×1010 drp/ml produced very significantly reduced 
antibody binding (Figure 3.6 A, p ≤ 0.0005, ***).  The lowest AAV-2 concentration of 
1.25×10
9 
drp/ml used did not reduce the level of specific IgG.  No reduction was 
observed in response to AAV-5 pre-incubation at any concentration (Figure 3.6 B).  
Taken together these data indicate that the ELISA protocol described in Chapter 2.2.4.3 
was specific for AAV-2.  
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Figure 3.6  Pre-incubation of plasma analyte with AAV-2 confirms the specificity of 
the IgG ELISA by competitive blocking.  A)  Analyte was pre-incubated with AAV-2 
at 1.25×10
9
, 5.00×10
9
 and 2.00×10
10
 drp/ml and then tested by ELISA for blocking of 
AAV-2-specific IgG.  B)  Pre-incubation with AAV-5 antigen did not produce 
significant blocking of AAV-2-specific IgG at any concentration. 
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3.3  DEVELOPMENT AND OPTIMISATION OF AAV-2-SPECIFIC IGG SUBCLASS ELISA  
 The IgG subclass ELISA assays were adapted from the finalised anti AAV-2 IgG 
ELISA protocol (Chapter 2.2.4.3) with minor modifications.  The main change to the 
protocol was the replacement of the anti-human IgG detection antibodies with one of 
four anti-human IgG subclass antibodies (Calbiochem).  As a very early run of the assay 
failed to show a positive signal for any of the 4 subclasses across a panel of plasma 
samples it was decided that a plate-bound IgG standard serum should be used both as a 
positive control during optimisation of the assay and as a means of quantifying the 
results in the finalised assay in terms of IgG subclass concentration.  A commercial 
pooled human IgG solution (NOR-01; Nordic Labs, Tilburg, Holland) containing 
validated IgG subclass concentrations was chosen and used for all assays. 
 
3.3.2 Optimisation of ELISA 
 The IgG subclass assay was designed to be similar to the pan-IgG assay, thus 
only the human standard serum and the four IgG subclass detection antibodies would 
require optimisation.  Therefore, a checkerboard titration was carried out.  Three 
dilutions within the recommended working ranges of each of the four detection 
antibodies were used; 1:500, 1:1000 and 1:2000.  Each antibody dilution was used to 
probe a six-point, ten-fold serial dilution of human serum control, ranging from 1:100 to 
1:10
7
. 
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 Results from this (Figure 3.7) allowed for the selection of optimal detection 
antibody and human standard serum dilutions.  Titration of the control serum revealed 
an upper dynamic detection limit for IgG1 and IgG2 near 10
 
µg/ml.  Above this 
concentration, the detection curves plateaued, showing that increasing antibody did not 
increase signal.  Similarly, the curves plateau below 10 ng/ml in both cases.  The 
detection antibodies for IgG3 and IgG4 could not accurately detect their respective 
antigens above concentrations of 1×10
6 
pg/ml.  However these antibodies were more 
sensitive than the anti-IgG1 and anti-IgG2 antibodies, detecting concentrations down to 
1×10
4
 pg/ml.  All four detection antibodies had a wide IgG detection range at a mean 
working plasma dilution of 1:1000.  The detection antibodies would all be used at a 
dilution of 1:1000.   
 Although it was established that the assay could specifically detect IgG 
subclasses 1-4 in a plate bound control serum, it was not clear that the assay was capable 
of detecting antigen bound IgG subclasses in seropositive plasma samples.  As it was 
not possible to pre-select plasma samples seropositive for AAV-2-specific IgG 
subclasses, it was decided that the ELISA would be modified to detect IgG subclasses 
specific for the related B19V VP2 antigen in serum samples from validated B19V 
seropositive donors (n = 8). B19V VP2 antigen and seropositive serum samples were 
kindly provided by Dr. Luke O’Shaughnessey and Prof. Sean Doyle of the NUIM 
Biotechnology laboratory.  B19V antigen VP2 was coated onto polystyrene plates in 
place of the AAV-2 VP1 antigen.  Confirmed B19V-seropositive serum samples were 
used at the analyte stage.  The ELISA was otherwise carried out as normal. 
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Figure 3.7  Optimisation of the IgG subclass ELISA.  The detectable concentration 
range of pooled human standard serum was tested using various dilutions of the 
anti-human IgG subclass detection antibodies.  Human standard serum containing 
validated concentrations of IgG subclasses 1-4 was titrated with a 6 point, 10-fold 
dilution.  Control serum was coated onto assay plates and probed using detection 
antibodies against IgG1 (A), IgG2 (B), IgG3 (C) or IgG4 (D) at a range of dilutions 
as indicated.  Points represent the mean of triplicate determinations and error bars 
represent the standard deviation. 
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 All four IgG subclasses were detectable in the B19V seropositive serum samples 
(Figure 3.8).  B19V-specific IgG1 was detectable in all 8 samples and was the highest of 
the four subclasses (1818 ±254 µg/ml).  IgG2 was detectable in 2 samples (19.03 ±9.51 
µg/ml), IgG3 in all 8 samples (1.79 ±1.36 µg/ml) and IgG4 in 2 samples (21.32 ±18.38 
µg/ml).  Based on studies of B19V IgG subclass levels in humans, it was expected that 
IgG1 would comprise the largest fraction of specific IgG overall, with levels of IgG2, 
IgG3 and IgG4 being lower (Franssila et al., 1996).  In particular, it was expected that 
IgG3 levels would be generally low unless donors were recently convalescent with some 
IgG 4 being present representing late convalescent donors.  The results obtained here 
supported these assumptions.  The subclass ELISA was demonstrated to detect both 
plate bound control IgG subclasses and to quantitatively detect antigen bound IgG 
subclasses in serum and was thus considered functional. 
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Figure 3.8  Validation of the IgG subclass ELISA using B19V VP2 antigen at the 
coating stage and B19V seropositive plasma samples at the analyte stage.  Each of 
subclasses 1-4 was detectable in at least 2 samples.  A)  Detection of subclass IgG1.  B) 
Detection of subclass IgG2.  C)  Detection of subclass IgG3.  D) Detection of subclass 
IgG4.  Points represent the mean of duplicate determinations.   
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3.4  AAV-2-SPECIFIC TOTAL IGG IS PREVALENT IN THE IRISH BLOOD DONOR 
POPULATION 
 Following optimisation and the pilot study, blood plasma and peripheral blood 
mononuclear cells (PBMC) were isolated from a new blood donor cohort (n = 39) so 
that cellular responses to AAV-2 could be studied directly in parallel to serological 
responses.  The cellular responses to AAV-2 in this donor group are detailed in Chapter 
4.  The plasma samples chosen as controls during the optimisation and pilot experiments 
had been significantly depleted during these processes and so new positive and negative 
control samples were chosen from amongst the first set of samples assayed from the new 
donor group.  Plasma from donor 22 was chosen as a negative and plasma from donor 
41 was chosen as a positive internal reference standard.  Both plasma samples were 
included on all plates assayed thereafter.  Reference curves derived from these new 
controls were similar to those generated during the pilot study (Chapter 2.2.4.3).  As 
sufficient sample volumes remained from each of the pilot study samples for a single 
ELISA run, these were re-examined and normalised along with the new samples, giving 
a total panel of 45 samples.  
 Plasma isolated from whole blood was assayed for the presence of AAV-2-
specific IgG by indirect ELISA using the in-house reference sera as controls.  Samples 
were considered AAV-2 seropositive if they displayed a specific IgG signal two 
standard deviations greater than the standard seronegative reference sample.  41 of the 
donors assayed displayed AAV-2-specific IgG above this cut off and were therefore 
considered seropositive (Figure 3.9).  This figure is close to that reported by Chirmule et 
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al. for a US population (Chirmule et al., 1999).  Using this approach the mean titre of 
AAV-2-specific IgG observed was 9.4 ±5.2 units, indicating a range of seropositivity in 
the study population (Figure 3.9). 
 
Figure 3.9  Detection of AAV-2-specific total IgG levels in donor plasma (n = 45).  
Negative cut-off (broken line) was defined at 2 standard deviations above the 
concentration of a known seronegative standard.  Specific IgG levels were determined in 
triplicate by indirect AAV-2 antigen ELISA.  Error bars represent the standard 
deviation.  Total IgG levels were normalised by comparison to positive and negative 
reference samples.   
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3.5  AAV-2-SPECIFIC IGG1 AND IGG2 ARE COMMON IN SEROPOSITIVE DONORS 
 Whilst total IgG gives an indicator of virus exposure in a population, it does little 
to inform understanding of the immunological mechanisms in operation.  Therefore 
plasma samples from IgG seropositive donors were further examined to determine the 
IgG subclasses involved in the specific recognition of AAV-2 (Figure 3.10, 3.11).  IgG1 
is commonly involved in antiviral responses (Franssila et al., 1996; Gregoreka et al., 
2000; Toptygina et al., 2005) and would be a likely component of responses to AAV-2 
as that subclass is typically involved in humoral responses to the closely related 
parvovirus infections (Corcoran et al., 2000; Franssila et al., 1996).  Significant levels of 
AAV-2-specific IgG1 were detected in all IgG positive samples assayed (p ≤ 0.05), with 
a mean concentration of 11.9 ±6.7 µg/ml (Figure 3.10 A).  A subset of the samples (n = 
5) displayed very high IgG1 levels (>20.0 µg/ml).  This elevation did not appear to 
correlate with total IgG levels or to have any relationship with levels of any other 
subclass.  IgG1 is the most prevalent subclass seen in the circulation.  IgG2 is the second 
most prevalent subclass and is also a major component of many antiviral responses.  
AAV-2-specific IgG2 was prevalent amongst the donors sampled in this study and was 
detected in 39 of 41 seropositive samples at a similar mean concentration to those 
observed for IgG1 (10.8 ±7.5 µg/ml) (Figures 3.10 A & B).  
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Figure 3.10  Detection of AAV-2-specific IgG subclasses levels in AAV-2 seropositive 
donor plasma samples (n = 41) by ELISA.  (A) Detection of subclass IgG1.  (B) 
Detection of subclass IgG2.  IgG subclass levels were determined in triplicate and 
quantified by comparison to a pooled human IgG reference serum.  Error bars represent 
the standard deviation. 
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3.6  AAV-2-SPECIFIC IGG3 IS MINIMAL AND IGG4 IS VARIABLE IN SEROPOSITIVE 
DONORS 
 IgG3 is a major mediator of humoral and cell-mediated responses against soluble 
antigen, having the strongest capacity to engage the complement cascade as well as 
having a high affinity for the FcγRI, FcγRII and FcγRIII receptors of phagocytes and B-
cells (Jefferis & Lund, 2002).  Despite having a role in immunity to parvovirus B19 
(Franssila, Söderlund et al. 1996), little AAV-2-specific IgG3 was detected in the donor 
population (mean 0.7 ±0.2 µg/ml) (Figure 3.11 A).  Depite this consistent low level of 
IgG3, AAV-2-specific antibody of this subclass was detected in plasma from all donors 
and the levels detected were consistent across all sero-positive donors.  
 IgG4 is typically the rarest of the four IgG subclasses in humans, comprising 
only 4% of circulating total IgG (Jefferis & Kumararatne, 1990).  The subclass has a 
role in humoral responses to some viruses but has no complement activation function 
and a relatively low Fc affinity by comparison to IgG1 and IgG3 (Jefferis & 
Kumararatne, 1990).  Concentrations of AAV-2-specific antibody of the IgG4 subclass 
were variable (mean 2.5 ±3.8 µg/ml) (Figure 3.11 B).  Nine of the 41 seropositive 
donors showed no detectable AAV-2-specific IgG4 and only four of the samples (from 
donors 26, 30, 33 and 49) displayed IgG4 concentrations greater than one standard 
deviation above the mean. 
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Figure 3.11  Detection of AAV-2-specific IgG subclasses levels in AAV-2 seropositive 
donor plasma samples (n = 41) by ELISA.  (A) Detection of subclass IgG3.  (B) 
Detection of subclass IgG4.  IgG subclass levels were determined in triplicate and 
quantified by comparison to a pooled human IgG reference serum.  Error bars represent 
the standard deviation. 
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3.7  AAV-2-SPECIFIC NEUTRALISING ANTIBODIES ARE DETECTABLE IN SEROPOSITIVE 
DONORS 
 Binding of AAV-2-specific antibody to AAV-2-based vectors may recruit 
complement and increase uptake of viral particles by phagocytes, thus reducing the 
therapeutic efficacy of the vectors.  Another major influence on therapeutic efficacy is 
neutralisation, whereby antibody specific for critical sites on the virus capsid bind and 
block capsid binding to cell surface receptors.  Animal studies have highlighted the 
significant impact of neutralization upon transduction with AAV-2 (Chirmule et al., 
2000; Moskalenko et al., 2000; Peden et al., 2004).  In humans, humoral memory for 
AAV-2 has been shown to exhibit neutralising activity in some individuals in different 
populations (Chirmule et al., 1999; Erles et al., 1999).    
 Although AAV-2-specific IgG is prevalent in the human population, the capacity 
of the antibody to block virus binding sites for infection or transduction is typically 
more limited, and not readily assessable by ELISA (Moskalenko et al., 2000).  To assess 
the prevalence of neutralising antibody in this study group, a model system was devised 
to measure the reduction in transformation of a target cell line.  A panel of six AAV-2-
specific IgG-seropositive plasma samples (from donors 17, 19, 21, 34, 42, 51) was co-
incubated with an AAV-2 vector encoding a GFP gene under the control of a CMV 
promoter.  The vectors were then incubated with HEK-293 cells following the HEK-293 
transduction protocol (Chapter 2.2.6.1).  Neutralising activity was demonstrated by 
reduction in the levels of GFP expression in the HEK-293 target cells, as assessed by 
flow cytometry (Figure 3.12).  The negative control (cells alone) exhibited a background 
121 
 
MFI of 5.7 and the positive control (cells incubated with AAV-2GFP alone) supported 
increased fluorescence (MFI=13.3).  MFI was reduced by comparison to positive 
controls in all vector-transduced cultures pre-incubated with seropositive plasma 
samples.  Plasma from donor 51 reduced the MFI to 11.1 and plasma from donor 42 
reduced the MFI to near background (5.8). 
 
 
Figure 3.12 AAV-2 seropositive plasma was assessed for neutralising activity against 
an AAV-2GFP vector.  Recombinant AAV-2 vectors encoding GFP were transduced 
into HEK-293 cells.  HEK-293 were transduced with AAV-2GFP untreated (+) or 
following incubation with plasma samples from a selection of healthy AAV-2 
seropositive donors (17, 19, 21, 34, 42, 51).  GFP expression was reported as the mean 
fluorescence intensity as assessed by flow cytometry and compared to a non-transduced 
negative control (-). 
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3.8  SUMMARY 
 Given the known prevalence of AAV-2 infection in humans (Chirmule et al., 
1999; Erles et al., 1999; Halbert et al., 2006), it was conceivable that widespread 
humoral memory for the virus might negatively impact on the usefulness of the virus as 
a gene therapy vector.  In this study, 41 of 45 donors tested displayed significant titres of 
AAV-2-specific IgG in blood plasma (Figure 3.9).  This represents a high prevalence 
when compared to AAV-2 seroprevalence data obtained in other European studies but is 
similar to that seen in US populations (Chirmule et al., 1999; Erles et al., 1999; Halbert 
et al., 2006).  However, as no AAV-2-specific IgG standards existed and there was no 
standardised method for assaying AAV-2 antibody level, it is possible that the high 
variability observed between studies is a result of differing methodologies as it is of 
geographical differences and population demographics.  Despite these differences, the 
available evidence suggests that humoral memory for AAV-2 is prevalent in the Irish 
population. 
 Plasma samples from a panel of six of the donors determined to be AAV-2 
seropositive were also assessed for their capacity to neutralise the transduction of a cell 
line using an AAV-2-based gene therapy vector.  All six samples demonstrated some 
capacity to neutralise AAV-2 transduction of HEK-293 cells.  This suggested that 
neutralising antibodies for AAV-2 are also common in the Irish blood donor population; 
however the small size of the study group prevented a meaningful comparison with 
neutralisation results from other studies.  AAV-2-specific IgG in this population 
consisted primarily of the IgG1 and IgG2 subclasses (Figure 3.10 and 3.11), with low 
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levels of IgG3 present in all donors (Figure 3.11 A) and some evidence of variable IgG4 
in a smaller subset (Figure 3.11 B). 
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CHAPTER 4 
 THE HUMAN CELL-MEDIATED IMMUNE 
RESPONSE TO AAV-2 
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4.1  INTRODUCTION 
 Although the humoral response to AAV-2 has been characterised herein 
(Chapter 3) and elsewhere (Chirmule et al., 1999; Halbert et al., 2006), cell-mediated 
immune responses to AAV have received little attention.  There have been some 
assumptions that AAV does not provoke such a response, or that the response is 
minimal (Büning et al., 2003; Hernandez et al., 1999; Samulski & Giles, 2005; Zaiss & 
Muruve, 2005).  There has been some evidence of cell-mediated responses to AAV-2 in 
humans from a study of a North American population, in which responses were found o 
be modest and low in frequency (Chirmule et al., 1999).  More recently, a clinical trial 
for gene therapy to correct haemophilia B (High et al., 2004) showed declining 
transgene expression and indications of tissue damage expression simultaneous to an 
apparent cytotoxic T-cell response (Manno et al., 2006).   
 Findings in humans have been followed by studies in mouse models that have 
been used to characterise T-cell responses to AAV-2 in greater detail (Chen et al., 2006; 
Li et al., 2009; Li et al., 2007; Wang et al., 2007).  However, inbred mouse strains used 
in research display limited MHC diversity by comparison to the highly polymorphic 
HLA genes in an outbred population.  The obvious prevalence of the humoral response 
to AAV-2 in humans and emerging data on the cell-mediated response in mice (Li et al., 
2009; Li et al., 2007) suggested that assumptions that AAV-2 immunity is T-cell 
independent might not be sound.   Given these findings and their potential relevance to 
application of AAV-based vectors in the clinic, it was clear that the cell-mediated 
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response to AAV-2 needed further characterisation in the natural host if such vectors 
were to be reliably used in a clinical setting. 
 In order to characterise the cell-mediated response to AAV-2 in humans, the 
recall response to AAV-2 was characterised ex vivo from a panel of 41 human blood 
donors.  This panel of donors represented a subset of the 45 donors examined for 
humoral responses in Chapter 3.  IgG responses (Chapters 3.4, 3.5 and 3.6) were 
correlated with proliferative cell-mediated responses from the corresponding donors.  
Furthermore these were associated with an analysis of the profile of cytokine responses 
induced by AAV-2 stimulation.   
 
4.2  AAV VECTORS STIMULATE EX VIVO HUMAN PBMC PROLIFERATION IN A DOSE-
DEPENDENT MANNER 
 It has been speculated that AAV-2 does not elicit cell-mediated immune 
responses (Büning et al., 2003; Hernandez et al., 1999; Samulski & Giles, 2005; Zaiss & 
Muruve, 2005), however the diversity of class switched AAV-2-specific IgG responses 
detected in the human cohort examined herein (Chapters 3.4, 3.5 and 3.6) suggested that 
T-cell help had been evoked by AAV-2 exposure in the study cohort.  Therefore the 
lymphoproliferative immune response to AAV-2 was examined.  To determine whether 
AAV-2 could induce PBMC proliferation and to assess the dose range, human PBMC 
isolated from whole blood donation, were co-incubated with AAV-2 at a range of 
concentrations.   
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 AAV-2 was observed to induce significant (p ≤ 0.05 compared to control) 
PBMC proliferation at doses of 2×10
10
 and 2×10
9
 drp/ml (Figure 4.1).  Below a dose of 
2×10
9
 drp/ml, stimulation indices were not significantly greater than negative controls.  
It was thus decided that for future stimulations, a dose of 2×10
10
 drp/ml would be used. 
 
4.3  AAV-2-STIMULATED CELL-MEDIATED RECALL IMMUNE RESPONSES IN HUMANS 
 To determine the prevalence and strength of cell-mediated responses to AAV-2 
in a larger sample set, PBMC were isolated from the same panel of donors described 
previously (n = 41) (Chapter 3.5).  These cultures were stimulated ex vivo with AAV-2 
and assessed for their capacity to support AAV-2-specific proliferation.  As before, the 
resulting proliferative responses were expressed as fold responses above negative 
controls to give stimulation indices (SI).  The resulting proliferative responses displayed 
a distribution falling into three distinct populations (Figure 4.2), a non-proliferating 
group (n = 13) with SI values ≤ 1.5, an intermediate group (n = 16) with SI values > 1.5 
and ≤ 3.0, and a strongly-proliferating group (n = 12) with SI values > 3.0.  These 
results were analysed for statistical significance by comparison to negative controls 
using the Student’s T test.  AAV-2-specific positives were defined as producing both an 
SI > 1.5 (the upper cut-off for the non-proliferating group) with a significance of p ≤ 
0.05 compared to controls.  By this stringent definition 19 of 41 Irish blood donors 
sampled displayed significant proliferation in response to stimulation (Figure 4.3).  
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Figure 4.1  Dose-response of PBMC (donor 4) stimulated with AAV-2.  Human PBMC 
were cultured for 96 hours in medium alone, stimulated with 10 µg/ml ConA mitogen or 
with AAV-2 at doses ranging from 2×10
7
 up to 2×10
10
 drp/ml.  PBMC proliferation is 
expressed in stimulation indices (SI) which is defined as fold proliferation over 
unstimulated negative control.  Results are representative of two independent 
experiments and SI values reported represent the mean of triplicate determinations.  
Error bars represent the standard deviation.   
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Figure 4.2  Distribution of PBMC proliferative responses to AAV-2 stimulation.  
Proliferation was determined in vitro by 
3
H-thymidine incorporation assay (Chapter 
2.2.5.1) using PBMC from a human cohort (n = 41).  Each point represents a single 
independent experiment for one donor culture, determined in triplicate.  Proliferation is 
expressed in stimulation indices (SI).  Three distinct populations are discernable; a non-
proliferating group (n = 13) with SI values ≤ 1.5 indicated by the broken horizontal line, 
an intermediate group (n = 16) with SI values > 1.5 and ≤ 3.0, and a strongly-
proliferating group (n = 12) with SI values > 3.0.   
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4.4   THE PRESENCE OF AAV-2-SPECIFIC TOTAL IGG DID NOT PREDICT T-CELL 
MEMORY 
 A total 41 of the 45 human plasma samples previously examined (Chapter 3.5) 
contained AAV-2-specific IgG, an indicator of prior infection and humoral memory for 
the virus.  In all cases where significant PBMC proliferation was detected in culture, the 
corresponding plasma samples were seropositive for AAV-2-specific IgG (Table 4.1).  
However, the presence of AAV-2-specific IgG did not predict the presence of a 
proliferative response indicating that serological assays will not be a reliable means of 
assessing whether candidate gene therapy recipients are likely to mount a proliferative 
response to AAV-2.  This may be due to differences in the sensitivity of serological 
assays versus cell-based assays.   
 
4.5  NEITHER THE STRENGTH OF TOTAL IGG, NOR THE DISTRIBUTION OF IGG 
SUBCLASS RESPONSES PREDICTED T-CELL RESPONSES TO AAV-2  
 The prevalence of humoral memory for AAV-2 in humans raises the possibility 
that assaying for circulating antibody may provide a convenient indicator for general 
AAV-2 immunity in prospective gene therapy recipients.  To determine if IgG ELISA 
results are a feasible surrogate measure of cell-mediated memory, a selection of AAV-2-
specific total IgG results (Chapter 3.2.3) were correlated with PBMC proliferation 
results from cultures isolated from the corresponding donors.   
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1 2 3 4
19 3.23 39 59 2 0 1.75
46 11.33 48 39 3 9 2.08
45 8.73 60 30 3 7 2.20
16 4.10 48 49 3 0 2.22
27 11.01 48 41 3 8 2.27
31 12.63 90 0 1 8 2.31
32 1.78 32 64 3 0 2.33
47 10.80 57 21 4 18 2.39
13 9.90 37 53 4 5 2.57
43 5.54 33 49 2 15 3.29
51 4.66 37 62 2 0 5.10
38 6.46 43 37 4 16 6.25
50 13.20 29 48 2 20 10.91
40 5.88 59 25 4 11 14.77
15 5.55 44 49 3 3 18.65
41 10.00 22 75 1 2 25.50
TABLE 4.1 Serological, lymphoproliferative profiles of cultures proliferating in response to 
AAV-2
Donor #
AAV-2 
specific total 
IgG (units)
AAV-2 specific IgG subclass (% total IgG)
a PBMC 
proliferation 
(SI)
a
  AAV-2-specific IgG subclass levels were determined by indirect ELISA (Chapter 
3.5 and 3.6).  Detectable specific subclass levels are expressed as a percentage of the 
total specific IgG.  
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 T cell responses were only detected in patients who were seropositive (Figure 
4.4 A, Table 4.1), however the high prevalence and the small number of seronegative 
donors in this study did not allow a meaningful comparison or correlation to be drawn 
on this relationship.  There was no correlation between the level of AAV-2 IgG detected 
in donor plasma and the presence of a T-cell recall response or the amount of 
proliferation produced by PBMC cultures from those donors (Figure 4.4 A, Table 4.1).  
When AAV-2-specific IgG subclass levels were compared to PBMC proliferation, there 
appeared to be only a weak correlation (Figure 4.4 B) (r = 0.25) between the combined 
levels of the subclasses and the extent of proliferation.  There were no obvious 
correlations between the PBMC proliferation levels and circulating IgG subclass levels 
for subclasses 1-3 for any donor.  The highest levels of IgG4 tended to be detected in 
plasma from donors from whom PBMC cultures produced AAV-2 stimulated 
proliferation with an SI of greater than 3.0.  However this association was extremely 
weak (r = -0.13) and the two most strongly proliferating cultures (from donors 15 and 
41) corresponded with very low IgG4 levels.  Overall these data suggest that diagnostic 
assessments of AAV cellular immunity are not likely to be reliably inferred from using 
serological responses as a surrogate.  
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Figure 4.4  Comparison of combined AAV-2-specific IgG subclass 1-4 concentrations 
with corresponding antigen specific PBMC proliferation.  Correlation was assessed by 
Pearson product-moment correlation coefficient.  PBMC proliferation (SI) in response 
to AAV-2 stimulation does not correlate with the combined concentration of AAV-2-
specific IgG subclasses (r = 0.25, p = 0.14).  Results from each donor culture for IgG are 
representative of single independent experiments, each performed in triplicate. 
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4.6  AAV-2 INDUCED T HELPER RESPONSES WITH DIFFERENT CYTOKINE PROFILES 
 Polarisation of antigen specific T helper responses along the T helper 1 (Th1), T 
helper 2 (Th2), T helper 17 (Th17) and T regulatory (T-reg) arms of the adaptive 
response might have a significant impact on the outcome of putative cell-mediated 
responses to AAV-2.  In particular, vigorous Th1 responses, detectable by T-cell 
secretion of IFN-γ, may mediate cytotoxic responses directed against host cells 
transiently presenting AAV-2 antigens.  To assess the T helper polarisation of responses 
to AAV-2 in vitro, supernatants from cultures (donors, n=16) that proliferated in 
response to antigen were assessed for the production of IFN-γ, IL-10 and IL-13, 
cytokines characteristic of Th1, Th2 and T-reg polarised recall responses respectively.  
This subset was selected as it was considered unrealistic to screen samples from donors 
where no proliferation was observed.  Ten cultures (donors #13, 15, 27, 31, 32, 38, 40, 
41, 50 and 51) produced significantly (p ≤ 0.05) increased IFN-γ (Figure 4.5).  Cultures 
from four donors (#27, 31, 32 and 46) showed increased IL-13 (Figure 4.6).    IL-10 
levels were increased in eight cultures (from donors #31, 38, 40, 43, 45 47, 50 and 51; 
mean concentration 140 pg/ml) (Figure 4.7).  Whilst the cytokine profiles produced in 
response to AAV-2 were diverse, these data support the induction of CD4+ T-cell 
responses against AAV-2 in a subset of the healthy human population. 
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Figure 4.5  Determination of IFN-γ production in PBMC cultures stimulated with 
AAV-2.  Supernatants from 10 PBMC cultures stimulated with AAV-2 displayed 
production of IFN-γ as detected by sandwich ELISA.  Results from each donor culture 
are representative of single independent experiments; each performed in triplicate and 
reported as the increase in IFN-γ relative to negative controls.  All IFN-γ increases 
reported were significantly (p  0.05) above respective negative background levels as 
determined by Student’s t-test.  Results for each donor are arranged in order of 
increasing antigen specific PBMC proliferation. 
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Figure 4.6  Determination of IL-13 production in PBMC cultures stimulated with 
AAV-2.  Supernatants from 4 PBMC cultures stimulated with AAV-2 displayed 
production of IL-13 as detected by sandwich ELISA.  Results from each donor culture 
are representative of single independent experiments; each performed in triplicate and 
reported as the increase in IL-13 relative to negative controls.  All IL-13 increases 
reported were significantly (p  0.05) above respective negative background levels as 
determined by Student’s t-test.  Results for each donor are arranged in order of 
increasing antigen specific PBMC proliferation. 
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Figure 4.7  Determination of IL-10 production in PBMC cultures stimulated with 
AAV-2.  Supernatants from 8 PBMC cultures stimulated with AAV-2 displayed 
production of IL-10 as detected by sandwich ELISA.  Results from each donor culture 
are representative of single independent experiments; each performed in triplicate and 
reported as the increase in IL-10 relative to negative controls.  All IL-10 increases 
reported were significantly (p  0.05) above respective negative background levels as 
determined by Student’s t-test.  Results for each donor are arranged in order of 
increasing antigen specific PBMC proliferation. 
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4.7  POLARISATION OF PROLIFERATIVE RESPONSES TO AAV-2 VARIED BETWEEN 
DONORS 
 Production of IFN-γ, IL-13 or IL-10 was detected in PBMC cultures from 14 of 
16 donors examined.  These cytokine responses were compared with the corresponding 
lymphoproliferative responses (Section 4.5) in ascending order of strength (Table 4.2).  
IL-10 responders were distributed between cultures of all proliferation levels, whereas 
IFN-γ and IL-13 levels showed a weak correlation with the extent of PBMC 
proliferation (Table 4.2).  IFN-γ levels tended to be increased in cultures from donors 
whose PBMC proliferation levels were strong (SI > 3.0) (as determined by Pearson 
product-moment correlation coefficient (r = 0.69, p = 0.0031)), whereas IL-13 was only 
detected in cultures from donors whose PBMC proliferation levels had been weakly 
positive (SI < 2.5) (Table 4.2).   
 For individual donors, IFN-γ and IL-13 levels appeared to be inversely 
proportional to one another and in many cases were mutually exclusive (Figure 4.8, 
Table 4.2).  It thus appears that AAV-2 induces polarised Th1 responses in some donors 
and Th2 responses in others. 
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a
 Cytokine levels in proliferation assay 
supernatants were determined by sandwich 
ELISA. Intermediate and negative cytokine 
production levels are indicated (-).  
Increases, where applicable, are measured in 
picograms per millilitre (pg/ml). 
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Figure 4.8  A)  Comparison of IFN-γ (green bars) and IL-13 (red bars) increases in 
supernatants from PBMC cultures stimulated with AAV-2.  Results are representative of 
single independent experiments; each performed in triplicate and reported as the 
cytokine increase relative to negative controls.  All increases reported were significantly 
(p  0.05) above respective negative background levels as determined by Student’s t-
test.  Results for each donor are arranged in order of increasing antigen specific PBMC 
proliferation.  B)  Comparison of proliferative responses and IFN-γ production.  A weak 
correlation (r = 0.69, p = 0.0031) was found between IFN-γ production and the strength 
of PBMC proliferation. 
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4.8  SUMMARY 
 At the study outset, there was an assumption that AAV-2 induced weak cell-
mediated immune response or that the response is absent (Büning et al., 2003; 
Hernandez et al., 1999; Samulski & Giles, 2005; Zaiss & Muruve, 2005), and few 
studies had examined this question in humans (Chirmule et al., 1999; Manno et al., 
2006).  This study represented the first detailed examination of human cell-mediated 
responses to AAV-2 and demonstrated that AAV-2 evoked robust proliferative and 
cytokine recall responses detectable in PBMC.   Of the 41 donors assayed for AAV-2 
stimulated PBMC proliferation, 19 demonstrated a statistically significant proliferative 
response to the antigen (Figure 4.3).  Of these, 9 donors supported stimulation indices of 
between 1.5 and 3.0; 10 donors produced higher stimulation indices, with 4 of these 
producing SI values above 10 (Figure 4.2 and 4.3).  Chirmule et al. also examined 
human PBMC proliferation in response to AAV-2 but found that only 3 of their 57 
subjects produced a stimulation index greater than 2.0 (Chirmule et al., 1999).  This 
discrepancy is most likely due to the relatively low concentration of AAV-2 used for the 
re-stimulation, a multiplicity of infection (MOI) of 100, compared to an MOI of 10,000 
(2×10
10
 drp/ml) for this study, as well as an extended stimulation time of 168 hours in 
culture compared to 96 hours for this study.  However, study population differences 
cannot be ruled out as an additional significant factor in this discrepancy.  
 Having demonstrated that the cell-mediated response to AAV-2 is more 
prevalent than previously thought, it was decided that a more detailed examination of 
the response in these positive cultures was warranted.  Given that some of the 
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proliferative responses observed were relatively strong and polarised towards a Th1 
response, there is clearly some risk that cytotoxic T-cell responses may be raised against 
AAV-2 and AAV-2-transduced cells in many recipients in a clinical setting.  Thus, an 
examination of stimulating epitopes on the AAV-2 capsid protein was pursued in order 
to establish whether common targets might be identified with a view to modifying or 
blocking immunostimulatory sequences.  Further, an analysis of any correlation between 
stimulating sequences and donor HLA expression might provide a means to predict the 
likely sequence specificity of candidate patients.  These avenues of investigation are 
explored in Chapter 5. 
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CHAPTER 5 
IDENTIFICATION OF AAV-2 EPITOPES 
RECOGNISED BY HUMAN T-CELLS 
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5.1  INTRODUCTION 
 Examination of in vitro cell-mediated responses to AAV-2 (Chapter 4) revealed 
evidence of T-cell responses in a population of healthy Irish blood donors (n = 41).  
These responses varied in strength and quality as determined by proliferation and 
cytokine production respectively.  PBMC from 19 of the 41 sampled donors displayed 
proliferative responses accompanied by varying cytokine responses following in vitro 
AAV-2 re-stimulation.  It was important to characterise the precise targets of human 
recognition of AAV-2 for three reasons.  First, CD4+ responses against AAV-2 may 
confound use of AAV-2 as a vector for gene therapy, so knowledge of T-cell epitopes 
recognised by humans may allow engineering or modification of the virus to replace 
strong epitopes.  Second, AAV-2 is an important human parvovirus; knowledge of 
epitopes may inform broader understanding of human immunology relating to these 
viruses and related viruses such as B19V (Corcoran et al., 2004).  Thirdly, AAV-2 could 
be used as a vaccine carrier and it would be important to design modifications of the 
capsid sequence that avoid destruction of T-cell epitopes (Liu et al., 2000; Zhang et al., 
2003).  The first goal of this chapter was to identify the T-cell epitopes of AAV-2 
recognised by a human population.  A strategy was adopted whereby cryopreserved 
PBMC from identified donors would be cultured and stimulated with a panel of short 
overlapping peptides derived from the AAV-2 VP1 capsid sequence to identify T-cell 
epitopes.  Epitopes identified would be correlated with the expression of specific HLA 
alleles. 
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 Mouse models have previously been used to characterize some T-cell responses 
to AAV-2 in some detail, including examinations of MHC expression and correlation 
with immunostimulatory epitopes within the AAV-2 capsid (Chen et al., 2006; Li et al., 
2007; Wang et al., 2007).  However, inbred mouse strains display limited MHC 
diversity in comparison to the highly polymorphic human HLA.  Furthermore mouse 
infection models may not represent the course of natural AAV-2 infection in humans, 
specifically failing to account for the influence of significant MHC polymorphism on 
antigen presentation and the influence of helper virus co-infection in shaping the 
effector and memory responses against AAV-2.  Thus, the second goal of this chapter 
was to characterise the HLA haplotypes of the Irish blood donor population studied.  
Following this, a bioinformatics approach was used to predict putative AAV-2 T-cell 
epitopes predicted for the haplotypes described.  Finally the results of both approaches 
were compared.  
 
5.2  IDENTIFICATION OF 59 NOVEL AAV-2 EPITOPES RECOGNISED BY AN IRISH 
POPULATION 
 There has been limited examination of the targets of cell-mediated immunity to 
AAV-2 in humans.  Therefore the ability of synthetic peptides corresponding to the 
entire sequence of the AAV-2 VP1 capsid protein to support recall responses from 
human PBMC was examined.  Frozen PBMC from the 16 donors characterised in 
Chapters 3 and 4 were reconstituted and stimulated with overlapping 20-mer peptides 
corresponding to the complete protein sequence of VP1 (Chapter 2, Table 2.2).  This 
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group represented a subgroup of the 19 donors whose PBMC produced significant 
proliferation in response to stimulation with whole AAV-2 capsid, specifically those 
donors from whom sufficient cryopreserved PBMC were available.   
 The sequence for VP1 contains the full sequence of the alternative capsid 
proteins VP2 and VP3, thus a strategy which examines VP1 covers the full range of 
epitopes present on the virus capsid.  Cultures were assessed for proliferation in 
response to the 20-mer peptides (Figure 5.1 - 5.8).  A stringent definition of an epitope 
was chosen; only stimulating pairs of adjacent 20-mer sequences were considered to 
represent an antigenic sequence recognised by T-cells, with the 12-mer consensus 
sequence overlap assumed as containing the T-cell epitope.  Peptides were considered to 
be stimulating when they elicited a stimulation index greater than one standard deviation 
above the mean proliferation level for all donors.  Using this definition, a total of 59 
epitopes were identified (Table 5.1) across the entire donor group, a finding which 
undermined the notion that the AAV-2 capsid may be easily modified to remove 
sequences which are recognised by T-cells. 
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Figure 5.1  Identification of human T-cell epitopes on AAV-2 capsid protein VP1.  
PBMC from donors studied in Chapters 3 and 4 were stimulated in vitro as described in 
Chapter 2.2.5.1.  Stimulation was performed using overlapping synthesised peptides 
(described in Chapter 2.1.4.1 and Table 2.2) corresponding to the VP1 capsid sequence 
of AAV-2.  Peptide used (horizontal axis) is graphed against SI (as described in Chapter 
2.2.5.1, horizontal axis) along with unstimulated negative controls (-) and ConA 
simulated positive controls (+).  Experiment was performed for A) donor 13 and B) 
donor 15 and was performed once for each donor.  Bars represent the mean of triplicate 
determinations. 
  
Donor 13 
Donor 15 
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Figure 5.2  Identification of human T-cell epitopes on AAV-2 capsid protein VP1.  
PBMC from donors studied in Chapters 3 and 4 were stimulated in vitro as described in 
Chapter 2.2.5.1.  Stimulation was performed using overlapping synthesised peptides 
(described in Chapter 2.1.4.1 and Table 2.2) corresponding to the VP1 capsid sequence 
of AAV-2.  Peptide used (horizontal axis) is graphed against SI (as described in Chapter 
2.2.5.1, horizontal axis) along with unstimulated negative controls (-) and ConA 
simulated positive controls (+).  Experiment was performed for A) donor 16 and B) 
donor 19 and was performed once for each donor.  Bars represent the mean of triplicate 
determinations.  
Donor 16 
Donor 19 
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Figure 5.3  Identification of human T-cell epitopes on AAV-2 capsid protein VP1.  
PBMC from donors studied in Chapters 3 and 4 were stimulated in vitro as described in 
Chapter 2.2.5.1.  Stimulation was performed using overlapping synthesised peptides 
(described in Chapter 2.1.4.1 and Table 2.2) corresponding to the VP1 capsid sequence 
of AAV-2.  Peptide used (horizontal axis) is graphed against SI (as described in Chapter 
2.2.5.1, horizontal axis) along with unstimulated negative controls (-) and ConA 
simulated positive controls (+).  Experiment was performed for A) donor 27 and B) 
donor 31 and was performed once for each donor.  Bars represent the mean of triplicate 
determinations.  
Donor 27 
Donor 31 
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Figure 5.4  Identification of human T-cell epitopes on AAV-2 capsid protein VP1.  
PBMC from donors studied in Chapters 3 and 4 were stimulated in vitro as described in 
Chapter 2.2.5.1.  Stimulation was performed using overlapping synthesised peptides 
(described in Chapter 2.1.4.1 and Table 2.2) corresponding to the VP1 capsid sequence 
of AAV-2.  Peptide used (horizontal axis) is graphed against SI (as described in Chapter 
2.2.5.1, horizontal axis) along with unstimulated negative controls (-) and ConA 
simulated positive controls (+).  Experiment was performed for A) donor 32 and B) 
donor 38 and was performed once for each donor.  Bars represent the mean of triplicate 
determinations. 
 
 
 
 
 
Donor 32 
Donor 38 
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Figure 5.5  Identification of human T-cell epitopes on AAV-2 capsid protein VP1.  
PBMC from donors studied in Chapters 3 and 4 were stimulated in vitro as described in 
Chapter 2.2.5.1.  Stimulation was performed using overlapping synthesised peptides 
(described in Chapter 2.1.4.1 and Table 2.2) corresponding to the VP1 capsid sequence 
of AAV-2.  Peptide used (horizontal axis) is graphed against SI (as described in Chapter 
2.2.5.1, horizontal axis) along with unstimulated negative controls (-) and ConA 
simulated positive controls (+).  Experiment was performed for A) donor 40 and B) 
donor 41 and was performed once for each donor.  Bars represent the mean of triplicate 
determinations. 
  
Donor 40 
Donor 41 
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Figure 5.6  Identification of human T-cell epitopes on AAV-2 capsid protein VP1.  
PBMC from donors studied in Chapters 3 and 4 were stimulated in vitro as described in 
Chapter 2.2.5.1.  Stimulation was performed using overlapping synthesised peptides 
(described in Chapter 2.1.4.1 and Table 2.2) corresponding to the VP1 capsid sequence 
of AAV-2.  Peptide used (horizontal axis) is graphed against SI (as described in Chapter 
2.2.5.1, horizontal axis) along with unstimulated negative controls (-) and ConA 
simulated positive controls (+).  Experiment was performed for A) donor 43 and B) 
donor 45 and was performed once for each donor.  Bars represent the mean of triplicate 
determinations. 
  
Donor 43 
Donor 45 
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Figure 5.7  Identification of human T-cell epitopes on AAV-2 capsid protein VP1.  
PBMC from donors studied in Chapters 3 and 4 were stimulated in vitro as described in 
Chapter 2.2.5.1.  Stimulation was performed using overlapping synthesised peptides 
(described in Chapter 2.1.4.1 and Table 2.2) corresponding to the VP1 capsid sequence 
of AAV-2.  Peptide used (horizontal axis) is graphed against SI (as described in Chapter 
2.2.5.1, horizontal axis) along with unstimulated negative controls (-) and ConA 
simulated positive controls (+).  Experiment was performed for A) donor 46 and B) 
donor 47 and was performed once for each donor.  Bars represent the mean of triplicate 
determinations. 
  
Donor 46 
Donor 47 
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Figure 5.8  Identification of human T-cell epitopes on AAV-2 capsid protein VP1.  
PBMC from donors studied in Chapters 3 and 4 were stimulated in vitro as described in 
Chapter 2.2.5.1.  Stimulation was performed using overlapping synthesised peptides 
(described in Chapter 2.1.4.1 and Table 2.2) corresponding to the VP1 capsid sequence 
of AAV-2.  Peptide used (horizontal axis) is graphed against SI (as described in Chapter 
2.2.5.1, horizontal axis) along with unstimulated negative controls (-) and ConA 
simulated positive controls (+).  Experiment was performed for A) donor 50 and B) 
donor 51 and was performed once for each donor.  Bars represent the mean of triplicate 
determinations. 
Donor 50 
Donor 51 
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5.3  IDENTIFICATION OF 17 AAV-2 EPITOPES RECOGNISED PROMISCUOUSLY BY 
HUMAN T-CELLS 
Despite the wide range of epitopes identified across the donor group, 17 
stimulating sequences were identified that were recognised by two or more donors 
(Table 5.1, labelled as sequences A-Q).  These 17 common antigenic sequences were 
identified as commonly recognised across a total of six donors (Table 5.3), hereafter 
called consensus sequences.   
Sequence A (KEVTQNDGTTTI) was the most commonly-recognised epitope, 
eliciting PBMC proliferation in cultures from 4 different donors (donors 16, 19, 50 and 
51; Tables 5.2 and 5.3).  Sequences B, C and D were each recognised in cultures from 3 
different donors and sequences E – Q were each recognised by 2 different donors 
(Tables 5.2 and 5.3).  The frequent recognition of these epitopes in the study group 
suggested that it might be reasonable to consider these sequences as representative of 
immunodominant epitopes.  Although the wide diversity of epitopes recognised by 
single donors (Table 5.1) might render mass production of modified, non-immunogenic 
AAV capsids unfeasible, the presence of a selection of immunodominant epitopes 
suggested that these might be attractive candidates for capsid modification in individual 
recipient-specific cases where alternatives to capsid modification may be undesirable. 
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a
 Consensus sequences were derived from the 12-mer overlap between pairs of PBMC 
stimulating VP1 peptides with the exception of the overlap between peptides 90 and 91 
which was 17-mer.  Pairs of peptides were considered positive if both supported an SI 
value greater than one standard deviation above the mean SI for all donors.   
  
b
 VP1 sequence was analysed using SYFPEITHI prediction for alleles of the HLA-A 
and HLA-B loci, output sequences were nonamers.   
  
c 
VP1 sequence was analysed using SYFPEITHI prediction for alleles of the HLA-
DRB locus, output sequences were 15-mers.  For both class I and II, the best score 
obtained was reported.  Scores below 20 were not reported. 
Class I 
score
b
Class II 
score
c
321 - 333 KEVTQNDGTTTI 16, 19, 50, 51 24 20 A
505 - 517 ATKYHLNGRDSL 13, 50, 51 B
241 - 253 TTSTRTWALPTY 16, 50, 51 21 24 C
681 - 693 EIEWELQKENSK 13, 50, 51 21 26 D
9 - 21 DWLEDTLSEGIR 16, 50 21 32 E
57 - 69 NGLDKGEPVNEA 16, 50 20 27 F
113 - 125 NLGRAVFQAKKR 50, 51 28 20 G
121 - 133 AKKRVLEPLGLV 40, 50 29 20 H
249 - 261 LPTYNNHLYKQI 16, 51 24 24 I
257 - 269 YKQISSQSGASN 16, 51 - 23 J
265 - 277 GASNDNHYFGYS 16, 51 26 - K
313 - 325 FKLFNIQVKEVT 16, 50 - 23 L
329 - 341 TTTIANNLTSTV 19, 50 22 24 M
393 - 405 YCLEYFPSQMLR 16, 50 21 28 N
457 - 469 QSRLQFSQAGAS 13, 16 - 25 O
553 - 565 DIEKVMITDEEE 13, 50 21 30 P
716 - 728 TNGVYSEPRPIGTRYLT 16, 51 24 21 Q
TABLE 5.2 Common VP1 consensus sequences
a
 recognised by human PBMC
Peptide VP1 consensus sequence
Respondant 
donors
SYFPEITHI 
Seq.
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5.4  CHARACTERISATION OF THE HLA HAPLOTYPES OF THE IRISH DONOR 
POPULATION USED IN THIS STUDY   
 T cell recognition of antigen in mammals is MHC restricted.  Humans are an 
outbred population with highly polymorphic HLA expression profiles.  In order to 
establish if the AAV-2 epitopes identified were associated with particular haplotypes, 
the HLA haplotype for each AAV-2 respondent donor was determined.  To achieve this, 
an sequence specific primer (SSP) PCR approach was adopted.  The HLA-A, B, C, DRB 
and DQB loci were characterised using a commercial SSP PCR kit (Texas Biogene, 
Richardson, TX).  The kit did not include primers for the HLA-DP, DRA or DQA loci.  
SSP PCR used a panel of lyophilised sequence-specific primers in a tray format.  Wells 
contained multiple primers acting as templates for products of differing sizes.  Genomic 
DNA was dissolved in a master mix and added to the primer tray, and PCR was 
performed (Chapter 2.2.4.7), resulting in multiple DNA products for each target locus.  
Genomic DNA was isolated from cryopreserved PBMC from the panel of 16 responding 
donors.  The combination of products and their size as read on an agarose gel could be 
used to identify the allele at the locus of interest following the documentation provided 
by the manufacturer (example gel depicted in Figure 5.9).   
 As would be expected in an outbred population, the donors characterised 
displayed considerable haplotype diversity (Table 5.3).  No obvious correlations 
between HLA expression and epitope recognition were detectable in a sample of this 
size.  However, the key observation from this study was that the dominant 17 epitopes 
described in Table 5.2 were recognised by donors of different HLA haplotypes, 
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indicating that these epitopes of the AAV-2 capsid are recognised promiscuously.  It is 
therefore reasonable to consider these epitopes immunodominant. 
 
a
 HLA type I and II alleles were determined by SSP PCR.  Alleles omitted where not 
determined.
Donor # Class I HLA alleles
a
Class II HLA alleles
a
13 A2, B7, B13, Cw5, Cw7 DR4/DR53, DR7/DR53, DQ2, DQ8(3)
15 B7, B8, Cw7 DR17(3)/DR52, DR15(2)/DR51, DQ2, DQ6(1)
16 A1, Cw7, Cw7 DR17(3)/DR52, DR51, DQ2, DQ6(1)
19 A68, B8, Cw7, Cw8 DR3/DR52, DR17(3)/DR52, DQ2, DQ6(1)
27 A1, A2, B*4440, B*5615, Cw5, Cw7 DQ2, DQ7(3)
31 A1, B8, B51(5) DR17(3)/DR52, DR8, DQ2, DQ4
32 A1, A29(19), Cw7, Cw7 DR17(3)/DR52, --/DR52, DQ2, DQ6(1)
38 A1, B63(15), B44(12), Cw5, Cw7 DR4/DR53, DR13(6)/DR52, DQ7(3), DQ6(1)
40 Cw1, Cw7 DR1, DR7/DR53, DQ2, DQ5(1)
41 A2, B44(12), B47, Cw4 DR4/DR53, DR7/DR53, DQ2, DQ7(3)
43 A31(19), B7, B71(70), Cw18||Cw6, Cw18
DR4/DR53, DR15(2)/DR51, DQ6(1), DQ6(1)
45 A2, A24(9), B7, B18, Cw5, Cw7 DR17(3)/DR52, DR15(2)/DR51, DQ2, DQ6(1)
46 B55(2), Cw1, Cw4 DR103, DR13(6)/DR52, DQ5(1), DQ6(1)
47 A1, B42 DR4/DR53, DR4/DR53, DQ8(3), DQ5(1)
50 A31(9), B*14, B*14, Cw*06, Cw*08 DR13(6)/DR52, DR15(2)/DR51, DQ9(3)
51 A66(10)/A26(10), B44(12), B57(17), Cw5, Cw6 DR4/DR53, DR15(2)/DR51, DQ6(1), DQ6(1) 
TABLE 5.3 HLA haplotypes of donors responding to AAV-2
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5.5  ANTIGENIC SEQUENCES IDENTIFIED CORRESPOND TO HLA-RESTRICTED 
EPITOPES PREDICTED IN SILICO 
 Probable HLA- and MHC-restricted epitopes may be predicted from an input 
protein sequence algorithmically and several such algorithms have been developed 
(Bhasin & Raghava, 2004; Rammensee et al., 1999). The SYFPEITHI algorithm 
evaluates every amino acid within an input protein sequence and assigns a score to each.  
The SYFPEITHI database and epitope scoring algorithm was thus used to generate a 
panel of probable HLA-restricted epitopes derived from the AAV-2 VP1 capsid 
sequence.  The scores assigned are based upon the frequency and binding effect of 
amino acids identified at each location within naturally-occurring HLA ligands, with the 
frequencies and binding effects being derived from a database of identified natural HLA 
ligands.   Each amino acid in the input sequence is assigned a score ranging from 1 
(indicating a slight benefit to HLA binding) to 15 (indicating an optimal anchor residue), 
or is assigned a negative score if the amino acid has a detrimental impact on HLA 
binding.  These scores are also dependant on the input HLA type.  At the time of testing, 
the algorithm only permitted assessment of a limited panel of class I and class II HLA 
types (Table 5.4) and the VP1 sequence was assessed for all available human class I and 
class II types.  For the class I epitopes, the sequence window size was limited to 
nonamers, whilst the class II sequences were 15-mers.  A panel of putative epitopes 
covering the full range of scores above 0 was generated for each HLA allele.  In each 
case, the SYFPEITHI score of the highest-scoring sequence possessing greater than 85% 
homology with the epitopes previously identified (Tables 5.1 and 5.2) was reported.  
Only scores greater than 20 were reported. 
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a
  HLA serotypes were determined by SSP PCR for HLA loci A, B, C DR and DQ. 
HLA class I
a
A B C DR DQ
13 ND ND Cw1, Cw7 DR1, DR7/DR53 DQ2, DQ5(1)
16 A68 B8 Cw7, Cw8
DR3/DR52, 
DR17(3)/DR52
DQ2, DQ6(1)
19 A2 B7, B13 Cw5, Cw7 DR4/DR53, DR7/DR53 DQ2, DQ8(3)
40 A1 B42 ND DR4/DR53, DR4/DR53 DQ8(3), DQ5(1)
50 ND B55(2) Cw1, Cw4 DR103, DR13(6)/DR52 DQ5(1), DQ6(1)
51 A31(19) B7, B71(70)
Cw18/Cw6, 
Cw18
DR4/DR53, 
DR15(2)/DR51
DQ6(1), DQ6(1)
A, B, D, E, H, I, J, K, M, N, P, 
Q
L
G
A, B, C, D, E, F, G, K, L, M, O
A, B, C, F, H, I, J, P, Q
C, N, O
TABLE 5.4  Donor PBMC with diverse HLA haplotypes recognise common consenus sequences 
Donor
HLA class II
a
Consensus sequences 
recognised
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 The 17 immunodominant sequences described in table 5.1 each showed greater 
than 85% homology with high-scored class I or class II HLA-restricted VP1 epitopes 
predicted by the algorithm (Table 5.1).  Combined with the frequency with which these 
epitopes elicited proliferation in PBMC cultures (Section 5.3) and the promiscuous 
recognition across multiple Class I and Class II HLA types (Section 5.4), the high 
SYFPEITHI scores gave further confidence that this panel of 17 sequences represented 
immunodominant epitopes in the study group. 
 
5.6  HLA HAPLOTYPES OF DONORS DISPLAYING MEMORY FOR AAV-2 DO NOT 
DIFFER FROM THE GENERAL POPULATION 
 The haplotypes of AAV-2-respondant donors displayed considerable diversity 
(Table 5.3).  This was also the case for donors responding to the most common 
stimulating capsid sequences (Table 5.4).  Although it is reported here that the DQ2, 
DQ3 (DQ7(3), DQ8(3), DQ9(3)) and DQ6(1) serotype alleles are present at a high 
frequency in our study group, these results broadly agree with recent detailed 
examinations of HLA allele frequencies in the Irish population, in which these serotypes 
represented the three most commonly identified (Dunne et al., 2008).  Thus, although 
the HLA data presented here is less exhaustive, the donors from which AAV-2-specific 
PBMC were isolated display HLA diversity comparable to the general Irish population. 
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Figure 5.10  3D structural diagram of the AAV-2 capsid showing the location of the 
immunodominant epitopes A-D (yellow) in the context of the capsid structure (blue).  
The icosahedral symmetry of the capsid is indicated in each case (red lines) and the 5-
fold, 2-fold and 3-fold axes of symmetry, which form the boundaries where VP subunits 
associate, are labelled (a, b and c, respectively).  In each case, capsid structure is 
presented as a 60 subunit polymer consisting entirely of VP3 subunits.  Structure is as 
determined by Xie et al., 2002 and is rendered using STRAP. 
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5.7  IMMUNODOMINANT EPITOPES OF AAV-2 COMPRISE FUNCTIONALLY SIGNIFICANT 
REGIONS OF THE VP1 CAPSID 3D STRUCTURE 
 Various motifs within the 3D structure of the AAV-2 capsid are involved in 
receptor binding and replication functions (Tratschin et al., 1984, Girod et al., 2002, 
Asokan et al., 2006, DiPrimio et al., 2008).  Since the immunodominant epitopes 
identified in Section 5.3 might be targets for modification in order to minimise adaptive 
recognition of the virus in a therapeutic setting, it was important to establish whether 
these epitopes lay within functionally important regions of the capsid.  Thus, where 
possible, the immunodominant epitope sequences were mapped onto a 3D structure of 
the AAV-2 capsid.   
 The most commonly-recognised immunodominant epitope identified in this 
study was sequence A (KEVTQNDGTTTI; Chapter 5, Table 5.1), which shared 4-mer 
homology with two other immunodominant epitopes, sequences L (FKLFNIQVKEVT) 
and M (TTTIANNLTSTV).  These sequences would thus be attractive targets for 
modification.  When sequence A was mapped onto the 3d model of the AAV-2 capsid 
(Figure 5.10) it was found that the sequence lies within part of the loop formed between 
beta strands H and I (HI loop) of the VP subunit, though to be essential for viral capsid 
assembly and viral DNA packaging into the capsid (DiPrimio et al., 2008).  Sequence B 
(ATKYHLNGRDSL) was found to be located at the base of a cluster of protrusions on 
the AAV-2 capsid, which is composed of overlapping loops from three subunits 
associating at the 3-fold symmetry axis at the centre of each icosahedral face (Figure 
5.10).  This sequence has been shown to have an integrin-binding function (Asokan et 
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al., 2006).  Sequence C is located in the region directly adjacent to the 5 fold capsid pore 
structure composed of sequences A, L and M (Figure 5.10 and Figure 5.11).  Sequence 
D is located along the icosahedral vertex connecting 5-fold symmetry axes, close to the 
2-fold subunit border region (Figure 5.10).  Sequence N which is located close to the 5-
fold axis may also serve a scaffolding function for the capsid pore (Figure 5.11).  
Sequence Q, like sequence D, is located close to the 2-fold subunit border (Figure 5.11). 
Epitope sequences E-H are located within the N-terminal VP1 unique region and thus 
could not be mapped onto the 3D structure as it was composed exclusively of VP3 
subunits.  The location and function of the unique region within the capsid 3D structure 
is not well-established (Kronenberg et al., 2005).   
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Figure 5.11  3D structural diagram of the AAV-2 capsid showing the location of the 
immunodominant epitopes I-Q (yellow) in the context of the capsid structure (blue).  
The icosahedral symmetry of the capsid is indicated in each case (red lines) and the 5-
fold, 2-fold and 3-fold axes of symmetry, which form the boundaries where VP subunits 
associate, are indicated (a, b and c, respectively).  In each case, capsid structure is 
presented as a 60 subunit polymer consisting entirely of VP3 subunits.  Structure is as 
determined by Xie et al., 2002 and is rendered using STRAP. 
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5.8  IMMUNODOMINANT EPITOPES OF AAV-2 ARE HIGHLY CONSERVED IN AAV 
SEROTYPES 1, 4, 6 AND 8 
 An alternative to the modification of AAV-2 capsids is use of capsids from other 
AAV serotypes.  The sequences of the VP1 capsid proteins vary between AAV 
serotypes and this may mean that immunodominant epitopes present on the AAV-2 
capsid may not be conserved in other serotypes.  When the VP1 sequences for AAV 
serotypes 1, 2, 4, 6 and 8 are compared for the conservation of the 4 most commonly-
recognised immunodominant epitopes described here (Section 5.3) it is evident that 
sequences A and D are fully or highly conserved across all 5 serotypes (Figure 5.12).  
Sequence C was fully conserved across all 5 serotypes whilst sequence B was less well 
conserved across the top 4 immunodominant epitopes.  The epitopes were least 
conserved in AAV-4; although sequence C was fully conserved, only 7 of 12 amino 
acids from epitope A were conserved, whilst sequences B and D were represented by 5 
of 12 and 8 of 12 amino acids respectively (Figure 5.12). 
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Figure 5.12  Multiple sequence alignment of immunodominant epitopes A-D.  The VP1 
capsid sequence of AAV-2 was aligned with the VP1 sequences of AAV-1, AAV-4, 
AAV-6 and AAV-8 using ClustalW.  Residue numbers are indicated with digits above 
each alignment.   
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5.9  SUMMARY 
 Stimulation of PBMC from a subset of donors (n=16) with overlapping VP1 
capsid peptides allowed the identification of 59 AAV-2-specific T-cell epitopes.  The 
AAV-2 capsid is composed of three proteins; VP1, VP2 and VP3 in a ratio of 1:1:10 
(Xie et al., 2002).  VP2 and VP3 are products of the splicing of Cap open reading frame 
mRNA, and both proteins represent subsequences of the VP1 protein.  Thus, the entire 
capsid sequence may be represented by VP1.  Using a restrictive definition, 17 
candidate epitope sequences were identified as recognised by at least two donors (Table 
5.2).  A further 42 sequences were recognised by a single donor each (Table 5.1).  The 
stringent epitope definition combined with limitations in assay sensitivity due to the 
modest level of PBMC proliferation induced by AAV-2 and its components mean that 
some of the more limited proliferative responses observed may have represented false 
negative results.  Thus, it is likely that further single-case candidate epitopes or 
confirmations of existing single-case candidate epitopes were not detected.  The panel of 
single-case and frequently recognised candidate epitopes includes sequences (Tables 5.1 
and 5.2) previously identified in human and mouse studies (Chen et al., 2006; Manno et 
al., 2006; Sabatino et al., 2005).  
 No significant correlation could be identified between donor HLA class I and 
class II haplotypes and the corresponding epitopes recognised.  The haplotypes of AAV-
2 respondent donors displayed considerable diversity (Table 5.4).  This was also the 
case for donors responding to the most common stimulating capsid sequences (Table 
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5.3).  Although it is reported here that the DQ2, DQ3 (DQ7(3), DQ8(3), DQ9(3)) and 
DQ6(1) serotype alleles are present at a high frequency in our study group, these results 
broadly agree with recent detailed examinations of HLA allele frequencies and 
haplotypes in the Irish population in which these three serotypes represented the three 
most commonly identified (Dunne et al., 2008).  Thus, although the HLA data presented 
here is less exhaustive, the donors from which AAV-2-specific PBMC were isolated 
display HLA diversity comparable to the general Irish population.  The observation that 
a number of epitopes can be recognised by donors of different HLA haplotypes indicates 
that epitopes A, B, C and K are candidate immunodominant human epitopes. 
 The induction of humoral immune responses by AAV-2 characterised in 
Chapters 3 gave some cause for concern that AAV-2-based gene therapy vectors might 
face neutralisation and targeted complement degradation if administered to AAV-2 
primed recipients in the Irish population.  The cell-mediated responses characterised in 
Chapters 4 might result in targeted destruction of AAV-2 vector transduced cells.  
Although it has been suggested (Manno et al., 2006) that vector modification strategies 
might be employed to circumvent both humoral and cell-mediated adaptive responses, 
the diverse panel of candidate immunostimulatory targets identified in this chapter 
undermines the practicality of such an approach.  Although other means of preventing 
immune memory recognition of AAV-2 are discussed in Chapter 7, one alternative 
strategy considered for investigation here would be to conduct transductions on human 
cells ex vivo and then infuse those cells into the recipient.  Typically such a strategy 
would demand that the transduced cells be autologous to the recipient, which is not 
practical for all applications.  However some types of adult stem cells such as 
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mesenchymal stem cells (MSC) have been shown to evade allorecognition and would 
thus be attractive candidate cells for such ex vivo transduction.  The transduction of 
murine MSC with gene delivery vectors including AAV-2 is investigated in Chapter 6. 
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CHAPTER 6 
THE IMPACT OF GENE DELIVERY ON 
MESENCHYMAL STEM CELLS 
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6.1  INTRODUCTION 
 Mesenchymal stem cells (MSC) are candidate agents for a variety of 
regenerative therapies (Djouad et al., 2009; Markert et al., 2009).  MSC possess a 
number of traits which make them attractive mediators of regenerative therapy.  They 
can be repeatedly subcultured whilst maintaining an undifferentiated state (Bianco et al., 
2008).  MSC are known to have a broad immunomodulatory functions (Aggarwal & 
Pittenger, 2005; Barry et al., 2005; English et al., 2007; English et al., 2008; Ryan et al., 
2007) and thus may be attractive gene therapy vectors in their own right if engraftment 
can be ensured.  They can undergo in vitro differentiation into cartilage, bone and fat 
tissue when cultured in media supplemented with appropriate growth factors (Mackay et 
al., 1998; Pittenger et al., 1999; Wakitani et al., 1994).  There is also evidence that MSC 
can contribute to tissue regeneration and repair in vivo, although it is unclear whether 
this is mediated by cell fusion, healing factor secretion, in vitro differentiation, or a 
combination of these mechanisms (Koc et al., 2002; Tran et al., 2003; Wang et al., 
2003).  Also, the previously-mentioned immunomodulatory capacity appears to afford 
allogeneically transplanted MSC some protection from allorejection (Deng et al., 2004).   
 This feature makes MSC of particular interest in transplant immunology.  It is 
conceivable that even if MSC cannot fulfil their differentiation potential in vivo, that 
MSC may have a therapeutic function when used in conjunction with organ 
transplantation, perhaps modulating the effects of graft versus host disease 
(Bartholomew et al., 2002; Le Blanc et al., 2004).  As differing factors mediate their 
immunomodulatory effects by different means, it was hypothesised that the overall 
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inhibition effect might be due to a combination of factors captured in the precursor 
cohort model of lymphocyte proliferation (Hawkins et al., 2007).  Carboxyfluorescein 
diacetate succinimidyl ester (CFSE) staining of naive T-cells co-incubated with MSC 
and examination of their proliferation by flow cytometry at multiple time points should 
highlight the relative importance of these factors.  Thus, a combination of tritiated 
thymidine incorporation and CFSE staining in conjunction with precursor cohort 
analysis was used to assess the immunomodulatory capacity of MSC.   
 The therapeutic potential of MSC may also be enhanced by transgenic 
modification.  If MSC can be genetically modified using viral vectors, this 
immunomodulatory function may serve to block potentially deleterious host immune 
responses to the vector.  Viral vector modification of MSC might provide therapies for 
the treatment of bone lesions (Gadi et al., 2001) and cancers (Mohr et al., 2008; Studeny 
et al., 2002).  The approach here was to determine whether murine MSC could be 
efficiently transduced using an AAV vector carrying a reporter transgene.  Initial studies 
would examine transduction using an eGFP reporter gene, and then progress to using a 
transgene with a therapeutic function.  The inhibition of T-cell proliferation mediated by 
MSC is dependent on a number of cell contact-dependent and independent factors.  One 
potential goal for genetic modification of MSC would be the enhancement the 
immunomodulatory function.  As the immunomodulatory function of MSC is at least 
partially mediated by indoleamine-pyrrole 2,3-dioxygenase (IDO) in both mouse models 
and in humans (English et al., 2007; Ryan et al., 2007; Yang et al., 2009), it was 
decided that the candidate transgene tested would be the IDO gene.  For the transduced  
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MSC to maintain their therapeutic potential, it would thus be important to determine 
whether features such as immunomodulation and differentiation capacity were impacted 
by the transduction protocol. 
 
6.2  CHARACTERISATION OF MURINE MSC 
 Murine mesenchymal stem cells (male BALB/c) were obtained from Dr. Karen 
English and Laura Tobin.  These cells had previously been characterised and displayed 
fibroblastic morphology, self-renewal, potency and immunomodulatory behaviour.  The 
cells were also positive for Sca-1, MHC class I and CD44 and negative for MHC class 
II, CD90, CD80, CD105, CD45, CD11b and CD34 (English, Barry et al. 2007).  
Following recovery of the cells from cryopreservation, these characteristics were 
reassessed to ensure that the results of this study would be comparable to previous work.  
The MSC used in this study displayed spindle-like fibroblastic morphology when 
examined by light microscopy (Figure 6.1 A), were MHC class I and Sca-1 positive and 
MHC class II and CD90 negative as assessed by flow cytometry (Figure 6.1 B).  
Potency was validated by differentiation assays for adipogenesis (Chapter 2.2.5.4) and 
osteogenesis (Chapter 2.2.5.5).  The MSC used here did not spontaneously differentiate 
but on appropriate stimulation differentiated into both fat and bone cells within 21 days 
of culture (Figure 6.2). Thus the cells were characteristic of MSC.  
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Figure 6.1  Characterisation of the morphology and surface marker expression profile of 
murine mesenchymal stem cells.  A)  Murine MSC as examined under light microscope. 
Light microscopy was performed at 200x magnification.  B) Analysis by of murine 
MSC by flow cytometry, showing forward (FSC) and side scatter (SSC) as well as 
expression of MHC class I, Sca-1, MHC class II and CD90.  Black peaks are isotype 
controls, whilst red peaks show receptor expression. 
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Figure 6.2  Characterisation of the potency of murine MSC in vitro.  MSC were 
cultured in growth medium or in differentiation medium for 21 days.  A) MSC cultured 
in growth medium show no evidence of adipogenesis when stained with Oil Red O, 
whilst B) MSC cultured in adipogenesis medium showed distinctive red-stained 
adipocytes.  C) MSC cultured in growth medium showed no evidence of the presence of 
osteocytes when stained with Alizarin Red S, whilst D) MSC cultured in osteogenesis 
medium  displayed many red cells and large plaques of red- and orange-stained calcified 
deposits.  Light microscopy was performed at 200x magnification. 
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 MSC immunomodulation was assessed by co-incubation of MSC with mitogen 
stimulated splenocytes.  A dose of 1×10
5
 MSC/ml significantly (p ≤ 0.05) suppressed 
mitogen stimulated splenocyte proliferation (Figure 6.3 A).  This immunomodulatory 
function extended to MHC mismatched lymphocytes.  Mouse naive T-cells (female 
BALB/c) were stimulated with αCD3e and IL-2 and incubated in medium alone or with 
varying concentrations of allogeneic murine MSC (female C3H).  At a concentration of 
1×10
5
 MSC/ml, T-cell proliferation was significantly (p ≤ 0.05) inhibited compared with 
mitogen stimulated controls (Figure 6.3 B).  This result is broadly in agreement with 
previous work demonstrating a dose-dependent suppression of murine splenocyte 
(English et al., 2007) and human PBMC proliferation (Ryan et al., 2007). 
 
6.3  LOW CONCENTRATIONS OF ALLOGENEIC MSC SYNERGISE WITH MITOGEN TO 
PROMOTE T-CELL PROLIFERATION 
 Concentrations of MHC-mismatched MSC of 1×10
5
 or greater inhibited 
mitogen-stimulated naive T-cell proliferation (Figure 6.3).  At 2×10
4
 MSC/ml 
proliferation of stimulated naive T-cells was observed, however this increase did not 
reach statistical significance.  However at 5×10
3
 cells/ml, MSC significantly (p ≤ 0.05) 
enhanced mitogen driven naive T-cell proliferation (Figure 6.3 B).  Given that murine 
MSC do not express MHC class II and modest levels of MHC class I, it is unclear 
whether this enhanced proliferation is in response to allorecognition between the 
BALB/c strain T-cell receptor and the C3H strain MSC MHC I receptor, or is the result 
of MSC derived soluble factors.   
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Figure 6.3  Characterisation of murine MSC immunomodulatory function.  A)  Murine 
splenocytes co-cultured with 1×10
5
 MSC/ml and stimulated with conA were compared 
with stimulated and unstimulated splenocyte controls.  B)  Co-culture of conA-
stimulated splenocytes with 1×10
5
, 2×10
4
 and 5×10
3
 allogeneic MSC/ml compared with 
stimulated and unstimulated splenocyte controls.  Proliferation by splenocytes was 
expressed as mean CPM of triplicate determinations.  Significant suppression of 
proliferation is indicated (*).  Error bars represent the standard deviation.  Experiments 
were performed twice independently. 
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6.4  MSC MEDIATE THEIR IMMUNOSUPPRESSIVE FUNCTIONS VIA CHANGES IN 
PROGRESSOR FRACTION AND MEAN DIVISION TIMES 
 To examine the immunosuppressive or immunostimulatory effects of MSC on 
naive allogeneic T-cells (Figure 6.3 B), a CFSE-based proliferation assay was 
employed.  CFSE is a cell-permeable dye which is detectable via flow cytometry.  When 
a cell stained with CFSE undergoes symmetric mitosis, the dye is divided equally 
between the two daughter cells.  It is thus possible to determine the number of divisions 
that a given cell has undergone by comparing the cell’s fluorescence intensity with that 
of undivided cells at the time of staining.  CD4
+
 CD62L
+
 naive T-cells were isolated 
(Chapter 2.2.1.3) and stained with CFSE (Chapter 2.2.5.3).  The isolation was validated 
by flow cytometry.  Isolated cells were labelled with fluorescently-labelled antibodies 
specific for the T-cell receptor CD3 and the naive marker CD62L (Chapter 2.2.1.3, 
Table 2.3).  Using the isolation kit following manufacturer’s protocol, splenocyte 
isolates were enriched from 25% CD3
+
 CD62L
+
 (Figure 6.4 A) up to 90% CD3
+
 
CD62L
+
 (Figure 6.4 B). 
 Stained naive T-cells were stimulated with αCD3, IL-2 and αCD28 and cultured 
alone or with MHC-mismatched MSC at 5×10
3
 or 1×10
5 
MSC/ml.  Lymphocyte 
proliferation was assessed by flow cytometry at 24, 48, 72 and 96 hours (Figure 6.5).  
Multiple parameters contributing to gross lymphocyte proliferation were then 
quantified; progressor fraction, cell survival, mean time to first division and subsequent 
mean division time (Chapter 2.3.2). 
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Figure 6.4  Validation of the CD3 CD62L naive T-cell isolation method.  Non-
separated (A) and separated (B) splenocyte suspensions were examined by flow 
cytometry and events were gated by side scatter (SSC-H) and forward scatter (FSC-
H) for live lymphocytes (gate labelled R0 in the scatter plots).  Cells were labelled 
with fluorescent antibodies for CD3 and CD62L.  Double positive cells, considered 
to be naive T-cells, lie within the upper right quadrant of the CD3/62L dot plots.  
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Figure 6.5  Characterisation of murine MSC immunomodulation of allogeneic 
splenocyte proliferation by CFSE assay.  A)  CFSE curves for naive T-cells stimulated 
with αCD3, IL-2 and αCD28 in co-culture with MSC at 1×105 and 1×103 cells/ml or 
without MSC. A peak representing cells in division 0 is visible at the 24 hour time point 
for all three treatments.  Peaks appearing to the left of this peak in later time points 
represented cell populations in division 1 and above.  B)  The progressor fraction 
(determined as described in Chapter 2) was compared in all three cultures (1×10
5 
MSC/ml co-culture, circular points; 1×10
3 
MSC/ml co-culture, square points; stimulated 
T-cells alone, triangular points) at 24 hours, 72 hours and 96 hours. 
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6.4.1  MSC reduced the mitogen-stimulated naive T-cell progressor fraction 
 Lymphocyte proliferation can be modulated by changes to the percentage of 
cells which enter into a first cell division from the resting state during the course of an 
experiment- a feature of lymphocyte proliferation models termed the progressor fraction 
(Chapter 2.3.2).  Progressor fractions for the naive T-cells incubated with MSC (1×10
5
 
MSC/ml) at 24, 48, 72 and 96 hours were compared to those of stimulated naive T-cells 
alone (Figure 6.5 B).  When MSC were co-incubated, the naive T-cell progressor 
fraction (0.19% of starting cell population) was only marginally higher than stimulated 
controls without MSC (0.15%) at 24 hours.  By 48 hours, the MSC co-incubated T-cell 
progressor fraction had risen to 12.16% whilst those of stimulated controls were 6.8%.  
However, by 72 hours the progressor fraction of the MSC co-incubated cells (28.93%) 
was less than that of the stimulated, MSC-negative controls (37.59%).  By 96 hours the 
progressor fraction in the stimulated controls (69.75%) had risen to more than double 
that of MSC co-incubated cells (28.34%).  These results indicated that modulation of 
progressor fraction was an important feature of the immunosuppressive capacity of 
MSC. 
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6.4.2  MSC concentrations below a threshold enhanced the mitogen-stimulated 
naive T-cell progressor fraction 
 Naive mouse T-cells stimulated with αCD3e and IL-2 were co-incubated with 
allogeneic MSC at a concentration (5×10
3
 MSC/ml) previously demonstrated to enhance 
mitogen-stimulated T-cell proliferation (Figure 6.3 B).  At the 48 hour and 72 hour time 
points, the progressor fraction for these MSC co-incubated T-cells was higher than those 
of either the stimulated controls or the T-cells co-incubated with 1×10
5
 MSC/ml (Figure 
6.5 B).  By 96 hours the stimulated control progressor fraction (69.75%) and the low 
concentration MSC co-incubated T-cell progressor fraction (68.62%) were comparable.  
Thus MSC concentrations below a threshold of 5×10
3
 MSC/ml enhance the mitogen-
stimulated naive T-cell progressor fraction 
 
6.4.3 MSC delayed naive T-cell entry to first division 
 Lymphocyte proliferation may be modulated by changes to the mean time to first 
division following stimulation.  A shortened mean time to first division will tend to 
enhance proliferation within a given time frame, whilst delay to first division will reduce 
gross proliferation.  The mean times to first division were therefore calculated (Chapter 
2.3.2) for naive T-cells stimulated with αCD3e and IL-2 alone or co-incubated with 
MSC at 5×10
3
 cells/ml or MSC at 1×10
5
 cells/ml (Table 6.1).  The mean time to first 
division was comparable between the stimulated controls (63.8 hours) and the naive T-
cells co-incubated with a low dose of MSC (63.6 hours).  Thus it seems that the 
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stimulatory effect driven by low doses of allogeneic MSC is not related to changes in 
time to first division.  However, naive T-cells co-incubated with the higher dose of MSC 
showed a delay in entering first division with a mean time of 71.8 hours.  Along with 
progressor fraction, it seems likely that delays to mean time to first division contribute 
to the T-cell immunosuppressive behaviour of MSC. 
 
6.4.4  MSC increased naive T-cell mean division time 
 The rate at which lymphocytes divide after first division also contributes to gross 
lymphocyte proliferation.  A longer mean division time will reduce the number of 
lymphocytes generated by mitosis per unit time.  Mean division times were comparable 
between mitogen stimulated naive T-cells in the absence (41.4 hours) or co-incubated 
with low dose of MSC (41.1 hours) (Table 6.1).  The stimulatory effect driven by low 
doses of allogeneic MSC was thus not related to changes in mean division time.  
However, the naive T-cells co-incubated with the higher dose of MSC did show an 
increased mean division time (83.0 hours).  Thus the immunosuppressive behaviour of 
MSC on naive mitogen stimulated T-cells was mediated by modulation of mean division 
time, progressor fraction and mean time to first division. 
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6.5  MSC ARE REFRACTORY TO TRANSDUCTION BY AAV-2 GFP 
 Evidence of successful transduction was also examined by flow cytometry.  A 
human embryonic kidney cell line (HEK 293) was used as a positive transduction 
control.  HEK 293 cells are permissive to AAV-2 transduction.  Transduction of these 
cells (Chapter 2.2.6.1) with an AAV-2GFP vector at two different doses (4×10
7
 drp/ml 
and 1.3×10
8
 drp/ml) for 24 hours resulted in GFP expression detectable as an increase in 
mean fluorescence intensity (MFI) on FL1 compared with non-transduced HEK 293 
(Figure 6.6).  This approach was also adopted for murine MSC.  BALB/c MSC were 
incubated with AAV-2GFP at two doses (4×10
7
 drp/ml and 1.3×10
8
 drp/ml) for 24 
hours.  Despite noticeable differences in scatter characteristics between MSC and HEK 
293 cells (Figure 6.6), the auto fluorescence for non-transduced cells was comparable 
for both cell populations.  Despite incubation with identical doses of AAV-2GFP for 
HEK 293 transduction, no increase in fluorescence could be detected for murine MSC.  
Although work in human and rat MSC has suggested that higher doses of AAV-2 might 
induce some GFP production (McMahon et al., 2006; Stender et al., 2007), limited 
stocks of the virus made testing this approach in our model impractical.  Thus in order to 
further explore the effects of gene delivery on MSC, an alternative approach was 
required. 
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Figure 6.6  Transduction of murine MSC with an AAV-2-based vector containing a 
GFP reporter gene.  A)  Examination of AAV-2 permissive HEK-293 cells and murine 
MSC following incubation with 7×10
7 
and 1.3×10
8 
drp/ml of AAV-2GFP.  Background 
autofluorescence (blue), 7×10
7
 drp/ml dose (green) and 1.3×10
8 
drp/ml dose (red).  B)  
Fluorescence (Mean fluorescence intensity, FL1) for MSC cultures (closed bars) was 
compared to control HEK-293 (open bars) following incubation with 7×10
7 
and 1.3×10
8 
drp/ml of AAV-2GFP.  Results are representative of two independent experiments. 
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6.6  MSC CAN BE TRANSFECTED WITH IDO BY LIPOFECTION 
 Since transduction of MSC with AAV was unsuccessful, it was decided to 
attempt direct transfection of the MSC using a plasmid via lipofection (Chapter 2.2.6.2).  
As IDO is a potentially useful gene for the enhancement of MSC immunomodulatory 
function, this gene was selected to be transfected into MSC under the control of a 
constitutively active promoter to assess the effects on MSC function and 
immunomodulatory characteristics.  A pSport6CMV plasmid (Figure 2.2) encoding an 
IDO gene was complexed with a Lipofectamine 2000 vector and transfected into murine 
MSC (BALB/c).  Successful transfection was assessed by RT-PCR for IDO RNA and 
western blot for IDO protein. 
 Examination of RNA isolated from transfected MSC by RT-PCR for IDO at 24 
hours revealed elevated IDO transcription compared with non-transfected MSC (Figure 
6.6 A).  IDO expression diminished after 24 hours but remained above that of non-
transfected cells until 7 days post transfection (Figure 6.7 A).  Western blot analysis 
(Chapter 2.2.4.10) was conducted on transfected and non-transfected MSC cell lysates.  
IDO protein product was detected in transfected cell lysates at a greater level than non-
transfected cells (Figure 6.7 B).  However, similar IDO levels were found in lysates 
from mock transfected cells, suggesting that IDO might be induced by the lipofectamine 
complex.  Nevertheless this work demonstrated that MSC could be transfected with 
immunomodulatory genes using a lipofection-based approach. 
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Figure 6.7  Transfection of murine MSC with an IDO plasmid by lipofection.  Murine 
MSC were transfected as described in Chapter 2.2.6.2.  A)  RNA for IDO was detected 
by semi-quantitative RT-PCR in transfected (+) MSC at day 1 and was still detectable 
but reduced at day 7.  B)  IDO protein upregulation was detected in transfected and 
mock transfected MSC.  C)  IDO product kynurenine was detectable in supernatants 
from transfected and mock transfected cultures by HPLC.  Supernatants were examined 
at 24 hours (open bars) and 48 hours (closed bars).  Kynurenine levels increased in 
supernatants from transfected MSC cultures between 24 and 48 hours. 
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6.6.1  MSC transfected with the IDO transgene produced active IDO 
 IDO mediates its immunosuppressive effects by catalysing the metabolism of 
tryptophan into kynurenine.  Thus kynurenine concentration may be used as a surrogate 
measure of IDO activity.  The resulting tryptophan-depleted microenvironment inhibits 
microbial growth as well as suppressing T-cell proliferation (Meisel et al., 2004; Mellor 
& Munn, 2001).  It is also thought that the kynurenine by-product may itself be an active 
immunomodulatory soluble factor (Frumento et al., 2002).  To determine whether 
transfection of MSC with IDO produced a functional IDO product, samples of 
supernatant from IDO-transfected, mock transfected and non-transfected MSC cultures 
were examined for the presence of kynurenine by HPLC (Chapter 2.2.5.6).  Despite an 
inability to detect differences in IDO levels between transfected and mock transfected 
cells, IDO activity was higher in transfected cells (Figure 6.7 C).  Kynurenine levels in 
supernatants from IDO transfected MSC were 1.0 µM at 24 hours post transfection and 
1.8 µM at 48 hours post transfection.  Mock transfection, which was previously shown 
to induce some IDO upregulation, also resulted in some kynurenine production, but 
levels had not increased above 0.5µM by 48 hours post transfection.  Although western 
blot results were ambiguous, PCR results and increased IDO activity as determined by 
HPLC indicated that the MSC had been successfully transfected with the IDO plasmid.  
A limitation of the methods employed herein to assess transfection is that the proportion 
of cells transfected in culture could not be determined.  Thus, transfection efficiency and 
the impact of outgrowth from any non-transfected cells were unknown. 
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6.6.2  Transfection of MSC with IDO did not alter cell morphology 
 Based on findings in the rat (McMahon et al., 2006), it was considered possible 
that transfection of murine MSC using a liposomal system might have profound 
influences on therapeutically beneficial cell behaviour including modulation of cell 
survival, changes to morphology and surface marker expression and potentially 
impacting on in vitro potency, immunomodulatory function and cell growth rates.  
Therefore, transfected MSC and non-transfected MSC were compared and examined for 
changes to these features.  Murine MSC (BALB/c), transfected and expressing IDO as 
previously described (Chapter 2.2.6.2), were examined to assess whether cell 
morphology was altered by the transfection protocol.  This was done over four culture 
passages.  Cells were directly imaged by light microscopy.  Transfected cell morphology 
did not change during the course of the culture period (18 days for non-transfected MSC 
and 22 days for transfected MSC) and was not different to morphology of non-
transfected MSC cultured under the same conditions (Figure 6.8).  It was noted during 
culture that the IDO transfected MSC grew slower than the non-transfected cells, with 
the non-transfected cells being split four times in 18 days whilst the transfected cells 
took 22 days. 
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Figure 6.8  Examination of MSC morphology following transfection with an IDO 
plasmid by lipofection.  Non-transfected and transfected cells were seeded into T-25 
flasks and subcultured four times (passages 7 – 10). Cultures were examined by light 
microscopy at 200x magnification. 
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6.6.3  Transduction with IDO modulated MSC growth rates and cell survival 
 The extended passage time observed in IDO transfected MSC suggested that the 
transfection process might be impacting negatively on MSC growth rates in culture.  
MSC, transfected MSC, mock transfected MSC or IFN-γ stimulated MSC were cultured 
and MSC growth rates were measured by performing viable cell counts with ethidium 
bromide and acridine orange (EB/AO) at 24 hour intervals.  Non-transfected MSC grew 
continuously in culture from 24 to 168 hours whilst IFN-γ stimulated, transfected and 
mock transfected MSC cell numbers declined between 24 and 72 hours (Figure 6.9).  At 
72 hours IFN-γ stimulated and mock transfected cell numbers were comparable, but 
transfected MSC numbers were significantly lower (p ≤ 0.05) than non-transfected, 
mock transfected and IFN-γ stimulated MSC.  Mock transfected and IFN-γ stimulated 
MSC cell numbers recovered from 72-96 hours and were comparable to non-transfected 
MSC numbers from 120 hours onwards.  Although transfected MSC cell numbers began 
to recover after 72 hours, growth was poor and had not risen above the initial seeding 
density by 168 hours post transfection.  Overall growth rates were determined 
performing a linear regression on each growth curve and finding the slope of the line.  
Non-transfected MSC had a growth rate of 360.9 ±45.67 cells/hour.  Mock transfected 
and IFN-γ stimulated MSC growth rates were elevated to 449.9 ±87.10 and 494.5 
±84.03 cells/hour, respectively.  The transfected MSC growth rate was a net negative 
rate (-8.267 ±75.79 cells/hour), despite a slow recovery after 24 hours.  Therefore it can 
be concluded that mock lipofection negatively impacts on cell survival and growth rate, 
although the effect was transient.  However lipofection with the IDO plasmid reduced 
the cell population in culture and reduced cell growth rate so significantly that it did not 
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recover within 7 days post transfection.  These findings cast doubt over the usefulness of 
lipofection for the transfection of murine MSC and also highlight a possible issue with 
the selected IDO plasmid. 
 
Figure 6.9  Cell survival and growth rate of lipofected murine MSC.  Non-transfected, 
IDO transfected, mock-transfected and IFN-γ stimulated MSC (see figure key) were 
cultured and cell counts were performed every 24 hours for 7 days.  Points (see key 
above) represent the mean of triplicate cell counts.  Error bars represent the standard 
deviation.  Results are representative of two independent experiments. 
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6.6.4  Transfection of MSC with IDO did not ablate MSC adipogenic or osteogenic 
differentiation capacity 
 MSC have the capacity to differentiate into tissue cells of the mesenchymal 
lineage including fat and bone, a feature which may have utility in a therapeutic setting 
(Pittenger et al., 1999).  This differentiation can be induced in vitro using growth 
medium supplemented with the appropriate growth factors.  To assess whether 
transfection with a therapeutic transgene can abrogate MSC differentiation capacity in 
vitro, IDO transfected and non-transfected MSC were induced to differentiate along the 
adipogenic and osteogenic pathways, then stained and examined by light microscopy 
after 21 days in culture (Chapter 2.1.4.3 and 2.1.4.4). 
 Both transfected and non-transfected MSC were capable of adipogenesis (Figure 
6.10) and osteogenesis (Figure 6.11).  Although these results show that potency is not 
eliminated by the transfection protocol, it would nonetheless be valuable in future work 
to quantify any differences in plastic capacity.  One drawback in the design of these 
experiments was the lack of a means to individually quantify potency in transfected 
cells.  Thus in future studies it would be important to ascertain whether differentiating 
cells in transfected cultures represented outgrowth of a non-transfected subpopulation. 
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Figure 6.10  IDO transfected murine MSC cultures retain adipogenic potency in vitro.  
A) non-transfected MSC cultured in growth medium showed no evidence of 
adipogenesis when stained with Oil Red O, whilst B) non transfected control MSC 
cultured in adipogenesis medium for 21 days showed distinctive red-stained adipocytes.  
Similar results were observed for C) IDO transfected MSC cultured in growth medium 
and D) IDO transfected MSC cultured in adipogenesis medium.  Cells were imaged by 
light microscopy at 200x magnification.  Results are representative of two independent 
experiments. 
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Figure 6.11  IDO transfected murine MSC cultures retain osteogenic potency in vitro.  
A) non-transfected MSC cultured in growth medium showed no evidence of 
osteogenesis when stained with Alizarin Red S, whilst B) non-transfected control MSC 
cultured in osteogenesis medium for 21 days showed distinctive red-stained osteocytes 
and red-stained solid deposits.  Similar results were observed for C) IDO transfected 
MSC cultured in regular growth medium and D) IDO transfected MSC cultured in 
osteogenic medium.  Cells were imaged by light microscopy at 200x magnification.  
Results are representative of two independent experiments. 
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6.6.5  Lipofection with IDO alters MSC cell surface marker expression 
 The MSC used in this study were characterised as MHC class I weak, Sca-1 
positive but MHC class II and negative for the hematopoietic stem cell marker CD90 
(Figure 6.1).  MHC class I and II are the main mediators of antigen presentation to T-
cells and the weak expression of MHC class I, coupled with the lack of class II is 
thought to contribute to MSC alloevasion (Barry et al., 2005; Le Blanc et al., 2003).  
Although MSC transfection by IDO plasmid did not change cell morphology or potency 
(Figure 6.8), cell survival and growth rate were reduced.  Non-transfected, transfected, 
mock transfected and IFN-γ MSC were examined by flow cytometry to assess whether 
cell surface marker expression was also modulated.  Forward and side scatter 
characteristics were not altered by mock-transfection or IFN-γ stimulation, nor were 
Sca-1 or CD90 expression (Figure 6.12).  Transfection appeared to alter forward and 
side scatter, resulting in a more morphologically heterogeneous population.  Sca-1 and 
CD90 expression remained unchanged for transfected cells.  MHC class I was 
upregulated relative to isotype controls on transfected, mock-transfected and IFN-γ 
stimulated MSC (MFI, 24.5, 24.0 and 27.1 for non-transfected, mock-transfected and 
IFN-γ stimulated MSC respectively).  However MHC I was more strongly increased on 
transfected MSC (MFI = 113.7) (Figure 6.13), indicating that transfection induced MHC 
I.  Likewise MHC class II was at background for non-transfected, mock-transfected and 
IFN-γ stimulated MSC (47.5, 13.3 and 8.9 respectively) (Figure 6.13) but increased in 
transfected MSC (MFI = 94.7).  This increased MHC class II expression is nonetheless 
modest when compared to that seen on professional antigen presenting cells such as DC 
(English et al., 2008).  These findings suggest that the IDO lipofection protocol, but not 
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mock transfection, may be inducing innate immune pathways in the murine MSC and 
may diminish their alloevasive capabilities. 
 
 
Figure 6.12  Analysis of surface marker expression on non-transfected (A), IDO 
transfected (B), mock-transfected (C) and IFN-γ stimulated MSC (D) by flow 
cytometry.  MSC were labelled with monoclonal antibodies specific for MHC class I, 
class II, CD90 or Sca-1 (red lines).  Binding of species-matched isotype controls (black 
lines) is indicated in each histogram.  Histograms represent results for the gated 
populations indicated in the forward and side scatter dot plots. 
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Figure 6.13  Analysis of MHC class I and class II cell surface expression on non-
transfected, IDO transfected, mock-transfected or IFN-γ stimulated MSC by flow 
cytometry.  Fluorescence of MHC class I (open bars) or MHC class II (closed bars) was 
compared for non-transfected, IDO transfected, mock-transfected or IFN-γ stimulated 
MSC.  MFI values were derived from the histograms in figure 6.11 and are based on the 
acquisition of at least 2000 events in each case. 
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6.6.6  Transfection of MSC with IDO did not enhance but reduced suppression of 
mitogen-stimulated lymphocytes 
 IDO was selected as a therapeutic transgene in this study in order to enhance 
MSC immunosuppressive activity.  Suppression of mitogen-stimulated lymphocyte 
proliferation by MSC was assessed by tritiated thymidine incorporation assay (Chapter 
2.2.5.2).   Non-transfected, IDO transfected, mock-transfected and IFN-γ stimulated 
MSC each at concentrations 1×10
4
, 1×10
3
 and 1×10
2
 cells/ml were co-cultured with 
MHC matched splenocytes (Figure 6.14).  ConA stimulated splenocytes alone produced 
a proliferation result of 20582 ±1123.5 CPM. 1×10
4
 non-transfected MSC/ml 
significantly (p ≤ 0.005) suppressed mitogen driven splenocyte proliferation (1159.6 
±557.6 CPM) to near background levels (unstimulated splenocytes alone; 371 ±47.8 
CPM), and the same concentration of IFN-γ stimulated MSC produced even stronger 
suppression (536 ±264 CPM).  The same dose of mock transfected MSC also suppressed 
splenocyte proliferation, but did so to a lesser degree (5547 ±4058 CPM) and with 
weaker statistical significance (p ≤ 0.05).  The IDO transfected cells were expected to 
produce enhanced suppression relative to non-transfected MSC but at the highest MSC 
concentration, proliferation was only slightly reduced (13,211 ±48) and the reduction 
was not statistically significant (p = 0.051).  Suppression of proliferation was dose-
dependent for all four MSC types, but at each concentration tested, IDO transfected 
MSC produced the weakest suppression, and suppression was not statistically significant 
at any concentration of transfected MSC.  Although increased IDO activity in 
transfected cultures had been confirmed by HPLC, these findings suggested that this 
increase was not sufficient to enhance MSC immunomodulation.  On the contrary, it 
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appeared that some side effect of the transfection protocol was reducing the 
immunomodulatory function. 
 
Figure 6.14  Analysis of the immunomodulatory capacity of lipofected MSC.  Non-
transfected, IDO transfected, mock-transfected or IFN-γ stimulated MSC were co 
cultured with ConA stimulated, MHC matched murine splenocytes.  Statistically 
significant suppression of splenocyte proliferation is indicated (*, p ≤ 0.05; **, p ≤ 
0.005; ***, p ≤ 0.0005).  Bars represent the mean of triplicate determinations expressed 
as CPM.  Error bars represent the standard error mean.  Results are representative of at 
least two independent experiments. 
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6.7  SUMMARY 
 The MSC used in this study were characterised and found to display spindle-like 
fibroblastic characteristics, were MHC class I and Sca-1 positive and MHC class II and 
CD90 negative (Figure 6.1).  Potency was validated by differentiation assays for 
adipogenesis and osteogenesis (Figure 6.2).  MSC immunomodulation was verified by 
co-incubation of MSC with mitogen-stimulated splenocytes (Figure 6.3).  MHC 
mismatched MSC also suppressed splenocyte proliferation at high MSC concentrations, 
but synergised with mitogen at low doses (Figure 6.3).  Suppression and stimulation of 
mismatched splenocyte proliferation by MSC was further examined using a CFSE-based 
assay, using a purified population of CD4
+
 CD62L
+
 naive T-cells.  Suppression involved 
reductions in the progressor fraction as well as lengthening of both mean time to first 
division and subsequent mean division times (Figure 6.5; Table 6.1).  The stimulatory 
effect previously observed may in part be explained by higher progressor fractions in the 
low MSC dose co-cultures at the 48 and 72 hour time points. 
 MSC are desirable targets for modification using gene therapy and may facilitate 
the delivery of transgenes for cancer therapy (Mohr et al., 2008).  Transduction of 
murine MSC using an AAV-2-based vector and lipofection was thus attempted and the 
MSC were examined for changes to their other therapeutic characteristics.  Murine MSC 
were refractory to transduction using an AAV-2 vector (Figure 6.6).  Lipofection 
successfully delivered an IDO transgene (Figure 6.7) without impacting on MSC 
morphology or potency (Figures 6.8, 6.10 and 6.11).  However, IDO protein 
upregulation was modest (Figure 6.7). Interestingly MSC survival and growth rate was 
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reduced (Figure 6.9) suggesting that IDO activity impairs MSC function or places a 
metabolic burden on the cells.  Transfection of MSC induced upregulation of surface-
expressed MHC class I and class II.  More importantly transfection of MSC with IDO 
(but not mock transfection) did not enhance but rather reduced suppression of mitogen-
stimulated lymphocyte proliferation (Figure 6.14).  Suppression of proliferation was 
dose-dependent for all MSC types, but IDO transfected MSC produced weaker 
suppression than non-transfected and mock transfected MSC at all MSC concentrations 
tested, and the suppression mediated was not statistically significant at any 
concentration of transfected MSC.  These data suggest that delivery of IDO to murine 
MSC by lipofection must undergo substantial optimisation if it is to become effective 
without abrogating desirable characteristics of the target MSC. 
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CHAPTER 7 
DISCUSSION 
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 The paucity of data available on immune responses to AAV-2 at the study outset 
raised the possibility that adaptive immunological responses were not important and that 
pre-existing immunity would not confound clinical use of AAV-2 as a therapeutic vector 
(Erles et al., 1999; Hernandez et al., 1999).  This study, and the work of others has 
disproved that hypothesis (Manno et al., 2006; Murphy et al., 2009).  Specifically, the 
loss of AAV-2-mediated transgene expression during clinical trials has indicated that 
memory for AAV-2 includes a cytotoxic T lymphocyte (CTL) response against 
transduced cells (Manno et al., 2006).  In this study, AAV-2-specific IgG was detected 
in plasma from 41 of 45 donors sampled (>90%).  IgG1 and IgG2 were the predominant 
IgG subclasses present.  IgG3 levels were limited and IgG4 was variable and often 
absent entirely.   
 Human T-cell proliferation in response to whole AAV-2 stimulation was 
demonstrated in nearly half (19 of 41) of PBMC cultures isolated from a panel of Irish 
blood donors.  The cytokine profiles associated with these responses were diverse, but 
IFN-γ and IL-13 production were detected indicating that an effector CD4+ Th recall 
response is evoked in humans.  59 candidate T-cell epitopes were identified within the 
VP1 capsid sequence.  Although a subset (n = 17) of these epitopes were recognized by 
PBMC from multiple donors, there was no significant correlation between stimulating 
epitope and respondent donor HLA haplotype, suggesting that these represent 
immunodominant epitopes promiscuously recognized.   
 Humoral memory was extensively examined in this project.  A majority of Irish 
donors (41 of 45 donors) tested displayed significant titres of AAV-2-specific IgG in 
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blood plasma.  This represents a high prevalence when compared to AAV-2 
seroprevalence data obtained in other European studies but is similar to that seen in US 
populations (Chirmule et al., 1999; Erles et al., 1999; Halbert et al., 2006).  However, as 
no AAV-2-specific IgG standards exist and there is no standardized method for assaying 
AAV-2 antibody levels, it is likely that the high variability observed between studies is 
as much a result of differing methods as it is of geographical differences and population 
demographics.  Despite these differences, the available evidence suggests that humoral 
memory for AAV-2 is prevalent. 
 The presence of antibodies to AAV-2 does not automatically imply neutralising 
activity (Erles et al., 1999).  To assess the prevalence of neutralising antibody in this 
study group, a model system was devised to measure the reduction in transformation of 
an AAV-2 permissive cell line.  A panel of six AAV-2-specific IgG-seropositive plasma 
samples (from donors 17, 19, 21, 34, 42, 51) was co-incubated with an AAV-2 vector 
encoding a GFP gene under the control of a CMV promoter.  Plasma from donor 51 
reduced the MFI from 13.3 to 11.1 and plasma from donor 42 reduced the MFI to near 
background (5.8). 
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 Whilst characterisation of total IgG and neutralising activity are informative, the 
subclass composition of an IgG response may vary greatly, impacting on factors such as 
APC activation, opsonisation and recruitment of complement (Jefferis & Kumararatne, 
1990).  AAV-2-specific IgG in this population consisted primarily of the IgG1 and IgG2 
subclasses, with low levels of IgG3 present in all donors and some evidence of variable 
IgG4 in a smaller subset.  The presence of IgG1 was anticipated as the subclass is 
commonly induced following viral infections such as measles, hepatitis B, HTLV-I and 
rubella.  It is also induced by B19V which, like AAV-2 is a member of the Parvoviridae 
(Franssila et al., 1996; Gregoreka et al., 2000; Lal et al., 1993; Thomas & Morgan-
Capner, 1988; Toptygina et al., 2005).  IgG1 is typically the predominating IgG subclass 
for these afore-mentioned viruses, and this study shows this is the case for AAV-2, in 
which IgG1 is a major component of the total specific IgG (Figure 7.1). 
 IgG2 was also a major constituent of the AAV-2-specific antibody response, 
comprising an average 42% of total IgG.  The proportions of AAV-2-specific IgG1 and 
IgG2 detected in this study broadly agree with data recently reported by Murphy et al. 
(Murphy et al., 2009).  Whilst IgG2 is a component of serological responses to some to 
measles and HTLV-I, it is notable that it is not a significant component of the response 
to the parvovirus B19V (Franssila et al., 1996; Lal et al., 1993; Toptygina et al., 2005), 
a finding supported by the modest B19V-specific IgG2 levels detected during the 
optimisation of the IgG subclass ELISA.  This suggests that there are differences 
between how the humoral response is primed by B19V and AAV-2, perhaps reflecting 
AAV requirement for a helper virus to disseminate. 
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 The IgG3 subclass is usually a significant component of virus-induced IgG, 
typically comprising 12% to 50% of circulating virus antigen-specific IgG for measles, 
rubella, HTLV-1 and hepatitis B viruses in seropositive individuals (Gregoreka et al., 
2000; Kalvenes et al., 1996; Lal et al., 1993; Toptygina et al., 2005).  Although AAV-2-
specific IgG3 was detected in all donors assayed, the subclass comprised an average of 
just 2.6% (0.7 ±0.2 µg/ml) of the total AAV-2-specific IgG detected in Irish donors 
(Figure 7.1).  Given the robust humoral response induced by AAV-2, the minimal IgG3 
induction is surprising but is supported by observation of similar levels in a recent US 
study (Murphy et al., 2009).  The average concentration of virus-specific IgG3 (0.6 
µg/ml) observed in that study is comparable to our observations, although the IgG3 
levels were considerably more variable, at times representing greater than 50% of total 
virus-specific IgG.  IgG3 did not represent greater than 6% of total AAV-2-specific IgG 
in any donor examined here.  The difference between the results reported by Murphy et 
al. and those reported here may reflect differences in population genetics, or in the 
prevalence and nature of various helper virus infections.  It has been speculated that 
helper viruses may determine the anatomical locale in which AAV-2 is first recognized 
in a strong inflammatory context (Murphy et al., 2009). 
 IgG3 is typically induced in CD40
+
 naive B cells recognising antigen in the 
context of a similar cytokine environment to that seen in IgG1 induction (Briere et al., 
1994).  Recognition of a soluble particulate antigen in the inductive immune sites of the 
upper respiratory tract typically produces a higher proportion of IgG3-producing B cells 
than does recognition in the circulation (Jefferis & Kumararatne, 1990).  Given that the 
route of natural AAV-2 infection is typically cited as oral or upper respiratory tract, 
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AAV-2 should encounter the pharyngeal or palatine tonsils during inhalation or 
ingestion and thus induce IgG3 (Blacklow et al., 1968a; Gould & Favorov, 2003; 
Rabinowitz & Samulski, 2000).  Thus, the failure of AAV-2 to induce significant titres 
of IgG3 in any donor examined here is somewhat unexpected and remains to be 
explained.  However it might be speculated that AAV-2 may have some capacity to 
evade or subvert strong IgG3 induction.  Such subversion might represent a means of 
evading the complement cascade.  This is supported by the observation that the classical 
complement pathway is only induced weakly by high titres of AAV-2 and the virus does 
not activate the alternative complement pathway (Zaiss et al., 2008).  It has been 
reported that the AAV-2 capsid binds complement protein iC3b and Factor H, both of 
which mediate a regulatory effect on the complement cascade by blocking the cleavage 
of C3 into C3a and C3b (Zaiss et al., 2008).  As IgG3 is the primary IgG subclass 
involved in C1 recruitment and thus the initiation of the classical complement pathway, 
the lack of IgG3 induction observed in this study may further explain the minimal 
involvement of the classical pathway in AAV-2 immunity observed by Zaiss et al. 
(Zaiss et al., 2008).  Similar to that seen in AAV-2, a minimal IgG3 response has been 
observed in the closely related parvovirus B19V.  B19V virus-specific IgG3 levels are 
high in early infection but decline significantly over time (Franssila et al., 1996).  A 
similar pattern of decline over time is observed following hepatitis B vaccination 
(Gregoreka et al., 2000).  It is not possible to conclude that AAV-2 follows such a 
pattern without examining the sera of recently infected individuals, although given the 
nature of infection such a cohort will be difficult to identify.   
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 Levels of AAV-2-specific IgG4 represented less than 10% on average of total 
IgG and were highly variable (2.5 ±3.8 µg/ml) with 12 of the 45 donors tested having no 
detectable IgG4.  By comparison to the serology of other viruses, the variable IgG4 
levels are perhaps unremarkable.  Hepatitis B infection and vaccination typically induce 
little IgG4, but levels are seen to increase post infection or vaccination (Gregoreka et al., 
2000).  Variable titres of IgG4 are also seen in B19V infection, and typically this is not 
observed until some 200 days post infection (Franssila et al., 1996).  IgG4 is also a 
feature of the humoral memory to some antigens of HTLV-I and measles (Lal et al., 
1993; Toptygina et al., 2005).  If the temporal characteristics of AAV-2 humoral 
memory mirror those of parvovirus B19V, the minimal IgG3 and elevated IgG4 levels 
detected here may be representative of late convalescent AAV-2 infections.  As IgG3 
and IgG4 levels are usable as an indicator of the stage of convalesce in B19V infection 
(Franssila et al., 1996), further examination of the temporal characteristics of IgG3 and 
IgG4 induction in AAV-2 infection may be similarly useful. 
 It has been assumed that AAV-2 does not induce a cell-mediated immune 
response (Hernandez et al., 1999), and few studies have examined this question in 
humans (Chirmule et al., 1999; Manno et al., 2006).  This study demonstrated that 
AAV-2 evoked robust proliferative and cytokine recall responses detectable in PBMC 
cultures.  Of the 41 donors assayed for PBMC proliferation, 19 demonstrated a 
statistically significant proliferative response to stimulation with AAV-2.  Of these, 9 
donors supported stimulation indices of between 1.5 and 3; 10 donors produced higher 
stimulation indices, with 4 of these producing SI values above 10.  Chirmule et al. also 
examined human PBMC proliferation in response to AAV-2 but found that only 6% 
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(3/57) of their subjects produced a stimulation index greater than 2.0 (Chirmule et al., 
1999).  This discrepancy is most likely due to the relatively low concentration of AAV-2 
used for the re-stimulation, a multiplicity of infection (MOI) of 100, compared to an 
MOI of 10,000 for this study.  These findings clearly point to the involvement of T-cells 
in the response to AAV-2. 
 The polarization of cell-mediated responses to antigens has significant impact on 
the nature and quality of responses generated.  For example, during natural viral or 
intracellular bacterial infections, T helper 1 responses can recruit cytotoxic T-cells 
potentially mediating targeted destruction of infected cells whilst Th2 responses will 
skew the response towards the generation of antibody.  The cytokine profiles produced 
by proliferating cultures can provide insight into the polarization of an in vitro response.  
Cultures stimulated with AAV-2 did not exhibit clear Th1 or Th2 polarization; although 
IFN-γ was the most frequently detected cytokine indicating that at least in some subjects 
AAV-2 can evoke a Th1 response.  IL-13 was only produced by weakly proliferating 
cultures (SI between 1.5 and 3) whereas IL-10 production was detected across a range of 
donors.  Chirmule et al. also examined AAV-2 stimulated PBMC cultures for cytokines, 
finding IFN-γ and IL-10 in 6% and 12% of the cultures.  The group did not examine IL-
13 levels, but did look for IL-4, failing to find the cytokine in any culture (Chirmule et 
al., 1999). 
 Neither the extent of PBMC proliferation elicited by AAV-2 nor the resulting 
cytokine production correlated with the levels of AAV-2-specific IgG or IgG subclasses 
detected in the corresponding donor plasma samples (Table 7.1).  AAV-2 serology as 
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currently determined is thus a poor predictor of the cell-mediated response.  Despite the 
capacity for AAV-2 to stimulate PBMC proliferation and cytokine production in this 
study, it is clear that the cellular recall response to AAV-2, at least in vitro, is not 
consistently polarized.  Although this response is not polarized, the induction of IFN-γ 
and IL-13 clearly suggests that AAV-2 can induce CD4
+
 T-cell responses in a healthy 
human population, and that at least in part, AAV-2 does not behave like a classical T-
independent antigen.  
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 The proliferative response characterised here was found only in PBMC cultures 
from donors also displaying circulating total IgG specific for AAV-2.  The low 
frequency of seronegative donors (4 seronegatives out of a cohort of 45) coupled with 
the frequency of cultures producing significant proliferation (19 positives of a cohort of 
41) made this observation unsurprising as it would be unlikely that an IgG seronegative 
PBMC proliferation-positive donor would be identified.  The presence of large numbers 
of seropositive donors whose PBMC did not support proliferative responses against 
AAV-2 indicated that the virus may not be acting as a T-cell dependent antigen during 
priming of the humoral response.  Furthermore, when the combined AAV-2 IgG 
subclass levels determined in the cohort group were compared to corresponding 
proliferative responses, no correlation was found (Figure 4.4, r = 0.25, p = 0.14).  
However it should be noted that differences in the sensitivity and specificity of 
immunoassays versus cell-based assays may undermine this finding. 
 The prevalence and strength of cell-mediated responses to AAV-2 suggest that 
there is some risk of cytotoxicity targeted against AAV-2 transduced cells.  One 
potential means to avoid such responses would be to identify and remove 
immunodominant epitopes in the virus capsid sequence.  In order to identify specific 
stimulating epitopes in the AAV-2 capsid, PBMC from the donors characterized in 
Chapters 3 and 4 were stimulated with overlapping peptides from the AAV-2 capsid 
sequence.  The AAV-2 capsid is composed of three proteins; VP1, VP2 and VP3 in a 
ratio of 1:1:10 (Xie et al., 2002).  VP2 and VP3 are products of the splicing of VP1 
mRNA and both proteins represent a subsequence of the VP1 protein.  Thus, the entire 
capsid sequence may be represented by VP1.  Using a restrictive definition, 17 
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candidate epitope sequences were identified as recognized by at least two donors.  A 
further 43 sequences were recognized by a single donor each.  Limitations in assay 
sensitivity due to the modest level of PBMC proliferation induced by AAV-2 and its 
components mean that some of the more limited proliferative responses observed may 
have represented false negative results.  Thus, it is likely that further single-case 
candidate epitopes or confirmations of existing single-case candidate epitopes were not 
detected here.   
 The panel of single-case candidate epitopes includes sequences (supplementary 
data) previously identified in human and mouse studies (Chen et al., 2006; Manno et al., 
2006; Sabatino et al., 2005).  The RDSLVNPGPAMA sequence recognized by donor 13 
was a 12-mer incorporated by the 15-mer NGRDSLVNPGPAMAS sequence identified 
by Sabatino et al. in C57BL/6 mice (Sabatino et al., 2005).  The sequence 
EIQYTSNYNKSV was also identified as a candidate epitope in donor 13 and shares a 
7-mer homology with the 9-mer sequence SNYNKSVNV identified in the C57BL/6 
strain (Sabatino et al., 2005).  The sequence GFRPKRLNFKLF identified in donor 16 
shares an 11-amino acid homology with the sequence FRPKRLNFKLFNIQV identified 
in BALB/c mice (Sabatino et al., 2005).  Likewise the sequence VPQYGYLTL 
identified as an epitope in BALB/c mice by Sabatino’s group (Sabatino et al., 2005) as 
well as in a single human case by Manno et al. (Manno et al., 2006) lies within the 
sequence VFMVPQYGYLTL identified as a candidate epitope for donor 16.  
Furthermore, Chen et al. identified an immunogenic sequence TSADNNNSEYSWTGA 
in mice which is contained in two sequences identified recognized by donor 50 
(SKTSADNNNSEY and NSEYSWTGATKY) (Chen et al., 2006). 
222 
 
 The panel of epitopes recognized by two or more donors and identified in this 
study (Table 7.2) have not been previously identified in human or animal models, with 
two exceptions.  Chen et al.  identified the sequence QVSVEIEWELQKENS as being 
immunogenic in mice (Chen et al., 2006), and this sequence shares 11 amino acids with 
the candidate epitope EIEWELQKENSK recognized by three donors (13, 50, 51) in this 
study (Sequence D, Table 7.2).  The second sequence, FKLFNIQV (sequence L, Table 
7.2), was recognized by donors 16 and 50 and shares an 8 amino acid  homology with 
the FRPKRLNFKLFNIQV sequence identified in mice by Sabatino et al., 2005.  
 No significant correlation could be identified between donor HLA haplotypes 
and the corresponding epitopes recognized.  The haplotypes of AAV-2 respondent 
donors displayed considerable diversity.  This was also the case for donors responding 
to the most common stimulating capsid sequences.  Although it is reported here that the 
DQ2, DQ3 (DQ7(3), DQ8(3), DQ9(3)) and DQ6(1) serotype alleles are present at a high 
frequency in our study group, these results broadly agree with recent detailed 
examinations HLA allele frequencies and haplotypes in the Irish population in which 
these three serotypes represented the three most commonly identified (Dunne et al., 
2008).  Thus, although the HLA data presented here is less exhaustive, the donors from 
which AAV-2-specific PBMC were isolated display HLA diversity comparable to the 
general Irish population.  The observation that a number of sequences can be recognized 
by donors of different HLA haplotypes, and indeed across species in two cases, 
indicates that epitopes A, B, C, D and K are immunodominant human epitopes. 
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Presence of immunodominant sequences in capsid sequences VP1, 2 and 3 are indicated 
as positive (+) or negative (-). 
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 Since the extent of humoral immunity to AAV-2 in the human population 
became clear, it has been suggested that AAV-2 capsid modification may enhance the 
efficacy of the virus as a vector (Monahan & Samulski, 2000).  It has also been 
suggested that if capsid antigen-specific cytotoxicity is a significant barrier to AAV-2-
mediated gene therapy, the administration of immunosuppressive drugs following vector 
administration may prevent cell-mediated immunity (Manno et al., 2006).  However 
systemic immunosuppression may be undesirable in candidates for gene therapy and 
thus the immunodominant sequences identified here may thus represent appropriate 
targets for capsid modification in rare cases.   
 Modification of the AAV-2 capsid to remove immunodominant epitopes is not 
without potential drawbacks.  The determination of the structure of the AAV-2 capsid 
by Xie et al. along with mutagenesis and neutralisation studies has shed light on the 
function of structural motifs on the capsid (Asokan et al., 2006; DiPrimio et al., 2008; 
Kern et al., 2003; Opie et al., 2003; Wu et al., 2000; Xie et al., 2002).  For example, 
studies of AAV-2 binding to the virus primary receptor HSPG have shown that a group 
of basic amino acids (Arginines 484, 487, 585, and 588 and Lysine 532) are critical for 
binding (Kern et al., 2003; Opie et al., 2003).  From the immunological perspective 
however, there would be little justification for the modification of this region as none of 
the immunodominant epitopes identified herein contains the relevant residues, although 
sequence B, discussed later, lies in the region between Arginine 487 and Arginine 585.   
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 The most commonly-recognised immunodominant epitope identified in this 
study was sequence A (KEVTQNDGTTTI), which shared 4-mer homology with two 
other immunodominant epitopes, sequences L (FKLFNIQVKEVT) and M 
(TTTIANNLTSTV).  These sequences would thus be attractive targets for modification.  
When sequence A was mapped onto a 3d model of the AAV-2 capsid it was found that 
the sequence is part of the loop formed between beta strands H and I (HI loop) of the VP 
subunit.  This loop is located at the capsid 5-fold axis of symmetry and overlaps with the 
HI loops of four neighbouring subunits to form a barrel-shaped protrusion surrounding a 
pore in the capsid.  Mutagenesis studies have demonstrated an important role for this 
motif in viral capsid assembly and viral DNA packaging into the capsid (DiPrimio et al., 
2008).  There is thus some reason to be concerned that modification of sequence A, or 
the adjacent sequences L and M, might reduce vector production efficiency or block 
production entirely.  DiPrimio et al. did however demonstrate that capsid assembly and 
infectivity of HI loop mutants could be rescued by substituting HI loop sequences from 
AAV-1 and AAV-8 (DiPrimio et al., 2008). 
 Sequence B (ATKYHLNGRDSL) was stimulatory in three independent PBMC 
cultures and is located at the base of a cluster of protrusions on the AAV-2 capsid which 
is composed of overlapping loops from three subunits associating at the 3-fold 
symmetry axis at the centre of each icosahedral face.  This sequence contains a motif 
(NGR) which is conserved in the majority of AAV serotypes and which has been shown 
to have an integrin-binding function (Asokan et al., 2006).  Mutagenesis of this region 
has been shown to significantly reduce binding of AAV-2 capsids to the cell surface of 
permissive HEK-293 cells as well as reducing virus internalisation (DiPrimio et al., 
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2008).  Thus, if modification of this sequence is to be pursued, it seems likely that the 
NGR motif must be left intact in order to preserve transduction efficiency and tissue 
tropism.  Furthermore, as previously mentioned, sequence B is located in a region 
between the arginine residues strongly associated with HSPG binding (Opie et al., 
2003), so it is conceivable that modification in this region which preserves the NGR 
motif may negatively impact on HSPG binding activity, thus reducing transduction 
efficiency and modulating tissue tropism. 
 Sequences C and D may represent more promising targets for modification.  
Both sequences were recognised in 3 donors and are not directly associated with any 
major capsid function.  Sequence C is located in the region directly adjacent to the 5 
fold capsid pore structure composed of sequences A, L and M.  There is some 
possibility that sequence C performs a scaffolding function for the 5-fold pore, though 
this would need to be determined by mutagenesis.  Similarly, sequence N which is 
located close to the 5-fold axis may also serve a scaffolding function for the capsid pore.  
Sequence D is located along the icosahedral vertex connecting 5-fold symmetry axes, 
close to the 2-fold subunit border region.  It may thus be involved in capsid assembly, 
but this again has not been established by experimentation.  This may also be a 
consideration for sequence Q, which is also located close to the 2-fold subunit border. 
 Epitope sequences E-H (Table 7.2) are located within the N-terminal VP1 unique 
region and would thus tend to be present in transduced recipient cells in approximately 
10-fold lower concentrations than those found in all three VP subunits.  The location of 
the unique region within the capsid 3D structure is not clear, although some 
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conformational data has been obtained using electron cryomicroscopy (Kronenberg et 
al., 2005).  It appears that the N-terminal region of the VP1 unique region may be 
located within the capsid, or become exposed on the surface, protruding through the 5-
fold pore structure.  The conditions prompting this conformational change in vivo are 
not known.  The region appears to contain a functional phospholipase A2 (PLA2) 
catalytic domain (Girod et al., 2002).  Deletion or mutation of the unique region results 
in significantly reduced infectivity although capsid assembly and viral DNA packaging 
remain intact (Tratschin et al., 1984).  Although viral gene expression following 
transduction was reduced, mutations in the active site of the PLA2 domain did not 
inhibit perinuclear accumulation in late endosomes or lysosomes, suggesting that PLA2 
activity might be required in a later step of infection (Girod et al., 2002). 
 An alternative to the modification of AAV-2 capsids is use of capsids from other 
AAV serotypes.  The sequences of the VP1 capsid proteins vary across the AAV 
serotypes and this may mean that immunodominant epitopes present on the AAV-2 
capsid may not be conserved.  When the VP1 sequences for AAV serotypes 1, 2, 4, 6 
and 8 are compared for the conservation of the top 4 immunodominant epitopes 
described here (Table 7.2) it is evident that epitopes A and D are fully or highly 
conserved across all 5 serotypes, raising the possibility that these serotypes may also 
induce cell-mediated recall responses in AAV-2 seropositive humans.  Epitope C was 
fully conserved across all 5 serotypes and it is this likely that these serotypes will induce 
cellular responses in a subset of seropositive humans.  Epitope B was less well 
conserved across the top 4 immunodominant epitopes.  The epitopes were least 
conserved in AAV-4; although epitope C was fully conserved, only 7 of 12 amino acids 
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from epitope A were conserved, whilst epitopes B and D were represented by 5 of 12 
and 8 of 12 amino acids respectively. 
 The observations herein that even a small sample of an outbred population can 
support diverse recall response against multiple T-cell epitopes means that genetic 
modification of AAV-2 to fully escape immune recognition by T-cells is not a feasible 
goal for general application.  A more promising strategy, as suggested elsewhere 
(Manno et al., 2006), might be that gene therapy recipients should undergo some form 
of immunosuppressive therapy during the relatively transient period during which AAV-
2 epitope cross-presentation can occur.  Vector capsid modification to remove identified 
epitopes might instead represent a strategy reserved for specific cases in which 
administration of immunosuppressive drugs is undesirable.  In such cases, screening of 
patient serum alone as a measure of immune status, whilst informative, is likely to be 
insufficient.  Serology has not been shown to reliably predict the presence of T-cell 
memory for AAV-2 (Chapter 4).  Thus, detailed screening of patient humoral memory 
and epitope recognition would be an essential tool in ensuring the delivery of an 
effective treatment. 
 The murine mesenchymal stem cells used in this study were obtained from Dr. 
Karen English and Laura Tobin, working at the NUIM Cellular Immunology Lab.  
Although already well-characterised (English et al., 2007; English et al., 2008), the cells 
were nonetheless validated to establish that continued culture and passaging by the 
author did not alter cell phenotype or functions.  MSC were found to display the same 
spindle-like fibroblastic morphology as used by English et al. and elsewhere for mouse 
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(Krampera et al., 2003), rat (McMahon et al., 2006) and human (Stender et al., 2007).  
The MSC were also comparable in terms of MHC expression, and were Sca-1 positive.  
Self-renewal was demonstrated by passaging and differentiation along osteogenic and 
adipogenic pathways demonstrated potency.  Finally, co-incubation of murine MSC 
with mitogen-stimulated splenocytes resulted in inhibition of splenocyte proliferation.  
These traits, morphology, surface marker expression, self-renewal, potency and 
immunomodulatory capacity were later used to assess the retention of the MSC 
phenotype.   
 The immunomodulatory functions of MSC co-incubated with naive T-cells were 
further characterised using a CFSE-based system which allowed the measurement a 
variety of factors determining gross T-cell proliferative response.  It was determined that 
MSC reduced the progressor fraction of the mitogen stimulated T-cell population as well 
as lengthening their time to initiate their first division after the resting state.  
Furthermore, MSC lengthened the subsequent mean division time.  Although this 
technique was not revisited during the course of this study, it is clear that this method 
could be an invaluable tool for delineating the roles of the various soluble factors and 
cell contact-dependent elements involved in MSC immunomodulation, particularly if 
used in combination with blocking studies, gene silencing and MSC sourced from 
knockout mice. 
 It was hoped that murine MSC might be amenable to transformation using the 
AAV-2-based vector examined in chapters 3 and 4, thereby rendering the MSC as a 
potential platform to deliver transgene products in a clinical setting whilst avoiding the 
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immune memory for AAV-2 characterised in chapters 3, 4 and 5 and elsewhere 
(Chirmule et al., 1999; Manno et al., 2006; Zaiss & Muruve, 2005).  However, murine 
MSC appeared resistant to transduction using an AAV-2GFP vector.  Similar results 
have been reported for human (Stender et al., 2007) and rat MSC (McMahon et al., 
2006).  Stender et al. showed some transduction of human MSC with a similar GFP-
encoding vector but the maximum transduction efficiency was 65% and the level of 
transgene expression in the transduced population increased in intensity only 4-fold over 
a 10,000 fold AAV dose range.  McMahon et al. conducted an examination of several 
transduction and transfection techniques using rat MSC as the target (McMahon et al., 
2006), including an AAV-2GFP vector but found the MSC to be resistant to 
transduction, despite successful transgene expression following adenoviral and lentiviral 
transduction. 
 Due to the lack of any detectable transduction and limited AAV-2 vector stocks, 
transduction of MSC with AAV-2 was not further examined, nor was the impact of the 
transduction protocol on MSC phenotype or therapeutic functions.  Despite this negative 
outcome, it is possible that AAV-2-mediated transduction of MSC might be optimised, 
and so a different approach was adopted.  Centrifugation of subconfluent MSC cultures 
in the presence of Adenoviral vectors results in efficient transduction and is well-
tolerated by the MSC (Mohr et al., 2008).  Alternatively, the use of antibodies bispecific 
for the AAV vector and a cell surface receptor on the MSC may allow efficient 
transduction, a strategy which has been successfully employed to allow efficient AAV 
mediated transduction of non-permissive megakaryocyte cell lines (Bartlett et al., 1999). 
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 To assess the impact of transfection of MSC with a plasmid vector, a lipofection 
protocol was instead adopted.  The chosen vector encoded IDO, an enzyme known to be 
involved in MSC immunomodulation.  It was thus hoped that successful transfection 
might enhance MSC immunomodulatory function without impacting on MSC self-
renewal and potency.  Transfection was successful producing IDO RNA and protein as 
well as demonstrating increased IDO function in the form of tryptophan metabolism.  
MSC morphology was not altered and osteogenic and adipogenic functions remained.  
However, MSC cell numbers in culture declined sharply in the 24 hours following 
transfection and growth rates were poor for up to 7 days.  Lipofectamine alone did not 
appear to be the cause, although it did appear to induce a small increase in endogenous 
IDO, possibly indicating some stress on the cells.  Thus it seemed likely that the 
introduction of the CMV-regulated plasmid might be the cause of the decline in cell 
numbers and poor cell growth.  Cell surface markers were also altered, with increased 
MHC class I observed in transfected cultures.  Perhaps most significantly, transfected 
MSC displayed a reduced capacity to suppress mitogen-driven lymphocyte proliferation.  
The cause of this was not established; however it is probable that the observed 
upregulation of cell surface MHC I contributed to this effect. 
 Lipofection has recently been shown to result in cell death and reduced 
proliferation in culture in both rat and human MSC (Helledie et al., 2008; McMahon et 
al., 2006).  Helledie et al. similarly noted that only lipofectamine-DNA complexes, and 
not lipofectamine alone, impacted negatively on MSC survival and proliferation.  
Further optimisation of the lipofection protocol might reduce MSC death and restore 
proliferation, but the observed changes in murine MSC immunomodulatory function as 
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a result of IDO transfection coupled with the cell death and loss of proliferation 
indicates that lipofection is a suboptimal method for the transfection of murine MSC.  
Viral vectors based on adenovirus and lentiviruses have proven more efficient and less 
cytotoxic than lipofection in other studies (McMahon et al., 2006).  If transduction of 
MSC with AAV cannot successfully be optimised, these vectors would seem to be the 
most promising candidates for further research. 
 In conclusion, this study demonstrated that both humoral and cell-mediated 
memory for AAV-2 is prevalent in the normal Irish population, supporting the 
hypothesis that immunity will complicate the use of AAV-2 in therapy.  Given the 
known prevalence of AAV-2 infection in humans (Chirmule et al., 1999; Erles et al., 
1999; Halbert et al., 2006), it is conceivable that widespread humoral memory for the 
virus might negatively impact on the usefulness of the virus as a gene therapy vector.  
Cell-mediated responses demonstrated here, when considered in the context of emerging 
data on the targeting of AAV transduced by the cell-mediated response (Li et al., 2009; 
Manno et al., 2006) suggest this may also be a significant confounding influence on the 
use of AAV vectors in the wider population.  With the identification of a panel of 
immunodominant epitopes and a wide range of single-case epitopes capsid modification 
strategies are unlikely to be a practical solution for most applications of AAV vectors 
due to the variety of epitopes recognized; however screening for patient cell-mediated 
and humoral responses may be an invaluable tool in bringing effective AAV-2 vectors 
to the clinic.  For cases where immunosuppression to avoid CMI is undesirable, 
screening of specific epitope responses might be a useful tool for the identification of 
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targets for capsid modification, though any such modified capsids would need to be 
further examined for their capacity to effectively transduce donor cells in vitro. 
 Attempts to transduce murine MSC with a vector based on AAV-2 were 
unsuccessful, and so a lipofectamine-based protocol was adopted in conjunction with a 
plasmid encoding IDO.  Transfection was successful producing IDO mRNA and protein 
as well as demonstrating increased IDO function in the form of tryptophan metabolism.  
MSC morphology and cell surface markers were not altered and potency was not 
affected.  However, MSC cell numbers in culture declined sharply and growth rates 
were poor.  Further optimisation of the lipofection protocol might be worth pursuing, 
but that changes in murine MSC immunomodulatory function as a result of IDO 
transfection were modest and taking the cell death and loss of proliferation into account, 
it is likely that lipofection is a suboptimal method for the transfection of murine MSC. 
 Transduction of MSC using AAV-2-based vectors was unsuccessful in this 
study.  However, given the potential risks of oncogenesis (Hacein-Bey-Abina et al., 
2003) and inflammation (Raper et al., 2003) that come with transduction using 
retroviruses and adenoviruses respectively, future optimisation of AAV-2-mediated 
transduction may yet be a worthwhile goal.  Humoral memory and antibody 
neutralisation should be avoided and concerns raised herein and elsewhere (Manno et 
al., 2006) regarding cell-mediated responses to AAV-2 vectors and AAV transduced 
cells might easily be negated by growing the transduced cells in culture until the 
transient presentation of exogenous AAV-2 capsid on class I MHC molecules has 
declined.  Given that the virus does not integrate with a high frequency (Kotin et al., 
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1990), does not cause significant MSC death (McMahon et al., 2006) and does not 
induce strong inflammatory responses in vivo (Zaiss et al., 2002), AAV-2 remains an 
attractive candidate vector for the transduction of MSC if poor transduction efficiency 
can be overcome.  
   
235 
 
 
 
 
CHAPTER 8 
REFERENCES 
 
236 
 
Aggarwal, S. & Pittenger, M. F. (2005). Human mesenchymal stem cells modulate 
allogeneic immune cell responses. Blood 105, 1815 - 1822. 
Altman, D. G. & Bland, J. M. (1994). Statistics Notes: Diagnostic tests 1: sensitivity 
and specificity. BMJ 308, 1552. 
Amado, L. C., Saliaris, A. P., Schuleri, K. H., St. John, M., Xie, J.-S., Cattaneo, S., 
Durand, D. J., Fitton, T., Kuang, J. Q., Stewart, G., Lehrke, S., 
Baumgartner, W. W., Martin, B. J., Heldman, A. W. & Hare, J. M. (2005). 
Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem 
cells after myocardial infarction. Proceedings of the National Academy of 
Sciences of the United States of America 102, 11474-11479. 
Arruda, V., Stedman, H., Nichols, T., Haskins, M., Nicholson, M., Herzog, R., 
Couto, L. & High, K. (2005). Regional intravascular delivery of AAV-2-F.IX to 
skeletal muscle achieves long-term correction of hemophilia B in a large animal 
model. Blood 105, 3458-3464. 
Artavanis-Tsakonas, S., Matsuno, K. & Fortini, M. E. (1995). Notch signaling. 
Science 268, 225-232. 
Asokan, A., Hamra, J. B., Govindasamy, L., Agbandje-McKenna, M. & Samulski, 
R. J. (2006). Adeno-Associated Virus Type 2 Contains an Integrin 
{alpha}5{beta}1 Binding Domain Essential for Viral Cell Entry. J Virol 80, 
8961-8969. 
Atchison, R. W. (1970). The role of herpesviruses in adenovirusassociated virus 
replication in vitro. Virology 42, 155-162. 
237 
 
Atchison, R. W., Casto, B. C. & Hammon, W. M. (1965). Adenovirus-associated 
defective virus particles. Science 149, 754-756. 
Augello, A., Tasso, R., Negrini, Simone M., Amateis, A., Indiveri, F., Cancedda, R. 
& Pennesi, G. (2005). Bone marrow mesenchymal progenitor cells inhibit 
lymphocyte proliferation by activation of the programmed death 1 pathway. 
European Journal of Immunology 35, 1482-1490. 
Baksh, D., Song, L. & Tuan, R. S. (2004). Adult mesenchymal stem cells: 
characterization, differentiation, and application in cell and gene therapy. 
Journal of Cellular and Molecular Medicine 8, 301-316. 
Barry, F. P. & Murphy, J. M. (2004). Mesenchymal stem cells: clinical applications 
and biological characterization. Int J Biochem Cell Biol 36, 568 - 584. 
Barry, F. P., Murphy, J. M., English, K. & Mahon, B. P. (2005). Immunogenicity of 
adult mesenchymal stem cells: lessons from the fetal allograft. Stem cells and 
development in press. 
Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., McIntosh, K., Patil, S., 
Hardy, W., Devine, S., Ucker, D., Deans, R., Moseley, A. & Hoffman, R. 
(2002). Mesenchymal stem cells suppress lymphocyte proliferation in vitro and 
prolong skin graft survival in vivo. Exp Hematol 30, 42 - 48. 
Bartlett, J. S., Kleinschmidt, J., Boucher, R. C. & Samulski, R. J. (1999). Targeted 
adeno-associated virus vector transduction of nonpermissive cells mediated by a 
bispecific F(ab'gamma)2 antibody. Nat Biotechnol 17, 181-186. 
238 
 
Becerra, S. P., Koczot, F., Fabisch, P. & Rose, J. A. (1988). Synthesis of adeno-
associated virus structural proteins requires both alternative mRNA splicing and 
alternative initiations from a single transcript. J Virol 62, 2745-2754. 
Becker, A. J., McCulloch, E. A. & Till, J. E. (1963). Cytological demonstration of the 
clonal nature of spleen colonies derived from transplanted mouse marrow cells. 
Nature 2, 452-454. 
Bhasin, M. & Raghava, G. P. S. (2004). Prediction of CTL epitopes using QM, SVM 
and ANN techniques. Vaccine 22, 3195-3204. 
Bianco, P., Robey, P. G. & Simmons, P. J. (2008). Mesenchymal Stem Cells: 
Revisiting History, Concepts and Assays. Cell Stem Cell 2, 313-319. 
Blacklow, N. R., Hoggan, M. D., Kapikian, A. Z., Austin, J. B. & Rowe, W. P. 
(1968a). Epidemiology of adenovirus-associated virus infection in a nursery 
population. Am J Epidemiol 88, 368-378. 
Blacklow, N. R., Hoggan, M. D. & Rowe, W. P. (1967). Isolation of adenovirus-
associated viruses from man. Proc Natl Acad Sci U S A 58, 1410-1415. 
Blacklow, N. R., Hoggan, M. D. & Rowe, W. P. (1968b). Serologic evidence for 
human infection with adenovirus-associated viruses. J Natl Cancer Inst 40, 319-
327. 
Bleker, S., Pawlita, M. & Kleinschmidt, J. A. (2006). Impact of Capsid Conformation 
and Rep-Capsid Interactions on Adeno-Associated Virus Type 2 Genome 
Packaging. J Virol 80, 810-820. 
239 
 
Bonab, M., Alimoghaddam, K., Talebian, F., Ghaffari, S., Ghavamzadeh, A. & 
Nikbin, B. (2006). Aging of mesenchymal stem cell in vitro. BMC Cell Biology 
7, 14. 
Boyle, M. P., Enke, R. A., Mogayzel, P. J., Guggino, W. B., Martin, D. B., Agarwal, 
S. & Zeitlin, P. L. (2003). Effect of Adeno-Associated Virus–Specific 
Immunoglobulin G in Human Amniotic Fluid on Gene Transfer. Hum Gene Ther 
14, 365-373. 
Bøyum, A. (1968). Isolation of mononuclear cells and granulocytes from human blood. 
Scand J Clin Invest 21, 77-89. 
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of 
microgram quantities of protein utilizing the principle of protein-dye binding. 
Analytical Biochemistry 72, 248-254. 
Briere, F., Servet-Delprat, C., Bridon, J., Saint-Remy, J. & Banchereau, J. (1994). 
Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells 
to secrete IgG1 and IgG3. J Exp Med 179, 757-762. 
Bruder, S. P., Jaiswal, N. & Haynsesworth, S. E. (1997). Growth kinetics, self-
renewal and the osteogenic potential of purified human mesenchymal stem cells 
during extensive subcultivation and following cryopreservation. J Cell Biochem 
64, 278-294. 
Büning, H., Ried, M. U., Perabo, L., Gerner, F. M., Huttner, N. A., Enssle, J. & Hallek, M. 
(2003). Receptor targeting of adeno-associated virus vectors. Gene Ther 10, 
1142-1151. 
240 
 
Buller, R. M. & Rose, J. A. (1978). Characterization of adenovirus-associated virus-
induced polypeptides in KB cells. J Virol 25, 331-338. 
Buller, R. M. L., Janik, J. E., Sebring, E. D. & Rose, J. A. (1981). Herpes Simplex 
Virus Types 1 and 2 Completely Help Adenovirus-Associated Virus Replication. 
J Virol 40, 241-247. 
Cassinotti, P., Weitz, M. & Tratschin, J. D. (1988). Organization of the adeno-
associated virus (AAV) capsid gene: mapping of a minor spliced mRNA coding 
for virus capsid protein 1. Virology 167, 176-184. 
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G., egrave, ve de, S., Gross, F., Yvon, 
E., Nusbaum, P., Selz, F., ccedil, oise, Hue, C., Certain, S., eacute, phanie, 
Casanova, J.-L., Bousso, P., Deist, F., oise, L. & Fischer, A. (2000). Gene 
Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease. 
Science 288, 669-672. 
Cerottini, J. C. & Brunner, K. T. (1974). Cell-mediated cytotoxicity, allograft 
rejection, and tumor immunity. Adv Immunol 18, 67-132. 
Chang, J., Sonoyama, W., Wang, Z., Jin, Q., Zhang, C., Krebsbach, P. H., 
Giannobile, W., Shi, S. & Wang, C.-Y. (2007). Noncanonical Wnt-4 Signaling 
Enhances Bone Regeneration of Mesenchymal Stem Cells in Craniofacial 
Defects through Activation of p38 MAPK. Journal of Biological Chemistry 282, 
30938-30948. 
Chang, S. C. N., Chuang, H. L., Chen, Y. R., Chen, J. K., Chung, H. Y., Lu, Y. L., 
Lin, H. Y., Tai, C. L. & Lou, J. (2003). Ex vivo gene therapy in autologous 
241 
 
bone marrow stromal stem cells for tissue-engineered maxillofacial bone 
regeneration. Gene Ther 10, 2013-2019. 
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J. & Walsh, C. E. (2000). 
Several log increase in therapeutic transgene delivery by distinct adeno-
associated viral serotype vectors. Mol Ther 2, 619-623. 
Chen, J., Wu, Q., Yang, P., Hsu, H. C. & Mountz, J. D. (2006). Determination of 
specific CD4 and CD8 T-cell epitopes after AAV2- and AAV8-hF.IX gene 
therapy. Mol Ther 13, 260-269. 
Chen, S.-l., Fang, W.-w., Ye, F., Liu, Y.-H., Qian, J., Shan, S.-j., Zhang, J.-j., 
Chunhua, R. Z., Liao, L.-m., Lin, S. & Sun, J.-p. (2004). Effect on left 
ventricular function of intracoronary transplantation of autologous bone marrow 
mesenchymal stem cell in patients with acute myocardial infarction. The 
American Journal of Cardiology 94, 92-95. 
Cheung, A. K., Hoggan, M. D., Hauswirth, W. W. & Berns, K. I. (1980). Integration 
of the adeno-associated virus genome into cellular DNA in latently infected 
human Detroit 6 cells. J Virol 33, 739-748. 
Chiorini, J. A., Kim, F., Yang, L. & Kotin, R. M. (1999). Cloning and 
characterization of adeno-associated virus type 5. J Virol 73, 1309-1319. 
Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R. & Wilson, J. M. 
(1999). Immune responses to adenovirus and adeno-associated virus in humans. 
Gene Ther 6, 1574-1583. 
Chirmule, N., Xiao, W., Truneh, A., Schnell, M. A., Hughes, J. V., Zoltick, P. & 
Wilson, J. M. (2000). Humoral Immunity to Adeno-Associated Virus Type 2 
242 
 
Vectors following Administration to Murine and Nonhuman Primate Muscle. J 
Virol 74, 2420-2425. 
Corcoran, A., Doyle, S., Waldron, D., Nicholson, A. & Mahon, B. P. (2000). 
Impaired Gamma Interferon Responses against Parvovirus B19 by Recently 
Infected Children. J Virol 74, 9903-9910. 
Corcoran, A., Mahon, BernardÂ P. & Doyle, S. (2004). B Cell Memory Is Directed 
toward Conformational Epitopes of Parvovirus B19 Capsid Proteins and the 
Unique Region of VP1. The Journal of Infectious Diseases 189, 1873-1880. 
Coura, R. d. S. & Nardi, N. B. (2007). The state of the art of adeno-associated virus-
based vectors in gene therapy. Virol J 4. 
Crigler, L., Robey, R. C., Asawachaicharn, A., Gaupp, D. & Phinney, D. G. (2006). 
Human mesenchymal stem cell subpopulations express a variety of neuro-
regulatory molecules and promote neuronal cell survival and neuritogenesis. 
Experimental Neurology 198, 54-64. 
D'Ippolito, G., Diabira, S., Howard, G. A., Menei, P., Roos, B. A. & Schiller, P. C. 
(2004). Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique 
population of postnatal young and old human cells with extensive expansion and 
differentiation potential J Cell Sci 117, 2971-2981. 
da Silva Meirelles, L., Caplan, A. I. & Nardi, N. B. (2008). In Search of the In Vivo 
Identity of Mesenchymal Stem Cells. Stem Cells 26, 2287-2299. 
De Ugarte, D. A., Morizono, K., Elbarbary, A., Alfonso, Z., Zuk, P. A., Zhu, M., 
Dragoo, J. L., Ashjian, P., Thomas, B., Benhaim, P., Chen, I., Fraser, J. & 
243 
 
Hedrick, M. H. (2003). Comparison of Multi-Lineage Cells from Human 
Adipose Tissue and Bone Marrow. Cells Tissues Organs 174, 101-109. 
Deng, W., Han, Q., Liao, L., Li, C., Ge, W., Zhao, Z., You, S., Deng, H. & Zhao, R. 
C. (2004). Allogeneic bone marrow-derived flk-1+Sca-1- mesenchymal stem 
cells leads to stable mixed chimerism and donor-specific tolerance. Exp Hematol 
32, 861 - 867. 
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, 
P., Grisanti, S. & Gianni, A. M. (2002). Human bone marrow stromal cells 
suppress T-lymphocyte proliferation induced by cellular or nonspecific 
mitogenic stimuli. Blood 99, 3838 - 3843. 
DiGirolamo, C. M., Stokes, D., Colter, D., Phinney, D. G., Class, R. & Prockop, D. 
J. (1999). Propagation and senescence of human marrow stromal cells in culture: 
a simple colony-forming assay identifies samples with the greatest potential to 
propagate and differentiate. British Journal of Haematology 107, 275-281. 
DiPrimio, N., Asokan, A., Govindasamy, L., Agbandje-McKenna, M. & Samulski, 
R. J. (2008). Surface Loop Dynamics in AAV Capsid Assembly. J Virol 82, 
5178-5179. 
Djeha, A. H., Thomson, T. A., Leung, H., Searle, P. F., Young, L. S., Kerr, D. J., 
Harris, P. A., Mountain, A. & Wrighton, C. J. (2001). Combined Adenovirus-
Mediated Nitroreductase Gene Delivery and CB1954 Treatment: A Well-
Tolerated Therapy for Established Solid Tumors. Molecular Therapy 3, 233-240. 
244 
 
Djouad, F., Bouffi, C., Ghannam, S., Noel, D. & Jorgensen, C. (2009). Mesenchymal 
stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev 
Rheumatol 5, 392-399. 
Dong, J.-Y., Fan, P.-D. & Frizzell, R. A. (1996). Quantitative Analysis of the 
Packaging Capacity of Recombinant Adeno-Associated Virus. Human Gene 
Therapy 7, 2101-2112. 
Douar, A. M., Poulard, K., Stockholm, D. & Danos, O. (2001). Intracellular 
trafficking of adeno-associated virus vectors: routing to the late endosomal 
compartment and proteasome degradation. J Virol 75, 1824-1833. 
Duan, D., Yue, Y., Yan, Z., McCray, P. B., Jr. & Engelhardt, J. F. (1998). Polarity 
influences the efficiency of recombinant adenoassociated virus infection in 
differentiated airway epithelia. Hum Gene Ther 9, 2761-2776. 
Dunne, C., Crowley, J., Hagan, R., Rooney, G. & Lawlor, E. (2008). HLA-A, B, Cw, 
DRB1, DQB1 and DPB1 alleles and haplotypes in the genetically homogenous 
Irish population. Int J Immunogenet 35, 295-302. 
Edelstein, M. L., Abedi, M. R. & Wixon, J. (2007). Gene therapy clinical trials 
worldwide to 2007 - an update. The Journal of Gene Medicine 9, 833-842. 
Edelstein, M. L., Abedi, M. R., Wixon, J. & Edelstein, R. M. (2004). Gene therapy 
clinical trials worldwide 1989-2004 - an overview. The Journal of Gene 
Medicine 6, 597-602. 
English, K., Barry, F. P., Field-Corbett, C. P. & Mahon, B. P. (2007). IFN-[gamma] 
and TNF-[alpha] differentially regulate immunomodulation by murine 
mesenchymal stem cells. Immunology Letters 110, 91-100. 
245 
 
English, K., Barry, F. P. & Mahon, B. P. (2008). Murine mesenchymal stem cells 
suppress dendritic cell migration, maturation and antigen presentation. 
Immunology Letters 115, 50-58. 
Engvall, E. & Perlmann, P. (1971). Enzyme-linked immunosorbent assay (ELISA). 
Quantitative assay of immunoglobulin G. Immunochemistry 8, 871-874. 
Erles, K., Sebökovà, P. & Schlehofer, J. R. (1999). Update on the prevalence of serum 
antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 59, 406-
411. 
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., 
Northrop, J. P., Ringold, G. M. & Danielsen, M. (1987). Lipofection: a highly 
efficient, lipid-mediated DNA-transfection procedure. Proceedings of the 
National Academy of Sciences of the United States of America 84, 7413-7417. 
Franssila, R., Söderlund, M., Brown, C. S., Spaan, W. J. M., Seppälä, I. & 
Hedman, K. (1996). IgG subclass response to human parvovirus B19 infection. 
Clin Diagn Virol 6, 41-49. 
Friedenstein, A. J. P., Deriglasova, U. F., Kulagina, N. N., Panasuk, A. F., 
Rudakowa, S. F., Luria, E. A. & Ruadkow, I. A. (1974). Precursors for 
fibroblasts in different populations of hematopoietic cells as detected by the in 
vitro colony assay method. Exp Hematol 2, 83-92. 
Friedenstein, A. J. P. & Petrokova, K. V. (1966). Osteogenesis in transplant of bone 
marrow cells. Journal of Embryological Experimental Morphology 16, 381-390. 
Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U. & Ferrara, G. B. 
(2002). Tryptophan-derived catabolites are responsible for inhibition of T and 
246 
 
natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp 
Med 196, 459 - 468. 
Gadi, T., Debbie, D. P., Ralph, M., Basan Gowda, K., Shuanhu, Z., Gadi, P., Amos, 
P., Yoram, Z., Ioannis, K. M. & Dan, G. (2001). Engineered human 
mesenchymal stem cells: a novel platform for skeletal cell-mediated gene 
therapy. The Journal of Gene Medicine 3, 240-251. 
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X. & 
Wilson, J. M. (2004). Clades of Adeno-Associated Viruses Are Widely 
Disseminated in Human Tissues. J Virol 78, 6381-6388. 
Gao, G. P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J. & Wilson, J. M. 
(2002). Novel adeno-associated viruses from rhesus monkeys as vectors for 
human gene therapy. Proc Natl Acad Sci U S A 99, 11854-11859. 
Girod, A., Wobus, C. E., Zadori, Z., Ried, M., Leike, K., Tijssen, P., Kleinschmidt, 
J. A. & Hallek, M. (2002). The VP1 capsid protein of adeno-associated virus 
type 2 is carrying a phospholipase A2 domain required for virus infectivity. J 
Gen Virol 83, 973-978. 
Glennie, S., Soeiro, I., Dyson, P. J., Lam, E. W. & Dazzi, F. (2005). Bone marrow 
mesenchymal stem cells induce division arrest anergy of activated T-cells. Blood 
105, 2821 - 2827. 
Goncalves, M. (2005). Adeno-associated virus: from defective virus to effective vector. 
Virology Journal 2, 43. 
Gould, D. J. & Favorov, P. (2003). Vectors for the treatment of autoimmune disease. 
Gene Ther 10, 912-927. 
247 
 
Greenwood, M. J. & Lansdorp, P. M. Telomeres, telomerase, and hematopoietic stem 
cell biology. Archives of Medical Research 34, 489-495. 
Gregoreka, H., Madalinski, K., Woynarowskib, M., Mikolajewiczc, J., Syczewskad, 
M. & Sochab, J. (2000). The IgG subclass profile of anti-HBs response in 
vaccinated children and children seroconverted after natural infection. Vaccine 
18, 1210-1217. 
Grimm, D., Zhou, S., Nakai, H., Thomas, C. E., Storm, T. A., Fuess, S., Matsushita, 
T., Allen, J., Surosky, R., Lochrie, M., Meuse, L., McClelland, A., Colosi, P. 
& Kay, M. A. (2003). Preclinical in vivo evaluation of pseudotyped adeno-
associated virus vectors for liver gene therapy. Blood 102, 2412-2419. 
Gronthos, S., Franklin, D. M., Leddy, H. A., Robey, P. G., Storms, R., W.  & 
Gimble, J., M. (2001). Surface protein characterization of human adipose tissue-
derived stromal cells. Journal of Cellular Physiology 189, 54-63. 
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., 
Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., Asnafi, V., 
Macintyre, E., Dal Cortivo, L., Radford, I., Brousse, N., Sigaux, F., 
Moshous, D., Hauer, J., Borkhardt, A., Belohradsky, B. H., Wintergerst, U., 
Velez, M. C., Leiva, L. E., Sorensen, R., Wulffraat, N., Blanche, S., 
Bushman, F. D., Fischer, A. & Cavazzana-Calvo, M. (2008). Insertional 
oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J 
Clin Invest 118, 3132-3142. 
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, 
N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., 
248 
 
Sorensen, R., Forster, A., Fraser, P., Cohen, J. I., de Saint Basile, G., 
Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, 
D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., 
Macintyre, E., Sigaux, F., Soulier, J., Leiva, L. E., Wissler, M., Prinz, C., 
Rabbitts, T. H., Le Deist, F., Fischer, A. & Cavazzana-Calvo, M. (2003). 
LMO2-Associated Clonal T-cell Proliferation in Two Patients after Gene 
Therapy for SCID-X1. Science 302, 415-419. 
Halbert, C. L., Allen, J. M. & Miller, A. D. (2001). Adeno-Associated Virus Type 6 
(AAV6) Vectors Mediate Efficient Transduction of Airway Epithelial Cells in 
Mouse Lungs Compared to That of AAV2 Vectors. J Virol 75, 6615-6624. 
Halbert, C. L., Miller, A. D., McNamara, S., Emerson, J., Gibson, R. L., Ramsey, 
B. & Aitken, M. L. (2006). Prevalence of Neutralizing Antibodies Against 
Adeno-Associated Virus (AAV) Types 2, 5, and 6 in Cystic Fibrosis and Normal 
Populations: Implications for Gene Therapy Using AAV Vectors. Human Gene 
Therapy 17, 440-447. 
Halbert, C. L., Standaert, T. A., Aitken, M. L., Alexander, I. E., Russell, D. W. & 
Miller, A. D. (1997). Transduction by adeno-associated virus vectors in the 
rabbit airway: efficiency, persistence, and readministration. J Virol 71, 5932-
5941. 
Halbert, C. L., Standaert, T. A., Wilson, C. B. & Miller, A. D. (1998). Successful 
readministration of adeno-associated virus vectors to the mouse lung requires 
transient immunosuppression during the initial exposure. J Virol 72, 9795-9805. 
249 
 
Hauswirth, W. W. & Berns, K. I. (1979). Adeno-associated virus DNA replication: 
Nonunit-length molecules. Virology 93, 57-68. 
Hawkins, E. D., Hommel, M., Turner, M. L., Battye, F. L., Markham, J. F. & 
Hodgkin, P. D. (2007). Measuring lymphocyte proliferation, survival and 
differentiation using CFSE time-series data. Nat Protoc 2, 2057-2067. 
Helledie, T., Nurcombe, V. & Cool, S. M. (2008). A Simple and Reliable 
Electroporation Method for Human Bone Marrow Mesenchymal Stem Cells. 
Stem cells and development 17, 837-848. 
Hellman, S., Grate, H. E., Chaffey, J. T. & Carmel, R. (1970). Hematopoietic stem 
cell compartment: patterns of differentiation following radiation or 
cyclophosphamide. Hemopoietic Cellular Proliferation, 36-48. 
Hernandez, Y. J., Wang, J., Kearns, W. G., Loiler, S., Poirier, A. & Flotte, T. R. 
(1999). Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-
Mediated Immune Responses in a Nonhuman Primate Model. J Virol 73, 8549-
8558. 
High, K. A., Manno, C. S., Sabatino, D., Hutchison, S., Dake, M., Razavi, M., Kaye, 
R., Aruda, V., Herzog, R., Rustagi, P., Rasko, J., Hoots, K., Blatt, P., 
Sommer, J., Ragni, M., Ozelo, M., Konkle, B., Lessard, R., Luk, A., Glader, 
B., Pierce, G., Couto, L. & Kay, M. (2004). Immune Responses to AAV and to 
Factor IX in a Phase I Study of AAV-Mediated, Liver-Directed Gene Transfer 
for Hemophilia B. Mol Ther 9, S383-384. 
Iso, Y., Spees, J. L., Serrano, C., Bakondi, B., Pochampally, R., Song, Y.-H., Sobel, 
B. E., Delafontaine, P. & Prockop, D. J. (2007). Multipotent human stromal 
250 
 
cells improve cardiac function after myocardial infarction in mice without long-
term engraftment. Biochemical and Biophysical Research Communications 354, 
700-706. 
Jackson, K. A., Mi, T. & Goodell, M. A. (1999). Hematopoietic potential of stem cells 
isolated from murine skeletal muscle. Proceedings of the National Academy of 
Sciences of the United States of America 96, 14482-14486. 
Janik, J. E., Huston, M. M. & Rose, J. A. (1984). Adeno-associated virus proteins: 
origin of the capsid components. J Virol 52, 591-597. 
Jankowski, R. J., Deasy, B. M. & Huard, J. (2002). Muscle-derived stem cells. Gene 
Ther 9, 642-647. 
Jefferis, R. & Kumararatne, D. S. (1990). Selective IgG subclass deficiency: 
quantification and clinical relevance. Clin exp Immunol 81, 357-367. 
Jefferis, R. & Lund, J. (2002). Interaction sites on human IgG-Fc for Fc[gamma]R: 
current models. Immunology Letters 82, 57-65. 
Jiang, Y., Jahagirdar, B. N., Reinhardt, R. L., Schwartz, R. E., Keene, C. D., Ortiz-
Gonzalez, X. R., Reyes, M., Lenvik, T., Lund, T., Blackstad, M., Du, J., 
Aldrich, S., Lisberg, A., Low, W. C., Largaespada, D. A. & Verfaillie, C. M. 
(2002a). Pluripotency of mesenchymal stem cells derived from adult marrow. 
Nature 418, 41 - 49. 
Jiang, Y., Vaessen, B., Lenvik, T., Blackstad, M., Reyes, M. & Verfaillie, C. M. 
(2002b). Multipotent progenitor cells can be isolated from postnatal murine bone 
marrow, muscle, and brain. Experimental Hematology 30, 896-904. 
251 
 
Johansson, B. M. & Wiles, M. V. (1995). Evidence for involvement of activin A and 
bone morphogenetic protein 4 in mammalian mesoderm and hematopoietic 
development. Mol Cell Biol 15, 141-151. 
Jones, E. & McGonagle, D. (2007). Human bone marrow mesenchymal stem cells in 
vivo. Rheumatology, kem206. 
Kalvenes, M. B., Kalland, K. H. & Haukenes, G. (1996). Immunoglobulin G subclass 
antibodies to rubella virus in chronic liver disease, acute rubella and healthy 
controls. FEMS Immunol Med Microbiol 13, 43-50. 
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., 
Bland, R. J., Young, D., Strybing, K., Eidelberg, D. & During, M. J. (2007). 
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) 
borne GAD gene for Parkinson's disease: an open label, phase I trial. The Lancet 
369, 2097-2105. 
Kern, A., Schmidt, K., Leder, C., Muller, O. J., Wobus, C. E., Bettinger, K., Von 
der Lieth, C. W., King, J. A. & Kleinschmidt, J. A. (2003). Identification of a 
Heparin-Binding Motif on Adeno-Associated Virus Type 2 Capsids. J Virol 77, 
11072-11081. 
Koc, O. N., Day, J., Nieder, M., Gerson, S. L., Lazarus, H. M. & Krivit, W. (2002). 
Allogeneic mesenchymal stem cell infusion for treatment of metachromatic 
leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow 
Transplant 30, 215 - 222. 
Kofron, M. D. & Laurencin, C. T. (2006). Bone tissue engineering by gene delivery. 
Advanced Drug Delivery Reviews 58, 555-576. 
252 
 
Kogler, G., Sensken, S., Airey, J. A., Trapp, T., Muschen, M., Feldhahn, N., 
Liedtke, S., Sorg, R. V., Fischer, J., Rosenbaum, C., Greschat, S., Knipper, 
A., Bender, J., Degistirici, O., Gao, J., Caplan, A. I., Colletti, E. J., Almeida-
Porada, G., Muller, H. W., Zanjani, E. & Wernet, P. (2004). A New Human 
Somatic Stem Cell from Placental Cord Blood with Intrinsic Pluripotent 
Differentiation Potential. J Exp Med 200, 123-135. 
Kotin, R. M., Siniscalco, M., Samulski, R. J., Zhu, X. D., Hunter, L., Laughlin, C. 
A., McLaughlin, S., Muzyczka, N., Rocchi, M. & Berns, K. I. (1990). Site-
specific integration by adeno-associated virus. Proc Natl Acad Sci USA 87, 
2211-2215. 
Krampera, M., Glennie, S., Dyson, J., Scott, D., Laylor, R., Simpson, E. & Dazzi, F. 
(2003). Bone marrow mesenchymal stem cells inhibit the response of naive and 
memory antigen-specific T-cells to their cognate peptide. Blood 101, 3722 - 
3729. 
Krause, D. S., Theise, N. D., Collector, M. I., Henegariu, O., Hwang, S., Gardner, 
R., Neutzel, S. & Sharkis, S. J. (2001). Multi-Organ, Multi-Lineage 
Engraftment by a Single Bone Marrow-Derived Stem Cell. Cell 105, 369-377. 
Kremer, E. J. & Perricaudet, M. (1995). Adenovirus and adeno-associated virus 
mediated gene transfer. Br Med Bull 51, 31-44. 
Kronenberg, S., Bottcher, B., von der Lieth, C. W., Bleker, S. & Kleinschmidt, J. 
A. (2005). A Conformational Change in the Adeno-Associated Virus Type 2 
Capsid Leads to the Exposure of Hidden VP1 N Termini. J Virol 79, 5296-5303. 
253 
 
Kucia, M., Reca, R., Campbell, F. R., Zuba-Surma, E., Majka, M., Ratajczak, J. & 
Ratajczak, M. Z. (2006). A population of very small embryonic-like (VSEL) 
CXCR4+SSEA-1+Oct-4+ stem cells identified in adult bone marrow. Leukemia 
20, 857-869. 
Lagasse, E., Connors, H., Al-Dhalimy, M., Reitsma, M., Dohse, M., Osborne, L., 
Wang, X., Finegold, M., Weissman, I. L. & Grompe, M. (2000). Purified 
hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 6, 
1229-1234. 
Lal, R. B., Buckner, C., Khabbaz, R. F., Kaplan, J. E., Reyes, G., Hadlock, K., 
Lipka, J., Foung, S. K. H., Chan, L. & Coligan, J. E. (1993). Isotypic and IgG 
Subclass Restriction of the Humoral Immune Responses to Human T-
Lymphotropic Virus Type-I. Clin Immunol Immunopathol 67, 40-49. 
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, 
M. & Ringdén, O. (2004). Treatment of severe acute graft-versus-host disease 
with third party haploidentical mesenchymal stem cells. The Lancet 363, 1439-
1441. 
Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E. & Ringden, O. (2003). 
HLA expression and immunologic properties of differentiated and 
undifferentiated mesenchymal stem cells. Exp Hematol 31, 890 - 896. 
Levine, B. L., Humeau, L. M., Boyer, J., MacGregor, R.-R., Rebello, T., Lu, X., 
Binder, G. K., Slepushkin, V., Lemiale, F., Mascola, J. R., Bushman, F. D., 
Dropulic, B. & June, C. H. (2006). Gene transfer in humans using a 
254 
 
conditionally replicating lentiviral vector. Proceedings of the National Academy 
of Sciences 103, 17372-17377. 
Li, C., Hirsch, M., DiPrimio, N., Asokan, A., Goudy, K., Tisch, R. & Samulski, R. 
J. (2009). Cytotoxic-T-Lymphocyte-Mediated Elimination of Target Cells 
Transduced with Engineered Adeno-Associated Virus Type 2 Vector In Vivo. J 
Virol 83, 6817-6824. 
Li, H., Murphy, S. L., Giles-Davis, W., Edmonson, S., Xiang, Z., Li, Y., Lasaro, M., 
High, K. A. & Ertl, H. C. (2007). Pre-existing AAV capsid-specific CD8+ T-
cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther 15, 792-
800. 
Lieberman, J. R., Le, L. Q., Wu, L., Finerman, G. A. M., Berk, A., Witte, O. N. & 
Stevenson, S. (1998). Regional gene therapy with a BMP-2-producing murine 
stromal cell line induces heterotopic and orthotopic bone formation in rodents. 
Journal of Orthopaedic Research 16, 330-339. 
Liu, D. W., Tsao, Y. P., Kung, J. T., Ding, Y. A., Sytwu, H. K., Xiao, X. & Chen, S. 
L. (2000). Recombinant adeno-associated virus expressing human 
papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a 
potential vaccine for cervical cancer. J Virol 74, 2888-2894. 
Mackay, A. M., Beck, S. C., Murphy, J. M., Barry, F. P., Chichester, C. O. & 
Pittenger, M. F. (1998). Chondrogenic differentiation of cultured human 
mesenchymal stem cells from marrow. Tissue Eng 4, 415 - 428. 
255 
 
Manning, W. C., Zhou, S., Bland, M. P., Escobedo, J. A. & Dwarki, V. (1998). 
Transient immunosuppression allows transgene expression following 
readministration of adeno-associated viral vectors. Hum Gene Ther 9, 477-485. 
Manno, C. S., Pierce, G., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J., Ozelo, 
M. C., Hoots, K., Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., 
Zajko, A., Zehnder, J., Rustagi, P. K., Nakai, H., Chew, A., Leonard, D., 
Wright, J., Lessard, R. R., Sommer, J. M., Tigges, M., Sabatino, D., Luk, A., 
Jiang, H., Mingozzi, F., Couto, L., Ertl, H. C., High, K. A. & Kay, M. A. 
(2006). Successful transduction of liver in hemophilia by AAV-Factor IX and 
limitations imposed by the host immune response. Nat Med 12, 342-347. 
Markert, C. D., Atala, A., Cann, J. K., Christ, G., Furth, M., Ambrosio, F. & 
Childers, M. K. (2009). Mesenchymal Stem Cells: Emerging Therapy for 
Duchenne Muscular Dystrophy. PM&R 1, 547-559. 
Martin, G. R. (1981). Isolation of a pluripotent cell line from early mouse embryos 
cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad 
Sci U S A 78, 7634-7638. 
Martinez-Agosto, J. A., Mikkola, H. K. A., Hartenstein, V. & Banerjee, U. (2007). 
The hematopoietic stem cell and its niche: a comparative view. Genes & 
Development 21, 3044-3060. 
Matsuoka, S., Ebihara, Y., Xu, M.-j., Ishii, T., Sugiyama, D., Yoshino, H., Ueda, T., 
Manabe, A., Tanaka, R., Ikeda, Y., Nakahata, T. & Tsuji, K. (2001). CD34 
expression on long-term repopulating hematopoietic stem cells changes during 
developmental stages. Blood 97, 419-425. 
256 
 
Maximow, A. A. (1906). Über experimentelle erzeugung von knochenmarks-gewebe. 
Anatomischer Anzeiger 28, 24-38. 
McMahon, J. M., Conroy, S., Lyons, M., Greiser, U., O'Shea, C., Strappe, P., 
Howard, L., Murphy, M., Barry, F. & O'Brien, T. (2006). Gene Transfer into 
Rat Mesenchymal Stem Cells: A Comparative Study of Viral and Nonviral 
Vectors. Stem cells and development 15, 87-96. 
McTaggart, S. & Al-Rubeai, M. (2002). Retroviral vectors for human gene delivery. 
Biotechnology Advances 20, 1-31. 
Meisel, R., Zibert, A., Laryea, M., Gobel, U., Daubener, W. & Dilloo, D. (2004). 
Human bone marrow stromal cells inhibit allogeneic T-cell responses by 
indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103, 4619 
- 4621. 
Mellor, A. L. & Munn, D. H. (2001). Tryptophan catabolism prevents maternal T-cells 
from activating lethal anti-fetal immune responses. J Reprod Immunol 52, 5 - 13. 
Mendelson, E., Trempe, J. P. & Carter, B. J. (1986). Identification of the trans-acting 
Rep proteins of adeno-associated virus by antibodies to a synthetic oligopeptide. 
J Virol 60, 823-832. 
Miller, C. L., Llenos, I. C., Dulay, J. R. & Weis, S. (2006). Upregulation of the 
initiating step of the kynurenine pathway in postmortem anterior cingulate cortex 
from individuals with schizophrenia and bipolar disorder. Brain Research 1073-
1074, 25-37. 
Miura, M., Gronthos, S., Zhao, M., Lu, B., Fisher, L. W., Robey, P. G. & Shi, S. 
(2003). SHED: Stem cells from human exfoliated deciduous teeth. Proceedings 
257 
 
of the National Academy of Sciences of the United States of America 100, 5807-
5812. 
Miura, M., Miura, Y., Padilla-Nash, H. M., Molinolo, A., A. , Fu, B., Patel, V., Seo, 
B.-M., Sonoyama, W., Zheng, J. J., Baker, C. C., Chen, W., Ried, T. & Shi, 
S. (2006). Accumulated Chromosomal Instability in Murine Bone Marrow 
Mesenchymal Stem Cells Leads to Malignant Transformation. Stem Cells 24, 
1095-1103. 
Mohr, A., Lyons, M., Deedigan, L., Harte, T., Shaw, G., Howard, L., Barry, F., 
O'Brien, T. & Zwacka, R. (2008). Mesenchymal stem cells expressing TRAIL 
lead to tumour growth inhibition in an experimental lung cancer model. Journal 
of Cellular and Molecular Medicine 12, 2628-2643. 
Monahan, P. E. & Samulski, R. J. (2000). AAV vectors: is clinical success on the 
horizon? Gene Ther 7, 24-30. 
Monahan, P. E., Samulski, R. J., Tazelaar, J., Xiao, X., Nichols, T. C., Bellinger, D. 
A., Read, M. S. & Walsh, C. E. (1998). Direct intramuscular injection with 
recombinant AAV vectors results in sustained expression in a dog model of 
hemophilia. Gene Ther 5, 40-49. 
Moore, K. A. & Lemischka, I. R. (2006). Stem Cells and Their Niches. Science 311, 
1880-1885. 
Mori, S., Wang, L., Takeuchi, T. & Kanda, T. (2004). Two novel adeno-associated 
viruses from cynomolgus monkey: pseudotyping characterization of capsid 
protein. Virology 330, 375-383. 
258 
 
Moskalenko, M., Chen, L., van Roey, M., Donahue, B. A., Snyder, R. O., 
McArthur, J. G. & Patel, S. D. (2000). Epitope Mapping of Human Anti-
Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene 
Therapy and Virus Structure. J Virol 74, 1761-1766. 
Moss, R. B., Milla, C., Colombo, J., Accurso, F., Zeitlin, P. L., Clancy, J. P., 
Spencer, L. T., Pilewski, J., Waltz, D. A., Dorkin, H. L., Ferkol, T., Pian, M., 
Ramsey, B., Carter, B. J., Martin, D. B. & Heald, A. E. (2007). Repeated 
aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-
controlled phase 2B trial. Hum Gene Ther 18, 726-732. 
Moss, R. B., Rodman, D., Spencer, L. T., Aitken, M. L., Zeitlin, P. L., Waltz, D. A., 
Milla, C., Brody, A. S., Clancy, J. P., Ramsey, B., Hamblett, N. & Heald, A. 
E. (2004). Repeated adeno-associated virus serotype 2 aerosol-mediated cystic 
fibrosis transmembrane regulator gene transfer to the lungs of patients with 
cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 125, 
509-521. 
Mountford, J. C. (2008). Human embryonic stem cells: origins, characteristics and 
potential for regenerative therapy. Transfusion Medicine 18, 1-12. 
Mueller, C. & Flotte, T. R. (2008). Clinical gene therapy using recombinant adeno-
associated virus vectors. Gene Ther 15, 858-863. 
Muraglia, A., Cancedda, R. & Quarto, R. (2000). Clonal mesenchymal progenitors 
from human bone marrow differentiate in vitro according to a hierarchical 
model. J Cell Sci 113, 1161-1166. 
259 
 
Muramatsu, S.-I., Mizukami, H., Young, N. S. & Brown, K. E. (1996). Nucleotide 
Sequencing and Generation of an Infectious Clone of Adeno-Associated Virus 3. 
Virology 221, 208-217. 
Murphy, S. L., Li, H., Mingozzi, F., Sabatino, D. E., Hui, D. J., Edmonson, S. A. & 
High, K. A. (2009). Diverse IgG subclass responses to adeno-associated virus 
infection and vector administration. J Med Virol 81, 65-74. 
Nishikage, S., Koyama, H., Miyata, T., Ishii, S., Hamada, H. & Shigematsu, H. 
(2004). In vivo electroporation enhances plasmid-based gene transfer of basic 
fibroblast growth factor for the treatment of ischemic limb. Journal of Surgical 
Research 120, 37-46. 
Nishizaki, K., Mazda, O., Dohi, Y., Kawata, T., Mizuguchi, K., Kitamura, S. & 
Taniguchi, S. (2000). In vivo gene gun-mediated transduction into rat heart with 
Epstein-Barr virus-based episomal vectors. The Annals of Thoracic Surgery 70, 
1332-1337. 
Ogura, N., Kawada, M., Chang, W.-J., Zhang, Q., Lee, S.-Y., Kondoh, T. & Abiko, 
Y. (2004). Differentiation of the human mesenchymal stem cells derived from 
bone marrow and enhancement of cell attachment by fibronectin. Journal of 
Oral Science 46, 207-213. 
Ohshima, S., Shin, J.-H., Yuasa, K., Nishiyama, A., Kira, J., Okada, T. & Takeda, 
S. i. (2008). Transduction Efficiency and Immune Response Associated With the 
Administration of AAV8 Vector Into Dog Skeletal Muscle. Mol Ther 17, 73-80. 
Okada, T. (1980). Cellular metaplasia or transdifferentiation as a model for retinal cell 
differentiation. Curr Top Dev Biol 16, 349-380. 
260 
 
Opie, S. R., Warrington, K. H., Jr., Agbandje-McKenna, M., Zolotukhin, S. & 
Muzyczka, N. (2003). Identification of Amino Acid Residues in the Capsid 
Proteins of Adeno-Associated Virus Type 2 That Contribute to Heparan Sulfate 
Proteoglycan Binding. J Virol 77, 6995-7006. 
Opitz, C. A., Litzenburger, U. M., Lutz, C., Lanz, T. V., Tritschler, I., Köppel, A., 
Tolosa, E., Hoberg, M., Anderl, J., Aicher, W. K., Weller, M., Wick, W. & 
Platten, M. (2009). Toll-Like Receptor Engagement Enhances the 
Immunosuppressive Properties of Human Bone Marrow-Derived Mesenchymal 
Stem Cells by Inducing Indoleamine-2,3-dioxygenase-1 via Interferon-beta and 
Protein Kinase R. Stem Cells 27, 909-919. 
Ortiz, L. A., DuTreil, M., Fattman, C., Pandey, A. C., Torres, G., Go, K. & 
Phinney, D. G. (2007). Interleukin 1 receptor antagonist mediates the 
antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung 
injury. Proceedings of the National Academy of Sciences 104, 11002-11007. 
Oswald, J., Boxberger, S., Jørgensen, B., Feldmann, S., Ehninger, G., Bornhäuser, 
M. & Werner, C. (2004). Mesenchymal Stem Cells Can Be Differentiated Into 
Endothelial Cells In Vitro. Stem Cells 22, 377-384. 
Parsch, D., Fellenberg, J., Brümmendorf, T., Eschlbeck, A.-M. & Richter, W. 
(2004). Telomere length and telomerase activity during expansion and 
differentiation of human mesenchymal stem cells and chondrocytes. Journal of 
Molecular Medicine 82, 49-55. 
261 
 
Partridge, K. A. & Oreffo, R. O. C. (2004). Gene Delivery in Bone Tissue 
Engineering: Progress and Prospects Using Viral and Nonviral Strategies. Tissue 
Engineering 10, 295-307. 
Peden, C. S., Burger, C., Muzyczka, N. & Mandel, R. J. (2004). Circulating Anti-
Wild-Type Adeno-Associated Virus Type 2 (AAV2) Antibodies Inhibit 
Recombinant AAV2 (rAAV2)-Mediated, but Not rAAV5-Mediated, Gene 
Transfer in the Brain. J Virol 78, 6344-6359. 
Peter, C., Anne, L. A., Alessandra, G., David, R. P. & Pamela, A. W. (2005). 
Mechanisms of MHC class I-restricted antigen processing and cross-
presentation. Immunological Reviews 207, 145-157. 
Pevsner-Fischer, M., Morad, V., Cohen-Sfady, M., Rousso-Noori, L., Zanin-
Zhorov, A., Cohen, S., Cohen, I. R. & Zipori, D. (2007). Toll-like receptors 
and their ligands control mesenchymal stem cell functions. Blood 109, 1422-
1432. 
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. 
D., Moorman, M. A., Simonetti, D. W., Craig, S. & Marshak, D. R. (1999). 
Multilineage potential of adult human mesenchymal stem cells. Science 284, 143 
- 147. 
Prindull, G., Prindull, B. & Meulen, N. v. d. (1978). Haematopoietic stem cells 
(CFUc) in human cord blood. Acta Paediatrica 67, 413-416. 
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V. & Srivastava, A. (1999). Human 
fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-
associated virus 2. Nat Med 5, 71-77. 
262 
 
Rabinowitz, J. E., Bowles, D. E., Faust, S. M., Ledford, J. G., Cunningham, S. E. & 
Samulski, R. J. (2004). Cross-dressing the virion: the transcapsidation of adeno-
associated virus serotypes functionally defines subgroups. J Virol 78, 4421-4432. 
Rabinowitz, J. E. & Samulski, R. J. (2000). Building a Better Vector: The 
Manipulation of AAV Virions. Virology 278, 301-308. 
Rammensee, H. G., Bachmann, J., Emmerich, N. P. N., Bachor, O. A. & 
Stevanović, S. (1999). SYFPEITHI: database for MHC ligands and peptide 
motifs. Immunogenetics 50, 213-219. 
Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G.-p., Wilson, J. 
M. & Batshaw, M. L. (2003). Fatal systemic inflammatory response syndrome 
in a ornithine transcarbamylase deficient patient following adenoviral gene 
transfer. Molecular Genetics and Metabolism 80, 148-158. 
Reya, T., Duncan, A. W., Ailles, L., Domen, J., Scherer, D. C., Willert, K., Hintz, 
L., Nusse, R. & Weissman, I. L. (2003). A role for Wnt signalling in self-
renewal of haematopoietic stem cells. Nature 423, 409-414. 
Reyes, M. & Verfaillie, C. M. (2001). Characterization of multipotent adult progenitor 
cells, a subpopulation of mesenchymal stem cells. Ann N Y Acad Sci 938, 231 - 
233. 
Robbins, P. D. & Ghivizzani, S. C. (1998). Viral Vectors for Gene Therapy. 
Pharmacology & Therapeutics 80, 35-47. 
Roos, A.-K., Eriksson, F., Timmons, J. A., Gerhardt, J., Nyman, U., 
Gudmundsdotter, L., Bråve, A., Wahren, B. & Pavel, P. (2009). Skin 
263 
 
Electroporation: Effects on Transgene Expression, DNA Persistence and Local 
Tissue Environment. PLoS One 4, e7226. 
Rossant, J. (2006). Stem cells and lineage development in the mammalian blastocyst. 
Reprod Fertil Dev 19, 111-118. 
Rubio, D., Garcia-Castro, J., Martin, M. C., de la Fuente, R., Cigudosa, J. C., 
Lloyd, A. C. & Bernad, A. (2005). Spontaneous Human Adult Stem Cell 
Transformation. Cancer Res 65, 3035-3039. 
Russell, D. W. & Kay, M. A. (1999). Adeno-Associated Virus Vectors and 
Hematology. Blood 94, 864-874. 
Rutledge, E. A., Halbert, C. L. & Russell, D. W. (1998). Infectious Clones and 
Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than 
AAV Type 2. J Virol 72, 309-319. 
Ryan, J., Barry, F., Murphy, J. M. & Mahon, B. (2005). Mesenchymal stem cells 
avoid allogeneic rejection. Journal of Inflammation 2, 8. 
Ryan, J. M., Barry, F., Murphy, M. & Mahon, B. P. (2007). Interferon-gamma does 
not break, but promotes the immunosuppressive capacity of adult human 
mesenchymal stem cells. Clinical and experimental immunology 149, 10. 
Sabatino, D. E., Mingozzi, F., Hui, D. J., Chen, H., Colosi, P., Ertl, H. C. J. & High, 
K. A. (2005). Identification of Mouse AAV Capsid-specific CD8+ T-cell 
Epitopes. Mol Ther 12, 1023-1033. 
Sakaguchi, Y., Sekiya, I., Yagishita, K., Ichinose, S., Shinomiya, K. & Muneta, T. 
(2004). Suspended cells from trabecular bone by collagenase digestion become 
264 
 
virtually identical to mesenchymal stem cells obtained from marrow aspirates. 
Blood 104, 2728-2735. 
Samulski, R. J. & Giles, J. (2005). Adeno-Associated Viral Vectors for Clinical Gene 
Therapy in the Brain. Prog Neurol Surg 18, 154-168. 
Schlehofer, J. R., Ehrbar, M. & zur Hausen, H. (1986). Vaccinia virus, herpes 
simplex virus, and carcinogens induce DNA amplification in a human cell line 
and support replication of a helpervirus dependent parvovirus. Virology 1, 110-
117. 
Shizuru, J. A., Negrin, R. S. & Weissman, I. L. (2005). Hematopoietic Stem and 
Progenitor Cells: Clinical and Preclinical Regeneration of the Hematolymphoid 
System. Annual Review of Medicine 56, 509-538. 
Silva, W. A. J., Covas, D. T., Panepucci, R. A., Proto-Siqueira, R., Siufi, J. L., 
Zanette, D. L., Santos, A. R. & Zago, M. A. (2003). The Profile of Gene 
Expression of Human Marrow Mesenchymal Stem Cells. Stem Cells 21, 661-
669. 
Siminovitch, L., McCulloch, E. A. & Till, J. E. (1963). The distribution of colony-
forming cells among spleen colonies. J Cell Physiol 62, 327-336. 
Song, L., Webb, N. E., Song, Y. & Tuan, R. S. (2006). Identification and Functional 
Analysis of Candidate Genes Regulating Mesenchymal Stem Cell Self-Renewal 
and Multipotency. Stem Cells 24, 1707-1718. 
Spaggiari, G. M., Capobianco, A., Becchetti, S., Mingari, M. C. & Moretta, L. 
(2006). Mesenchymal stem cell-natural killer cell interactions: evidence that 
265 
 
activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-
induced NK-cell proliferation. Blood 107, 1484-1490. 
Srivastava, A., Lusby, E. W. & Berns, K. I. (1983). Nucleotide sequence and 
organization of the adeno-associated virus 2 genome. J Virol 45, 555-564. 
Stender, S., Murphy, M., O'Brien, T., Stengaard, C., Ulrich-Vinther, M., Søballe, 
K. & Barry, F. (2007). Adeno-associated viral vector transduction of human 
mesenchymal stem cells. Eur Cell Mater 13, 93-99. 
Stenderup, K., Justesen, J., Clausen, C. & Kassem, M. (2003). Aging is associated 
with decreased maximal life span and accelerated senescence of bone marrow 
stromal cells. Bone 33, 919-926. 
Stilwell, J. L. & Samulski, R. J. (2004). Role of viral vectors and virion shells in 
cellular gene expression. Mol Ther 9, 337-346. 
Straus, S. E., Sebring, E. D. & Rose, J. A. (1976). Concatemers of alternating plus and 
minus strands are intermediates in adenovirus-associated virus DNA synthesis. 
Proc Natl Acad Sci U S A 73, 742-746. 
Studeny, M., Marini, F. C., Champlin, R. E., Zompetta, C., Fidler, I. J. & Andreeff, 
M. (2002). Bone Marrow-derived Mesenchymal Stem Cells as Vehicles for 
Interferon-{beta} Delivery into Tumors. Cancer Res 62, 3603-3608. 
Summerford, C., Bartlett, J. S. & Samulski, R. J. (1999). AlphaVbeta5 integrin: a co-
receptor for adeno-associated virus type 2 infection. Nat Med 5, 78-82. 
Summerford, C. & Samulski, R. J. (1998). Membrane-associated heparan sulfate 
proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72, 
1438-1445. 
266 
 
Suzawa, M., Takada, I., Yanagisawa, J., Ohtake, F., Ogawa, S., Yamauchi, T., 
Kadowaki, T., Takeuchi, Y., Shibuya, H., Gotoh, Y., Matsumoto, K. & 
Kato, S. (2003). Cytokines suppress adipogenesis and PPAR-[gamma] function 
through the TAK1/TAB1/NIK cascade. Nat Cell Biol 5, 224-230. 
Temple, S. (2001). Stem cell plasticity: building the brain of our dreams. Nat Rev 
Neurosci 2, 513-520. 
Thomas, H. I. J. & Morgan-Capner, P. (1988). Rubella-Specific IgG Subclass 
Concentrations in Sera Using an Enzyme-Linked Immunosorbent Assay 
(ELISA): The Effect of Different Sources of Rubella Antigen. Epidemiol Infect 
101, 599-604. 
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., 
Marshall, V. S. & Jones, J. M. (1998). Embryonic Stem Cell Lines Derived 
from Human Blastocysts. Science 282, 1145-1147. 
Tobiasch, E., Rabreau, M., Geletneky, K., Laruë-Charlus, S., Severin, F., Becker, 
N. & Schlehofer, J. (1994). Detection of adeno-associated virus DNA in human 
genital tissue and in material from spontaneous abortion. J Med Virol 44, 215-
222. 
Toptygina, A. P., Pukhalsky, A. L. & Alioshkin, V. A. (2005). Immunoglobulin G 
Subclass Profile of Antimeasles Response in Vaccinated Children and in Adults 
with Measles History. Clin Diagn Lab Immunol 12, 845-847. 
Tran, S. D., Pillemer, S. R., Dutra, A., Barrett, A. J., Brownstein, M. J., Key, S., 
Pak, E., Leakan, R. A., Kingman, A., Yamada, K. M., Baum, B. J. & Mezey, 
267 
 
E. (2003). Differentiation of human bone marrow-derived cells into buccal 
epithelial cells in vivo: a molecular analytical study. The Lancet 361, 1084-1088. 
Tratschin, J. D., Miller, I. L. & Carter, B. J. (1984). Genetic analysis of adeno-
associated virus: properties of deletion mutants constructed in vitro and evidence 
for an adeno-associated virus replication function. J Virol 51, 611-619. 
Tse, W. T., Pendleton, J. D., Beyer, W. M., Egalka, M. C. & Guinan, E. C. (2003). 
Suppression of allogeneic T-cell proliferation by human marrow stromal cells: 
implications in transplantation. Transplantation 75, 389 - 397. 
Uprichard, S. L. (2005). The therapeutic potential of RNA interference. FEBS Letters 
579, 5996-6007. 
Van Weemen, B. K. & Schuurs, A. H. (1971). Immunoassay using antigen-enzyme 
conjugates. FEBS Lett 15, 232-236. 
Verfaillie, C. M. (2002). Adult stem cells: assessing the case for pluripotency. Trends in 
Cell Biology 12, 502-508. 
Vignau, J., Jacquemont, M. C., Lefort, A., Imbenotte, M. & Lhermitte, M. (2004). 
Simultaneous determination of tryptophan and kynurenine in serum by HPLC 
with UV and fluorescence detection. Biomedical Chromatography 18, 872-874. 
Vincent-Lacaze, N., Snyder, R. O., Gluzman, R., Bohl, D., Lagarde, C. & Danos, O. 
(1999). Structure of adeno-associated virus vector DNA following transduction 
of the skeletal muscle. J Virol 73, 1949-1955. 
Von Lüttichau, I., Notohamiprodjo, M., Wechselberger, A., Peters, C., Henger, A., 
Seliger, C., Djafarzadeh, R., Huss, R. & Nelson, P. J. (2005). Human Adult 
CD34- Progenitor Cells Functionally Express the Chemokine Receptors CCR1, 
268 
 
CCR4, CCR7, CXCR5, and CCR10 but Not CXCR4. Stem cells and 
development 14, 329-336. 
Wagers, A. J. & Weissman, I. L. (2004). Plasticity of Adult Stem Cells. Cell 116, 639-
648. 
Wagner, J. A., Messner, A. H., Moran, M. L., Daifuku, R., Kouyama, K., Desch, J. 
K., Manley, S., Norbash, A. M., Conrad, S. K., Friborg, S., Reynolds, T., 
Guggino, W. B., Moss, R. B., Carter, B. J., Wine, J. J., Flotte, T. R. & 
Gardner, P. (1999). Safety and biological efficacy of an adeno-associated virus 
vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic 
fibrosis maxillary sinus. Laryngoscope 109, 266-274. 
Wagner, J. A., Nepomuceno, I. B., Messner, A. H., Moran, M. L., Batson, E. P., 
Dimiceli, S., Brown, B. W., Desch, J. K., Norbash, A. M., Conrad, C. K., 
Guggino, W. B., Flotte, T. R., Wine, J. J., Carter, B. J., Reynolds, T. C., 
Moss, R. B. & Gardner, P. (2002). A Phase II, Double-Blind, Randomized, 
Placebo-Controlled Clinical Trial of tgAAVCF Using Maxillary Sinus Delivery 
in Patients with Cystic Fibrosis with Antrostomies. Human Gene Therapy 13, 
1349-1359. 
Wakitani, S., Goto, T., Pineda, S. J., Young, R. G., Mansour, J. M., Caplan, A. I. & 
Goldberg, V. M. (1994). Mesenchymal cell-based repair of large, full-thickness 
defects of articular cartilage. J Bone Joint Surg Am 76, 579-592. 
Walsh, J. & Andrews, P. W. (2003). Expression of Wnt and Notch pathway genes in a 
pluripotent human embryonal carcinoma cell line and embryonic stem cells. 
Apmis 111, 197-211. 
269 
 
Walters, R. W., Pilewski, J. M., Chiorini, J. A. & Zabner, J. (2002). Secreted and 
transmembrane mucins inhibit gene transfer with AAV4 more efficiently than 
AAV5. J Biol Chem 277, 23709-23713. 
Walters, R. W., Yi, S. M. P., Keshavjee , S., Brown, K. E., Welsh, M. J., Chiorini, J. 
A. & Zabner, J. (2001). Binding of Adeno-associated Virus Type 5 to 2,3-
Linked Sialic Acid Is Required for Gene Transfer. J Biol Chem 276, 20610-
20616. 
Wang, L., Figueredo, J., Calcedo, R., Lin, J. & Wilson, J. M. (2007). Cross-
Presentation of Adeno-Associated Virus Serotype 2 Capsids Activates Cytotoxic 
T-cells But Does Not Render Hepatocytes Effective Cytolytic Targets. Hum 
Gene Ther 18, 185-194. 
Wang, X., Willenbring, H., Akkari, Y., Torimaru, Y., Foster, M., Al-Dhalimy, M., 
Lagasse, E., Finegold, M., Olson, S. & Grompe, M. (2003). Cell fusion is the 
principal source of bone-marrow-derived hepatocytes. Nature 422, 897-901. 
Weitzman, M. D., Kyöstiö, S. R., Kotin, R. M. & Owens, R. A. (1994). Adeno-
associated virus (AAV) Rep proteins mediate complex formation between AAV 
DNA and its integration site in human DNA. Proceedings of the National 
Academy of Sciences of the United States of America 91, 5808-5812. 
Wert, G. d. & Mummery, C. (2003). Human embryonic stem cells: research, ethics 
and policy. Hum Reprod 18, 672-682. 
Wexler, S. A., Donaldson, C., Denning-Kendall, P., Rice, C., Bradley, B. & Hows, J. 
M. (2003). Adult bone marrow is a rich source of human mesenchymal 'stem' 
270 
 
cells but umbilical cord and mobilized adult blood are not. British Journal of 
Haematology 121, 368-374. 
Wiles, M. V. & Johansson, B. M. (1999). Embryonic Stem Cell Development in a 
Chemically Defined Medium. Experimental Cell Research 247, 241-248. 
Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., 
Flotte, T. & Muzyczka, N. (2000). Mutational analysis of the adeno-associated 
virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered 
tropism. J Virol 74, 8635-8647. 
Wu, Z., Asokan, A. & Samulski, R. J. (2006). Adeno-associated Virus Serotypes: 
Vector Toolkit for Human Gene Therapy. Mol Ther 14, 316-327. 
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G. & Wilson, J. M. 
(1999). Gene Therapy Vectors Based on Adeno-Associated Virus Type 1. J 
Virol 73, 3994-4003. 
Xiao, W., Chirmule, N., Schnell, M. A., Tazelaar, J., Hughes, J. V. & Wilson, J. M. 
(2000). Route of administration determines induction of T-cell-independent 
humoral responses to adeno-associated virus vectors. Mol Ther 1, 323-329. 
Xiao, W., Warrington, K. H., Jr., Hearing, P., Hughes, J. & Muzyczka, N. (2002). 
Adenovirus-Facilitated Nuclear Translocation of Adeno-Associated Virus Type 
2. J Virol 76, 11505-11517. 
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A. & Chapman, M. 
S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for 
human gene therapy. Proc Natl Acad Sci USA 99, 10405-10410. 
271 
 
Yang, S.-H., Park, M.-J., Yoon, I.-H., Kim, S.-Y., Hong, S.-H., Shin, J.-Y., Nam, H.-
Y., Kim, Y.-H., Kim, B. & Park, C.-G. (2009). Soluble mediators from 
mesenchymal stem cells suppress T-cell proliferation by inducing IL-10. Exp 
Mol Med 41, 315-324. 
Zaiss, A. K., Cotter, M. J., White, L. R., Clark, S. A., Wong, N. C. W., Holers, V. 
M., Bartlett, J. S. & Muruve, D. A. (2008). Complement Is an Essential 
Component of the Immune Response to Adeno-Associated Virus Vectors. J 
Virol 82, 2727-2740. 
Zaiss, A. K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S. & Muruve, D. A. 
(2002). Differential Activation of Innate Immune Responses by Adenovirus and 
Adeno-Associated Virus Vectors. J Virol 76, 4580-4590. 
Zaiss, A. K. & Muruve, D. A. (2005). Immune responses to adeno-associated virus 
vectors. Current Gene Therapy 5, 323-331. 
Zhang, J., Wu, X., Qin, C., Qi, J., Ma, S., Zhang, H., Kong, Q., Chen, D., Ba, D. & 
He, W. (2003). A novel recombinant adeno-associated virus vaccine reduces 
behavioral impairment and [beta]-amyloid plaques in a mouse model of 
Alzheimer's disease. Neurobiol Dis 14, 365-379. 
Zwezdaryk, K. J., Coffelt, S. B., Figueroa, Y. G., Liu, J., Phinney, D. G., LaMarca, 
H. L., Florez, L., Morris, C. B., Hoyle, G. W. & Scandurro, A. B. (2007). 
Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in 
human mesenchymal stem cells. Experimental Hematology 35, 640-652. 
 
 
